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I 
ABSTRACT 
Dissolution of drugs is a prerequisite for oral absorption and bioavailability. Drugs in 
the gastrointestinal tract are exposed to a medium of partially digested food, comprising 
mixtures of fat, protein and carbohydrate in addition to bile components. Despite this, 
the compendial. media are still simple hydrochloric acid solutions or phosphate buffers. 
In this investigation, biorelevant dissolution media were developed to examine the 
impact of fat, protein, carbohydrate, amino acids and bile components on the dissolution 
behaviours of two azole anti-fungal drugs (itraconazole and ketoconazole). The drugs 
are Biopharmaceutics Classification System Class Il (poorly soluble with good 
permeability) and so they are more likely to exhibit dissolution rate-limited absorption. 
Furthermore, their bioavailability is affected by food ingestion. 
The intrinsic dissolution rates of the drugs were evaluated using the stationary disk 
method in USP Apparatus II. Powders of the drugs were compressed to form disks with 
a constant surface area. No evidence of polymorphic change was observed due to drug 
compaction. 
The dissolution and solubility of the drugs were assessed in simulated gastric fluid 
(SGF) containing milk with different fat contents, SGF containing albumin (hen egg 
white), gelatin (bovine skin), casein (bovine milk), gluten (wheat), carbohydrates 
(glucose, lactose and starch) and amino acids (glycine, alanine, leucin, lysine and 
aspartic acid) to mimic gastric fluid at fed state. Most of the dietary components 
enhanced the solubility compared to SGF but to differing extents. The greatest increase 
in dissolution of itraconazole was observed with the addition of milk or albumin. The 
greatest enhancement of ketoconazole dissolution was observed in media containing 
neutral amino acids or milk. The rate and extent of the increase in solubility and 
dissolution varied between the two drugs and this was attributed to differences in their 
physical and chemical structure, in particular their lipophilicity. The formation of 
complexes with food additives likely accounted for the solubilising effect and in milk- 
containing media the effect was attributed to the whole complex structure of milk. 
The dissolution and solubility were assessed in simulated gastric fluid at fasted state 
(FaSSGF) using formulations based on natural (bile salts and phospholipids) and 
synthetic surfactants. The inclusion of surfactants increased the dissolution however 
i 
variable dissolution profiles in the media were obtained. This was presumably due to 
different solubilising mechanisms of the surfactant-containing media which rendered 
the formulations of synthetic surfactants as inappropriate alternative for FaSSGF which 
contained natural surfactants. 
The dissolution was also assessed in the presence of key endogenous surfactants in 
conditions representing fasted and fed state simulated intestinal fluids (FaSSIF and 
FeSSIF). The dissolution in the fed simulated medium was higher than the fasting 
simulated medium due to the greater amount of bile components and the lower pH of 
the fed simulating medium. The dissolution profiles of the drugs in FaSSIF and FeSSIF 
were compared to the profiles acquired in simplified media containing synthetic 
surfactants, sodium dodecyl sulphate and hexadecyltrimethyl ammonium bromide. 
These simplified media did not provide identical dissolution to that in FaSSIF and 
FeSSIF, however, approximate simulation was achieved which may be of value for 
replacing FaSSIF and FeSSIF for the quality control tests of the dosage forms. 
The physical properties of the media were assessed in terms of viscosity and surface 
tension. The viscosity of the media did not show important variations, apar-t from media 
containing milk, albumin, and gelatin. Surface tension was an important determinate of 
dissolution as media with high surface activity exhibited high solubilising capacity of 
the drugs in addition to enhancing the wettability of drugs. 
Thus, the results confirm the importance of using biorelevant media in dissolution 
studies and highlight the potential effect of the ingested meals on drug dissolution and 
subsequent bioavailability. 
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Chapter 1: Introduction 
1.1 Introduction to dissolution and solubility 
Dissolution is a prerequisite for the oral absorption of solid dosage forms because for a 
drug to be absorbed it must dissolve first. Dissolution can be the rate-limiting step for 
the absorption of poorly soluble drugs administered orally, consequently limiting their 
bioavailability and systemic efficacy (Kramer et al., 2005). 
The dissolution test has proved to be a useful tool for many purposes and at many stages 
of formulation development. It is used in quality control, batch to batch similarity and 
during drug development to help in choosing appropriate excipients and formulations. 
The test allows prediction of drug behaviour and determination of bio-equivalency 
in vivo which makes it a potential tool for in vitro-in vivo correlation (Figure 1.1). 
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Figure 1.1 The applications of dissolution testing, from Jamzad and Fassihi (2006) 
When a solid dosage form is immersed in dissolution media or in the fluids of the 
gastrointestinal (GI) tract, there are three possible steps for drug dissolution (Figure 
1.2): 
1) disintegration to granules or aggregates 
2) deaggregation into fine particles 
3) dissolution. 
These three steps can also occur simultaneously or the dissolution process can start 
directly from the intact solid or granules without going through all stages (Martin, 
1993c). 
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Figure 1.2 Steps for drug dissolution from a solid dosage, from Wagner (1971) 
I 
Dissolution can be explained as the process where solid particles leave the solid phase 
and become emerged in the solvent phase. It was defined by Viness and Reza (1999) as 
"Dissolution of the drug substance is a multi-step process involving heterogeneous 
reactions/interactions between the phases of the solute-solute and solvent-solvent 
phases and at the solute-solvent interface". Dissolution was expressed as a quantitative 
term called dissolution rate which was defined as "the amount of drug substances that 
goes into solution per unit time under standardized conditions of liquid/solid interface, 
temperature and solvent composition" (Abdou, 1989b). 
A saturated solution is the state where a maximum amount of solute is dissolved in 
solvent and so equilibrium is maintained between the solution and the solid phases. 
Based on that, solubility was described by Martin (1993c) as the concentration of the 
dissolved substance in its saturated solution at a certain temperature. 
There is another term for solubility called the intrinsic solubility which was defined as 
the solubility of an un-dissociated species, i. e. the solubility of a compound in its free 
form as an acid or a base (Alsenz and Kansy, 2007). 
To distinguish between solubility and dissolution, dissolution is a kinetic parameter 
quoted as the amount dissolved per unit time, so it is a dynamic process whereas 
solubility is an equilibrium parameter that expresses the maximum amount of the 
substance dissolved per volume unit. 
2 
1.2 Theory of dissolution mechanisms 
There are three prevailing models that describe the dissolution process (Figure 1.3). The 
dissolution concept, in terms of theories and historical development were reviewed 
thoroughly by Abdou (I 989b) and Banakar (I 992a). 
a. Diffusion layer model 
b. Danckwerts' model 
c. Interfacial layer model C) 
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Figure 1.3 Schematic diagram illustrating different mechanisms of the dissolution process. C refers 
to the conccntration in the bulk solution and C, to the saturation solubility, reproduced from 
Higuchi, (1967) 
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1.2.1 Diffusion layer model (film theory) 
This diffusion layer model is probably the most commonly used. It considers the 
process of dissolution to be composed of two consecutive steps; the first step, which 
occurs quickly, is the formation of a layer of solution around the solid which becomes a 
stagnant film adjacent to the solid surface. During the next step, the particles move from 
the surrounding layer to the bulk solution. 
One of the first equations modelling dissolution was Fick's law for diffusion under 
constant conditions (Topp, 2000). Dissolution was expressed by the term "diffusion 
current" Q) which was defined as the amount of drug that passes vertically per unit of 
time per unit of area (Eq. (1.1)). D is the diffusion coefficient and Oc/& is the 
concentration gradient in the x direction which is considered constant. 
-D 
ac 
ax 
Eq. (1.1) 
Since the first equation of Fick's law assumed steady state, whereas the concentration of 
the drug will change with time, another equation (Eq. (1.2)) was derived and called 
Fick's second law, which express the dissolution rate Oc / Ot as: 
ac 
= Dr 
alc 
at ýTP 
Eq. (1.2) 
Noyes and Whitney (1897) studied the kinetics of the dissolution of benzoic acid and 
lead chloride using rotating cylinders of the substances. By using slightly soluble 
compounds placed around cylinders, a constant surface area was maintained throughout 
the course of the experiment. It was noticed that the rate of the dissolution was 
proportional to the difference between the saturation solubility at the solid-liquid 
interface and the instant concentration in the bulk medium (Eq. (1.3)). 
dc 
- k(C. - Ct) dt 
Eq. (1.3) 
Where dcldt is the change in concentration as a function of time, C, is the saturation 
solubility, Ct is the concentration at time t and k is the dissolution rate constant. This 
equation is expressed schematically in Figure 1.4. 
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Figure 1.4 Schematic diagram for the dissolution process from a solid particle representing the 
Noyes-Whitney equation 
Bruner and Tolloczko (1900) and Nernst (1904) incorporated a diffusion layer 
perception by proposing a thin film formed around the particles with thickness h and 
considered that the diffusion process took place from that layer to the bulk solvent. 
Based on Fick's second law, the Nernst-Brunner equation was developed (Eq. (1 -4)). 
D is the diffusion coefficient of the substance, S is the surface area of the particles, h is 
the thickness of the diffusion layer and V the volume of the dissolution medium. 
dc 
= 
DS 
(Cý - Ct) dt Vh 
Eq. (1.4) 
Instead of expressing the dissolution rate as dcldt, Hixson and Crowell (193 1) expressed 
the dissolution rate in terms of a change in the weight of dissolved particles with time. 
Thus, Hixson and Crowell's cubic root model was proposed which relates time to the 
cube root of the weight. In a special case, when C, was too small and considered 
constant and consequently (C, - C, ) was constant, the equation took the simple form (Eq. 
(1.5)) assuming that the shape of the particles is not changing during the dissolution. 
wo 
1/3 
_w 
1/3 
= kit Eq. (1.5) 
Where wo is the initial weight of solid particles, w is the weight of the undissolved 
particles at time t and ki is the cube-root dissolution constant. 
1.2.2 Penetration or surface renewal theory (Danckwerts' Model) 
Danckwerts (195 1) suggested a new model for dissolution based on the hypothesis that 
the surface is continuously being replaced and assumed that the agitated solvent is 
composed of packets that are continuously exposed to solid particles. These packets 
absorb the solute molecules and carry them into the solution; thus these solvent packets 
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are constantly renewed. This model proposes that the equilibrium occurs at the solid- 
solution interface. The concentration of the solute on the interface, CA, is less than the 
saturation solubility due to persistent contact with the fresh solvent that has a 
concentration far less than CA. Therefore, this theory does not support the existence of a 
stagnant layer that has a concentration C, The rate-limiting step is the diffusion of the 
solvent from the bulk through to the solid phase. The mathematical equation of 
Danckwerts' theory is expressed by Eq. (1.6) where dwldt is the change of the weight of 
the dissolved particles with time, y is the interfacial tension and Ct is the concentration 
of the solute in the bulk medium. 
dw 
= S(, yD)"'2 (Cs - Ct) dt 
(Eq. 1.6) 
1.2.3 Interfacial barrier model (double barrier mechanism or limited 
solvation theory) 
This interfacial barrier model is based on the assumption that the reaction occurs at the 
interfacial barrier between a solid surface and a liquid. This barrier has an intermediate 
concentration of the solute, which is less than the saturation concentration. Different 
faces of crystals may have different interfacial barriers and thus different dissolution 
profiles. Higuchi (1961) considered the rate limiting step as the diffusion of solute 
molecules from the solid interface, which demands high energy, rather than diffusion 
through the static film. 
These three models were also employed in combination to explain the dissolution 
process. One of the new theories considered the dissolution as a heterogeneous mass 
transfer process composed of three steps " (i) removal of the solute from the solid phase, 
(ii) accommodating the solute in the liquid phase, and (iii) diffusive and/or convective 
transport of the solute away from the solid/liquid interface into the bulk phase" (Kramer 
et al., 2005). 
1.3 The process of dissolution: energy changes 
in order for the dissolution process to occur, the interaction between the solute-solvent 
should be stronger than the interaction between solute-solute and solvent-solvent 
(Brittain, 2007). The molecule must be able to move from an environment where it is 
surrounded by identical molecules to the solution where it is surrounded by non- 
identical molecules. 
6 
For the dissolution process to take place spontaneously the change in the free energy of 
the system at constant pressure should be negative. In this case, the attraction forces 
between solute-solvent should exceed the forces of attraction of solid-solid and solvent- 
solvent. Thereby, the solvation energy released during the dissolution process must be 
greater than the sum of the crystal lattice free energy and the free energy of cavity 
fortnation in the solvent (Brittain, 1999a). The general thermodynamic equation (Eq. 
(1.7)) applies where AG is Gibbs free energy, AH is the change in the enthalpy that 
occurs due to the thermodynamic change while absorbing or evolving energy, AS is the 
change in entropy which indicates the change in the disorder of the system and T is the 
thermodynamic temperature. 
AG=AH-TAS Eq. (1.7) 
AS is always positive during a dissolution process and this can be explained by the 
particles leaving the solid mass as a process that increases the randomness of the 
system. Therefore, for AG to be negative, AH must less than TAS (Aulton, 2002). 
The changes in AH during the dissolution process is the sum of two enthalpies: i) the 
heat absorbed to separate the molecules of solute against the intermolecular interactions 
which is expressed as crystal lattice enthalpy (AHI) and it is always positive, ii) the heat 
absorbed when the solute is immersed in solvent (AH,,,, ) which is normally negative 
(Eq. (1.8)). 
AH = AHci + AMoiv Eq. (1.8) 
Dissolution overall can be either endothermic or exothermic. In most cases, AHj > 
ABý, I, so the dissolution process will be endothermic. If the affinity of the solute to the 
solvent is very high, AH becomes negative and the process will be exothermic (Aulton, 
2002). 
1.4 Compendial dissolution test 
1.4.1 History 
Studies carried out in the period of 1950-1970 highlighted the importance of the 
dissolution test in evaluating drug performance and bio-equivalency among generic 
products. The trigger for these studies was the perceived inconsistency in bioavailability 
of identical generic products such as digoxin tablets. Since digoxin is poorly soluble 
with a narrow therapeutic index and a narrow absorption window, any slight variation in 
7 
its bioavailability will have a serious impact. Shaw et al. (1973) suggested that 
differences in the bioavailability of digoxin could be attributed to different in vitro 
dissolution patterns. Accordingly, these findings demanded more extensive dissolution 
studies to standardize drug products to achieve bio-equivalency. 
The disintegration process is the step prior to dissolution where the dosage form breaks 
up into granules or small particles. The disintegration test is an indicator for dosage 
form performance but it does not evaluate the drug release. It was introduced as an 
official quality control test by the USP Edition 14 in 1950, however, it was noticed that 
it was not sufficient to standardize products or give information about drug 
bioavailability (Campbell et al., 1957). Consequently, these concerns led to the 
introduction of dissolution requirements for tablet and capsule monographs in 
pharmacopoeias and the proliferation of dissolution apparatus designs. A detailed 
review of the history of pharmaceutical dissolution evolution is described by Kramer et 
al. (2005) and Dokoumetzidis and Macheras (2006). 
One of the first methods utilized to study the dissolution of dosage forms was the 
Beaker method. It was initially developed by Levy and Hayes (1960) where a pellet of 
the drug was centred in a beaker containing the dissolution medium and a rotating 
motion was applied. The main problem with this system was that the pellets formed a 
mound at different positions on the base of beaker and this change in pellet position led 
to variable results. Thus, a round bottom flask was utilised and this method was called 
the flask-stirrer method. Thereafter, rotating and basket methods were developed and 
described in most pharmacopoeias. 
Of all dissolution apparatuses, Apparatus I (rotating basket) and II (paddle assembly) 
are the most widely utilized because they are simple, robust, and are sufficiently 
standardized. 
It is important to note that the Food and Drug Administration (FDA) and the 
pharmacopoeias recommended the maintenance of sink conditions throughout the 
dissolution test period, which was defined when the concentration of the drug substance 
dissolved in the bulk medium (C) was less 1/3 of the saturated concentration (Cs) in that 
medium (USP, 2008). A stricter definition considered that sink conditions applied when 
the bulk concentration was <10% of the Cs (Aulton, 2002). This could be met when the 
dissolving medium was sufficiently diluted, i. e. by using a volume of dissolution 
medium that is at least three times greater than that required to form a saturated solution 
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of the drug or by using a method that allows constant removal of the solutes from the 
medium. 
1.5 Intrinsic dissolution rate 
The intrinsic dissolution rate (IDR) is the dissolution rate of a pure drug substance under 
constant conditions of surface area, temperature, agitation-stirring speed, pH and ionic 
strength of the dissolution medium. Therefore, the IDR is a useful tool to characterise a 
drug substance without the interaction of excipients and it also allows screening of new 
drug candidates to understand their behaviour in physiological fluids (Abdou, 1989b). 
In addition, it allows the study of the dissolution of excipients and their effect on the 
dissolution of the dosage form. 
The IDR gives an indication of drug performance and potential bioavailability; if it is 
less than 0.1 mg min-' cm-2 then the dissolution rate is low and probably the rate-limiting 
step to absorption. If is greater than 0.1 mg min" 1 CM-2 , drug dissolution is not expected 
to be an impediment for absorption (Kaplan, 1974). 
1.5.1 Methodology 
The general procedure for determining IDR is to compress the pure drug powder to 
form a non-disintegrating disk under specific conditions of pressure and die dimensions 
without any additive to the drug powder. Thereafter, these disks are transferred to the 
dissolution apparatus where only one face of the compressed solid remains exposed to 
the dissolution medium. Dissolution then occurs under certain conditions of temperature 
and agitation rate. Samples are withdrawn and analyzed to determine drug concentration 
and calculate the IDR. 
1.5.1.1 Rotating disk methods 
The rotating disk method was initially described by Levy and Sahli (1962). In this 
method, a flat-faced tablet was mounted in a plexiglass holder which was rotated at 
555rev min" in 200ml of dissolution medium placed in a 500-ml three necked flask. 
Drawbacks of this method included high rotating speeds and some drugs producing 
fragile disks that could easily break when handled. Thus, the Wood apparatus was 
developed (Wood et al., 1965). In this apparatus, the die containing the compressed 
pellet was attached to a rotor where one surface was facing the bottom of the beaker 
(Figure 1.5). The advantage of this system was the utilization of a compression 
assembly to form a compressed tablet that served as a tablet holder within the 
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dissolution apparatus. A finther design of the rotating apparatus was developed by 
Underwood and Cadwallader (1978), where a disk of the drug was produced and held in 
a cup attached to a shaft that could rotate. Another type of apparatus that allows 
dissolution from a constant surface area was devised by attaching a cup containing drug 
pellets into USP basket apparatus where the rotation speed was set at 100rev min-' 
(Hanson, 1991). Further variations of designs for the determination of IDR were 
reviewed by Abdou (19 8 9b). 
The USP (2008) considered a modification of the Wood apparatus for determining IDR. 
Drug powder was placed in the die cavity and compressed forming a smooth compact 
pellet with a predetermined surface area. The die was attached to the holder which was 
mounted on the shafts of a stirring device such as the modified USP Apparatus 11. The 
USP (2008) recommended plotting a graph of the cumulative dissolved amount per unit 
area, until 10 % of drug is dissolved, versus time and so the slope of the regression line 
represents the IDR. 
Rotating Shaft 
Die 
Drug Pellet 
7 mm 
- 
.-1 
ýv , a. a... aaaaa 
Dissolution Vessel 
Die Holder 
25.4mm 
Figure 1.5 Schematic diagram for rotation disk apparatus, from Dyas and Shah (2007) 
Recently, a miniaturized rotating disk apparatus was developed (Persson et al., 2008). 
This apparatus has the advantage of working on a small scale as it consumes only a 
small amount of drug substance, 5mg, compared to a minimum of 100mg required in 
the above methods and it only needs a small volume of dissolution medium (15ml). The 
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drug powder was compressed directly into a gold-plated magnetic bar holder and then a 
continuous flow system was pumped over the disk. However, a problem with this 
arrangement was the formation of a reproducible disk surface. 
1.5.1.2 Stationary disk methods 
Milosovich (1964) devised an apparatus that used stationary pellets in a stiffed 
dissolution system. Samples were prepared by compressing 300mg of drug powder in a 
die using a punch and a hardened steel block. One surface of the disk was covered and 
the opposite one was left exposed to dissolution medium. This configuration was 
inserted into a stainless steel beaker where the disk surface was vertical on the beaker 
base. Stirring at 300rpm was produced using shafts driven by a motor. Khoury et al. 
(19 8 8) used an apparatus which consisted of a holder unit for a tablet die with magnet- 
driven stirring. The drug powder was compressed in a die against the plate and then the 
die containing the pellet was introduced into the neck of a 200ml 3-necked flask and 
mounted via the die holder unit. The last two configurations allowed securing a fixed 
position and avoiding misalignment problems. 
Viegas (2001) illustrated a stationary system provided by Distek. Inc. that easily fits 
into the USP apparatus II. The drug was compressed using a punch and die system and 
then the die was immersed in a dissolution vessel where only one face was subjected to 
the dissolution medium. The stirring was produced by rotating shafts with the distance 
between the bottom of the stirring paddle and the pellet face was specified as 2.54cm 
(Viegas, 2001). 
The stationary method was recommended by the USP (2007) for cases where the use of 
rotating apparatus was not appropriate due to the formation of bubbles. However, the 
method was later adopted with the rotating disk in the USP (2008) (Figure 1.6). The 
drug substance was compressed using a steel punch, die, and a base plate. Then, the die 
was placed at the bottom of the flat bottomed-vessel of the dissolution tester II with one 
smooth surface facing upwards. 
1.5.1.3 Stationary apparatus versus rotating disk apparatus 
Viegas (2001) compared the two apparatus used for determining IDR, namely, the 
rotating disk (Wood) and the stationary disk (Distek Inc. ), and noticed that different 
mechanisms controlled the dissolution operation; a forced shear-like process in the 
former and a solvent shear-like process in the latter. 
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Gasket 
Plastic Cap -/ I Plunger 
Figure 1.6 Schematic diagram for stationary disk apparatus, from the USP (2008) 
The stationary disk method is a simple system that could fit into the USP Apparatus II, 
as it only requires the use of flat vessels, whereas a rotating disk needs special 
arrangements such as a shaft with a hollow die holder so that the disk can be attached to 
it and the surface of the compressed drug will face downward. 
Two drawbacks were observed with the rotating apparatus; one due to the 
hydrodynamics which were more likely to cause bubbles that cover the surface of the 
disk, decrease the active dissolution surface and consequently lead to a low dissolution 
rate. The second drawback was due to less temperature control at the beginning of the 
experiment caused by the relatively big assembly. As by lowering the shafts heat loss 
through the shafts occurred which consequently decreased the temperature by 
approximately 2*C. No obvious changes in temperature were observed in the stationary 
system since the device was small and was totally immersed in the fluid in the vessel. 
1.5.2 Calculations 
Intrinsic dissolution rate per unit of surface area, J, (mass flux) was calculated by 
integrating the modified equation of Noyes and Whitney. Under sink conditions C is 
very small, so it can be neglected and since the surface area S is constant, J was 
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expressed by Farraj et al. (1989) by Eq. (1.9) where m is the mass of dissolved drug at 
time t. 
j=D cs = 
dm I 
Eq. (1.9) 
h dt S 
By integrating this equation, it was found that plotting of WS against t yielded J (Eq. 
(1.10)) 
m 
-= it Eq. (1.10) s 
Levich (1962) deduced Eq. (1.11) that can be applied for calculating J from rotating 
disk methodology, where v denotes the kinematic viscosity and fl the angular velocity 
of the disk. 
J=0.62D' 13V-1160112(C s_C t) Eq. (1.11) 
The mass flux according to the Levich equation included both processes that usually 
occur during the dissolution process; convection and diffusion (Wall et al., 1985). Eq. 
(1.12) indicated that the dissolution rate from the rotating disk apparatus was 
proportional to the square root of the rotating velocity, where a is the proportionality 
constant. 
dc 
= ad 
/2 
dt 
Eq. (1.12) 
Colton and Smith (1972) computed the average of dissolution flux from the stationary 
disk in rotating fluid where a new term was introduced (0): a dimensionless ratio of the 
fluid velocity at some axial distance below the paddle to the maximum paddle tip 
velocity. Based on their findings the following relationship for the dissolution flux from 
static disk was developed by Mauger et al. (2003) (Eq. (1.13)). 
J=0.77D 213V-1/601/201/2(C s_C t) Eq. (1.13) 
1.6 Factors affecting the dissolution of drug 
There are various factors that affect the dissolution behaviour of drugs. These are 
classified as factors related to; the physicochernical properties of the drug, type of 
dissolution device, hydrodynamic conditions, experimental conditions such as 
temperature and agitation, factors related to the dosage form and its formulation such as 
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the excipicnts, coatings and the manufacturing procedures. Furthermore, in vivo, the 
dissolution process will also be affected by physiological factors. 
This section will focus only on the physicochemical and physiological factors that 
influence drug dissolution in the upper GI tract. A detailed review is described by 
Banakar (1992b) and Horter and Dressman (2001). 
1.6.1 Physicochemical factors 
The physicochemical parameters affecting the dissolution rate of drugs are discussed 
herein through the modified form of Noyes-Whitney equation (Eq. (1.14)). 
DR = 
dm 
= 
DS 
(Cs -M Eq. (1.14) dt hv 
Where DR is the dissolution rate, m is the mass of the dissolved substance, C, is the 
saturation solubility, V is the volume of the dissolution media, S is the area of the 
dissolving interface, D is the diffusion coefficient of the solute in solvent and h is the 
thickness of the diffusion layer. 
1.6.1.1 Drug solubility 
Saturation solubility is a fundamental factor in determining dissolution rate. Under sink 
conditions where C, >> Ct, a linear relationship is expected from a plot of the 
dissolution rate versus solubility. Various physicochemical and physiological factors 
can affect the solubility: 
1.6.1.1.1 Solidphase characteristics 
Solids may exist in multiple physical forms such as crystals, amorphous forms, hydrates 
and solvates, and even the crystalline form can adopt different crystal structures, known 
as polymorphs. Polymorphisin is defined as the ability of a substance to exist as two or 
more crystalline phases with different arrangements and/or conformations in the crystal 
lattice (Grant, 1999). These forms can behave differently when they are in the solid state 
which leads to different physicochemical. properties such as melting point, chemical 
reactivity and density. A difference in the internal energy of the polymorph states can 
lead to different lattice energy and consequently different solubility. Critically, this can 
change the dissolution pattern and result in a different bioavailability. 
In a polymorphic system, the polymorphs with the lowest energies are 
thermodynamically more stable while the polymorphs with the highest free energies are 
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the metastable fonns. Because of their high energy, the solubility of the metatable forms 
is higher than the corresponding stable forms and they tend to dissolve faster (Gong et 
al., 2007). 
Amorphous forms are more disordered and so their entropy and enthalpy are greater 
than the crystalline states, resulting in higher free energy and so greater solubility. 
Hancock and Parks (2000) predicted that the solubility of amorphous forms was higher 
than the most stable crystal form by a range of 16-fold to 1600-fold. Consequently, a 
solution of the metastable form had a higher concentration (supersaturated) compared to 
a saturated solution of the stable form. However, the less stable forms tend to revert to 
the stable form during the solubility experiment as the time required to reach 
equilibrium is relatively long which allows nucleation and so the formation of more 
stable forms. Therefore, in general, it is difficult to measure the solubility of the 
metastable form using the typical equilibrium methods. For instance, carbamazepine 
was found to exist in both anhydrate and dihydrate forms, with the former 
spontaneously converting to the latter upon contact with water. The dissolution rate of 
the anhydrous phase is normally higher than the hydrates but this statement is not 
necessarily applicable to solvates (Brittain, 1999a). 
Ueda et al. (1984) demonstrated that chlorpropamide has many polymorphs of which 
four metastable forms exhibited higher dissolution rates. The dissolution study showed 
that the metastable form 11 of chlorpropamide instantly converted to the stable form 
under the dissolution conditions. Manipulation of the dissolution medium may allow 
inhibition of the transformation between the polymorphs. For example, 
hydroxylpropylmethylcellulose (HPMC) showed an ability to inhibit the conversion of 
the anhydride form of carbamazepin into the hydrated form (Tian et al., 2007). 
L 6.1-1.2 pKa of the drug andpH ofthe medium 
The PH of the dissolution medium Plays a crucial role in the dissolution of ionisable 
drug substances because the solubility increases due to the contribution of the charged 
species. The charge state of the substance at a particular PH is expressed by its 
ionisation constant (Ka). 
The solubility-pH profile can be predicted using simple Henderson-Hasselbalch 
equations. The relationship between the solubility of acidic compounds versus the pH is 
illustrated by Eq. (1.15) (Avdeef, 2007). At pH << pKa, a horizontal line is produced as 
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log S is approximately equal to the logarithm of the intrinsic solubility (log So). When 
the pH >> pKa, logarithm of solubility (log S) increases linearly with an increase in pH 
of the medium. 
logs = log So + log 
(I 
0-pKa+pH + 1) Eq. (1.15) 
For basic compounds, at pH << pKa the solubility increases with a decrease in pH (Eq. 
(1.16)). However, at pH >> pKa a horizontal line between log S and pH reflects the 
similarity between log S and log So. 
logs = log So + log(, OpKa-pH + 1) Eq. (1.16) 
Correlating the pH of the gastro-intestinal system with the pKa of a drug can explain 
why, when a basic drug is taken after food it is less soluble in the gastric medium which 
has a relatively high pH in the fed state. As an example, the bioavailability of the basic 
drug, ketoconazole, was reduced in hypochlorhydria (Blum et al., 1991). As a result, a 
basic drug delivered from the stomach to the duodenum might precipitate due to the 
change in pH. Kostewicz et al. (2004) developed an in vitro system composed of 
gastric-intestinal chambers where basic poorly soluble drugs were dissolved in 
simulated gastric fluid (SGF). The solution was then pumped into a chamber containing 
simulated intestinal fluid (SIF) representing fasted and fed conditions at pH 6.5 and 5, 
respectively. Precipitation was monitored in the acceptor. The study showed the 
possibility of drug precipitation and supersaturation upon entry to the small intestine at 
the fasted state. 
The pH of the surrounding layer affects the dissolution of ionisable drugs. Different pH 
values were observed in the bulk medium from that recorded on the surface of the 
dissolving solid. Moreover, different dissolution profiles were obtained in buffered and 
unbuffered systems which indicated that the buffer capacity of the media can affect the 
dissolution (Ozturk et at., 1988). 
Furthermore, different salts of the same compound can exhibit different dissolution. Li 
et al. (2005) found that different salts of haloperidol, the basic drug had different 
dissolution and solubility. Haloperidol mesylate had a higher dissolution rate between 
pH 2 and 5 than its hydrochloric salt or the free base. 
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1.6.1.1.3 Surfactants in dissolution media 
Surfactants are amphiphilic molecules composed of a hydrophilic or polar moiety 
known as the head and a hydrophobic or nonpolar moiety, usually a lipid or a long- 
chain hydrocarbon, known as the tail (Malmsten, 2002). The surfactant head can be 
charged (cationic, anionic or dipolar) or non-ionic. In dilute solutions surfactant 
molecules are positioned at the interface and at a certain concentration the surfactant 
molecules organize, forming micelles. This point is called the critical micellar 
concentration (CMC) and at this point the physicochemical characteristics of the system 
change suddenly. Surfactants can enhance the dissolution of drugs by lowering the 
interfacial tension of the media and forming micelles and at concentrations below the 
CMC the surfactant can allow better penetration of the solving liquid to the dosage 
form. 
The fluid in the GI system has a low surface tension due to the presence of bile salts and 
phospholipids, aiding the dissolution and subsequent absorption of drugs with limited 
aqueous solubility. Therefore, to achieve better prediction of drug behaviour, adding 
various surfactants to the dissolution media has been investigated extensively. One of 
the first dissolution studies that utilized surfactant was a comparative study of the 
dissolution of two drugs in gastric juice and hydrochloric acid media containing 
different amounts of polysorbate 80 (Tween 80) (Finholt and Solvang, 1968). 
For example, the USP (2008) recommended the addition of sodium dodecyl sulphate 
(SDS) to study the dissolution of carbarnazepine tablets (1%, w/v SDS in water) and 
danazol capsules (0.75%, w/v SDS in water). However, using synthetic surfactants 
could be problematic as they might interact with the drugs forming insoluble salts (Chen 
et al., 2003). SDS is the most frequently used surfactant due to its good solubilising 
capacity, low cost and ease of use. However, drawbacks were observed with its use as it 
can hydrolyze in solutions with a pH value lower than 4. Furthermore, it may interact 
with gelatin which makes it inapplicable for use with gelatin capsules (Zhao et al., 
2004). 
In addition to synthetic surfactants, the effect of natural surfactants was investigated by 
utilizing bile salts such as sodium taurocholic with or without phospholipids. These 
systems also influenced the dissolution by forming mixed micellar systems (Bakatselou 
et al., 1991; Mithani et al., 1996) 
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1.6.1.1.4 Complexation 
The complexation of drugs with co-solvent materials leads to an increase in drug 
dissolution. The mechanism of forming complexes is due to intermolecular interactions 
such as dipolar and ionic bonds, London dispersion, n-bonding and hydrophobic 
interactions. For example, polyvinylpyrrolidone (PVP) was utilized as a complexing 
agent and it enhanced the solubility and dissolution of a variety of drugs. Different 
theories have been suggested to explain this phenomenon, for example, O'Driscoll and 
Corrigan (19 82) attributed the enhancement in dissolution of chlorothiazide to a soluble 
complex formed with PVP. I-methyl 2-pyrrolidone (NMP) was used as a solubilizing 
agent for itraconazole as it formed a complex with the aromatic ring and halogen groups 
of the drug. An aqueous solution of 8ýtg ml-lof itraconazole was prepared from the 
poorly soluble drug (<O. I [tg ml-1) by adding NMP. Soluble vitamins and amino acids 
also increased the solubility of poorly soluble nucleosides and their derivatives such as 
adenine, guanosine and acyclovir through complex formation (Chen et al., 1994). 
Nicotinamide and caffeine have been demonstrated to solubilize a variety of drugs by 
complexation through 7r donor-7c accepter of the aromatic rings and moreover through 
hydrotropic effects. Lim and Go (2000) found that both agents increased the solubility 
of the aromatic anti-malarial agent halofantrine and caffeine did this to a greater extent. 
This was explained by the degree of aromaticity that affects the solubilizing capacity; 
caffeine has two aromatic rings while the nicotinamide has only one ring. 
Cyclodextrins (CD), as cyclic oligosaccharides, can form non-covalent dynamic 
inclusion complexes by accommodating drug molecules in their core cavities, resulting 
in large increases in solubility. Chemical modification of the CD structure, such as B- 
CD derivatives, resulted in an even greater solubilization capability (Challa et al., 2005). 
Alkylated cyclodextrins such as dimethyl-B-CD were the most efficient in solubilizing 
itraconazole compared to other types of cyclodextrins (Brewster et al., 2007). 
Cyclodextrin's solubilisation properties have been exploited in drug formulations; for 
example 3-hydroxypropyl-CD was used in SporanoxTm (itraconazole) oral and 
parenteral solution (Challa et al., 2005). 
Complexation with co-ingested food has a significant effect on drug dissolution in vivo. 
For instance, milk was found to increase the dissolution of drugs through drug binding 
to milk components (Macheras et al., 1990). 
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1.6.1.2 Surface area 
1.6.1. ZI Particle size 
The dissolution rate is proportional to the surface area of the dissolving solid and since 
the surface area increases with decreasing particle size then the dissolution is 
proportional to I/particle size. Consequently, the smaller the particle, the higher the 
surface area exposed to the dissolution medium (Aulton, 2002). 
This was further evidenced by micronizing particles which led to an obvious increase in 
drug dissolution and bioavailability. For example, metronidazole dissolution increased 
as a result of reducing the size of drug particles (Lauwo, 1985). 
Dispersibility of solids in the dissolving medium affects the active surface area because 
some solid powders of hydrophobic drugs tend to form aggregates during the 
dissolution process. For example, Finholt and Solvang (1968) revealed that although 
reducing the size of solid particles usually increases the dissolution rate, it did not in the 
case of phenacetin in 0. IN HCL This was attributed to the poor wetting properties of the 
medium. By using diluted human gastric juice, which had lower surface tension, the rate 
of dissolution increased with a decrease in particle size. The porosity of solids also 
affects dissolution as more open porous particles will have a greater effective surface 
area exposed to the dissolving medium. Aulton (2002) stated that large pores permit 
fluid to penetrate and allow the diffusion of the solutes to the bulk solution. 
By utilizing IDR methodology, which provides a constant surface area, the effect of 
variability resulting from the size of the particles, the ongoing reduction in particle size 
and porosity effects will be minimised. 
1.6.1.22 Weitability 
The wettability of drug particles by a liquid can be estimated by measuring the contact 
angle which is defined as the angle between a droplet of the liquid and the horizontal 
surface over which it spreads (Figure 1.7). When the contact angle is 0', ideally, the 
drug is completely wetted with the liquid and if the angle is approaching 180* then the 
wetting is negligible. 
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Figure 1.7 Contact angle between a drop of liquid and a solid surface 
S 
The contact angle, 0, is obtained from a balance of interfacial energy between three 
intersections of solid, liquid and gas and is expressed by Young's equation (Eq. (1.17)), 
where 7si, , yi, v and ysv are the sol id-liquid, 
liquid -vapour and solid-vapOLir interfacial 
energies, respectively. 
Cos 0 
ysv - YSI, 
yl, v 
) Eq. (1.17) 
Thus, surfactants enhance the wettability by inducing changes in the surface energy to 
replace solid-vapour interfaces with solid-liquid interfaces. 
Bile salts, which arc believed to exist in the stomach due to rellux, play an important 
role in wetting poorly soluble drugs. Several formulations have been suggested to 
simulate the gastric fluid using synthetic surfactants instead of bile salts, such as Triton 
X-100 (Galia et al., 1999). This nonionic surfactant improved the dissolution of several 
dosage forms of albendazole and this effect was attributed to an enhanced wettability of 
the drug. 
Luner and VanDer Kamp (2001b) assessed the effect of changes to the gastro-intestinal 
environment on the wettability of a model surface of poly (methyl methacrylatc) 
(PMMA). This surface was chosen as representative of a polar low energy surface that 
might behave like a poorly soluble drug. The fluids were formulated to be 
physiological ly-rclevant to the gastric region in the fed and fasting conditions. It was 
found that adding lecithin (0.025mM) to taurodcoxycho late solution (0.1 mM) decreased 
the surface tension from 58mN m-1 to 45mN m-1. However, this decrease in surface 
tension was not reflected in the wettability, as the contact angle for taurodeoxycholate 
yl, v 
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solution (O. ImM) measured 580 and with lecithin added (0.025mM) it was 64*. Fed 
state simulated gastric fluid (FeSSGF), which is richer in bile and phospholipids, had a 
lower surface tension (26mN m"') and induced better wettability compared to the fasting 
fluids. 
Luner and VanDer Kamp (2001 a) also assessed the wettability of fluids that simulate 
the intestinal fluids. The fluids were solutions or dispersions of bile salts and lipids. It 
was reported that wetting was affected by the type and concentration of lipid in the 
micellar phase solutions. For example, adding 5mM monoolein to a micellar solution of 
lOmM of taurodeoxycholate in simulated intestinal fluid (SIF) resulted in a 2P 
decrease in wettability, whilst upon the addition of SmM of lecithin to the same solution 
the contact angle increased by 7". A significant difference in the wetting properties was 
observed also between fluids representing fed and fasting fluids. 
1.6.1.3 Factors affecting diffusivity 
The solubility of a drug depends on temperature; therefore it is very important to keep 
the temperature constant throughout the dissolution process. Temperature is usually 
maintained at 37 ± 0.51C for oral dosage forms. The diffusion of a solute molecule also 
depends on the temperature of the medium. This relationship is expressed by the Stock- 
Einstein equation (Eq. (1.18)) where D is the diffusivity, T is the temperature, q is the 
viscosity, r is the radius of the drug molecule and kb is the Boltzmann constant. 
D= 
kbT 
61rqr 
Eq. (1.18) 
It can be deduced from the Stock-Einstein equation for small particles that viscosity is 
inversely proportional to D and consequently to the dissolution rate. This phenomenon 
is more obvious when the dissolution of the drug is via a diffusion controlled process. 
The effect of viscosity on the dissolution rate is believed to be through increasing the 
thickness of the boundary layer (Aulton, 2002) and decreasing the penetration rate of 
the dissolving fluid into the particles which reduces the wetting (Parojcic et al., 2008). 
The influence of viscosity on dissolution was investigated by Reppas et al. (1998) who 
studied the effect of elevating the viscosity of dissolution media on the behaviour of 
drugs. For example, when guar (2%) was added to normal saline the dissolution rate 
constant decreased by 2- to Mold. Parojcic et al. (2008) used HPMC K4M (0.5-1%) as 
a viscosity enhancing agent and studied the dissolution of paracetamol tablets, where it 
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was found that increasing the viscosity greatly delayed and prolonged the dissolution 
process. 
1.6.1.4 Volume of dissolution media 
The volume of dissolution medium is supposed to be sufficient to maintain sink 
conditions throughout the test. This requires the volume to be at least three times more 
than the saturation volume (USP, 2008). Keeping sink conditions for very poorly 
soluble drugs is difficult, requiring a large volume of liquid. Therefore, different 
approaches were developed, such as continuous flow-through cell apparatus or the 
addition of surfactants to the medium (Abdou, 1989a). 
1.6.1.5 Boundary layer thickness 
The dissolution rate is inversely proportional to the thickness of the boundary layer h 
around the dissolving particles, which depends on the hydrodynamic conditions 
(Levich, 1962). Factors affecting h are degree of agitation, including stiffing speed, 
position and shape of stiffer, shape and dimension of dissolution vessels, the volume 
and viscosity of the dissolution medium (Aulton, 2002). 
1.6.2 Physiological factors 
The physiological conditions of the gastro-intestinal system can have a vital effect on 
the dissolution of drugs. Consequently, these conditions were considered by 
investigators for predicting the dissolution kinetics of drugs in vivo and developing 
physiologically-relevant dissolution media (Mullertz, 2007). 
1.6.2.1 Surface tension of the luminal fluids 
The surface tension of GI fluids is low and it varies within the different GI regions and 
according to fed state. The surface tension of fasting gastric aspirate was reported as 
35-45mN m-1 (Finholt and Solvang, 1968; Efentakis and Dressman, 1998). Kalantzi et 
al. (2006a) measured the surface tension of the liquid in fasted stomach as 
41.9-45niN m" and in the fed state, the values dropped to 3 0-3 1 mN m". The reason for 
this low surface tension is still a controversial issue. It has been attributed to the 
duodenal reflux of the bile salts to the gastric medium although some subjects showed a 
very low level of bile salt (0-ImM) in their gastric fluid (Efentakis and Dressman, 
1998). Therefore, Kalantzi et al. (2006a) suggested that other gastric components such 
22 
as pepsin may affect the surface tension. A 0.1 mg ml" pepsin solution in SGF has low 
surface tension (57mN m") (Vertzoni et al., 2005). 
In the small intestine, the surface tension of fasting duodenal fluid was reported as being 
32.3mN m-1, whereas after having a meal the value dropped to 28.1-28.8mN m" 
(Kalantzi et al., 2006a). This lower surface tension was attributed to the bile 
components. The endogenous surfactants that exist in the small intestinal fluids are bile 
acids, bile salts, phospholipids and cholesterol which are secreted by the bile, and fatty 
acids and monoglycerides produced from lipid digestion. The average bile salt 
concentration in intestinal fluids in fasted state was reported as being 4 to 6mM, while 
in the fed state the concentration is two to four times higher (Rautureau et al., 1981). 
The ratio between bile salts and phospholipid in the fasted conditions is between 2: 1 and 
10: 1 and in the fed conditions it varies from 2: 1 to 5: 1 depending on the phospholipid 
level in the food (Persson et al., 2005; Persson et al., 2006). 
Both bile salts and lecithin play an important role in digesting food and solubilizing 
poorly soluble drugs. Bile may increase the dissolution of poorly soluble drugs by 
enhancing the wettability of the drug and/or by increasing the solubility via micellar 
solubilisation (Charman et al., 1997). Wetting usually occurs when the concentration of 
the bile salts is below the CMC and at higher concentrations; the effect of the micelles 
will be predominant. For example, hydrocortisone dissolution was studied in sodium 
taurocholate (NaTC) solution or a mixture of 4: 1 NATC with lecithin (Naylor et al., 
1993). The bile mixture formed a mixed micellar system which increased the solubility 
of hydrocortisone 2 times compared to the solubility in NaTC alone. Mixing NaTC with 
lecithin reduced the CMC from 4.7 to 0.25mM (25*C) which indicated that the mixed 
micelles had a more effective solubilisation capacity. Consequently, even in the fasted 
state micelles are expected to be formed and so both wetting and solubilisation may 
affect the dissolution of poorly soluble drugs (Pedersen et al., 2000a). Furthermore, 
during lipid digestion lipolytic products, such as fatty acids and monoglycerides are 
produced. These compounds interact with the bile salts and form mixed micelles that 
solubilise lipophilic drugs (Christensen et al., 2004). 
1.6.2.2 pH profile of the gastrointestinal tract 
The pH of the gastric fluid in fasting state is highly variable, pH values were measured 
over a range from I to 7 (Kalantzi et al., 2006a) exhibiting a median value of 1.7 
(Dressman et al., 1990). Efentakis and Dressman (1998) found that these values are 
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usually in the range of pH I to 2. Hydrochloric acid output in a healthy human at fasted 
state is in the range of 0-11 mEq h-1 whereas following ingestion of a meal this output is 
elevated to 10-63mEq If 1 (Barrett, 2006a). Despite this, the gastric pl-I rises to a value 
ranging from 3 to 7 due to the buffering capacity and diluting effect of food and this 
increase depends on the type of the meal. For example, thirty minutes after having a 
meal of Ensure plUSTM the average pH of the aspirated gastric fluid was 6.4 (Kalantzi et 
al., 2006a). The time needed to restore the fasting pH of the stomach depended on the 
ingested meal. Thus, this shows the importance of gastric residence at fasted state for 
weak basic drugs as they are expected to be primarily dissolved in the stomach. For 
example, cimetidine, a I-12-receptor blocker, reduced the amount of ketoconazole 
absorbed by about 60% by elevating the gastric pH (Van Der Meer et al., 1980). In 
general, the gastric medium contributes little to the dissolution of acidic drugs. 
The intestinal pH is normally within the range of 4.9 to 8, but there is a pH gradient in 
the intestinal regions. This higher pH compared to the gastric fluid is due to 
neutralization of the received gastric fluid by carbonate ions that are secreted by the 
pancreas (Barrett, 2006a). The median duodenum pH at the fast state measured 6.2 and 
120min following food ingestion the pH had dropped to 5.2 (Kalantzi et al., 2006a). 
Buffer capacity of the dissolving medium mainly affects the pH of the boundary layer 
adjacent to the drug particle surface and consequently the C, of the ionisable drug. The 
dominant buffer species in human body fluids, including the gastrointestinal fluids, are 
bicarbonates (Boni et al., 2007). 
1.6.2.3 Viscosity of the luminal fluid 
The viscosity of the lurninal fluids can influence the dissolution by affecting the 
diffusivity of the dissolving drug. The viscosity of the luminal contents can be altered 
by administering food that contains soluble polymers or water soluble fibres such as 
guar gum, that usually work as regulators for bowel movement, or by giving a 
suspension of a dosage form that contains thickeners (Reppas et al., 1998). 
1.6.2.4 Hydrodynamic patterns 
The motility of the GIT affects the dissolution of drugs, mainly by affecting boundary 
layer thickness. Hence a brief introduction is provided herein outlining the motility in 
the proximal GIT. Between meals, the motility undergoes a cyclic motor pattern, known 
as the migrating motor complex (MMC). Phase I is characterized as quiescent (not 
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active), it lasts about 40min. Then, activity recommences by a gradual increase in 
contractions (phase 11), which reaches a peak of intense contractions (phase 111) that 
lasts only 10min. Phase III allows clearing of the remaining gastric contents to the 
intestine, and thereafter the initial conditions of phase I quiescence is returned. This 
whole cycle takes from 90 to 120min. After having a meal, motility events switch to the 
fed patterns of intermittent phasic contractions in the small intestine and the distal 
stomach accompanied by a tonic relaxation in the proximal stomach (Barrett, 2006b). 
The absorption of a dosage form is affected by the motor pattern and meal ingestion. By 
analyzing the MMC stages, the first phase allows drug to dissolve since it is the longest, 
however if fluid is stagnant an increase in the boundary layer (h) occurs. In contrast, 
contractions at phase III reduce h but with a very short resident time which does not 
allow significant drug dissolution, and at phase 11 dissolution is expected to be 
intermediate (Horter and Dressman, 2001). 
1.6.2.5 Gastric emptying time 
Most drugs are not absorbed from the stomach, which serves as a reservoir, but from the 
intestine whose anatomical structure and mucosa means it serves as the main site for 
absorption. Consequently, delayed gastric emptying will delay the absorption of drugs 
that are absorbed mainly in the small intestine. However, for drugs which are poorly 
soluble in the gastric environment, longer residence in the stomach might increase 
bioavailability by dissolving more before passing to the absorption site in the intestinal 
region. 
The time needed for gastric emptying is highly variable and can take from a few 
minutes up to 3h, depending on the dietary conditions including the type, volume of the 
meal and the conformation of the dosage form. Gastric emptying is usually faster at the 
fasting state than at the fed state. The size of the solid dosage particles affects their 
emptying time whereby undissolved particles with a diameter less than 0.4mm. take 
34-57min and particles bigger than 10mm can take up to 6 hours (Hunter et al., 1982). 
Emptying of drug solutions from the stomach exhibits a rapid pattern that is relatively 
unaffected by food digestion state (Davis et al., 1986). 
1.6.2.6 Effect of Food 
The effect of food on drug dissolution and absorption can be through physicochemical 
interactions or physiological changes. For instance, it was reported that a protein- 
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containing meal elevated the gastric pH due to the high buffering capacity of protein 
which led to a reduction in the absorption of the basic drug, indinavir (Carver et al., 
1999). 
Complexation and chelating interactions can occur with metal ions present in a meal 
such as the chelating of tetracycline with calcium in milk which led to limited 
absorption of the drug due to formation of insoluble complexes (Sweetman, 2009b). 
Food affects the physiology by delaying gastric emptying, stimulating intestinal motility 
and elevating pancreatic and bile secretions, digestive enzymes and blood flow (Fleisher 
et al., 1999). These complex responses to food ingestion can increase or decrease 
absorption, which makes it difficult to predict the likely overall effect of food on 
systematic bioavailability (Charman et al., 1997). For example, itraconazole, which is a 
highly lipophilic drug, exhibited a marked increase in bioavailability when taken with 
food. This was attributed to an increase in drug solubility and solubilization and a 
longer gastric residence time. No significant effect was seen when fluconazole was co- 
administered with food which was postulated to be due to its hydrophilic character and 
weak lipophilicity (Van Peer et al., 1989). 
1.6.2.7 Volume of fluid 
The volume of the liquid in which the dosage form can dissolve depends on the fluid co- 
administrated with the dosage form and on the secretions output from the GI system. 
The volume of fluid in the gastric medium is 15-20ml at fasting conditions and 
depending on the intake volume, this can increase up to 1.5L (Horter and Dressman, 
2001). 
1.6.2.8 Permeability of gut wall 
The permeability of the intestinal mucosa can be an indirect factor that affects drug 
dissolution, since the driving force for dissolution is the gradient of solubility and the 
concentration of drug in solution. Hence, drugs with high permeability are expected to 
have a constant low concentration in intestinal fluids (Ct) due to absorption which leads 
to more dissolution (Dressman and Reppas, 2000). The permeability is mainly governed 
by the chemical structure of a drug and in particular its lipophilicity expressed by the 
octanol-water partition coefficient (log P) (Martinez et al., 2002). 
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1.7 Biopharmaceutics Classification System (BCS) 
1.7.1 BCS concept 
In 1995, Amidon et al. (1995) introduced the Biopharmaceutics Classification System 
(BCS) framework, and five years later the FDA's centre for Drug Evolution and 
Research (CDER) adopted this system. The BCS takes into account three major factors 
that govern the rate and extent of drug absorption from immediate release solid oral 
dosage forms (IR): dissolution, solubility and intestinal permeability. Drugs were 
categorized by this system according to their solubility as related to dose, and 
permeability into four classes: 
Class 1: High solubility-high permeability. 
Class II: Low solubility-high permeability. 
Class III: High solubility-low permeability. 
Class IV: Low solubility-low permeability. 
BCS guidelines (FDA, 2000) defined the terms of high solubility, permeability and 
rapid dissolving as follows: 
"A drug substance is considered highly soluble when the highest dose strength is 
soluble in: 5 250ml water over a pH range I to 7.5. " 
"A drug substance is considered highly permeable when the extent of absorption in 
humans is determined to be ý: 90% of an administered dose, based on mass-balance or in 
comparison to an intravenous reference dose. " 
"A drug product is considered to be rapidly dissolving when > 85% of the labelled 
amount of drug substance dissolves within 30 minutes using USP apparatus I or 11 in a 
volume of < 900 ml buffer solutions. " 
Therefore, to find out whether a drug is highly soluble or not according to those 
definitions, the dose is divided by the solubility to provide the dose: solubility ratio (ml) 
and then compared to the FDA criterion for a highly soluble drug, which is 250ml. The 
solubility test is recommended to be performed by either the shake-flask method or acid 
or base titration methods. 
Since the bioavailability (BA) and bioequivalence (BE) of drug products have an 
important role in drug development and post approval changes, the FDA included 
definitions for those two terms. BA is defined as "The rate and extent to which the 
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active ingredient or active moiety is absorbed from a drug product and becomes 
available at the site of action" (FDA, 2003). 
Two pharmaceutical products were considered bioequivalent if they exhibited 
comparable rates and extents of absorption when given at the same molar dose under 
same conditions. 
The aim of the BCS is to utilize the dissolution test as a prognostic tool for drug 
behaviour in vivo which may then be able to replace certain BE studies. So if two drug 
products exhibit the same dissolution profiles under all luminal conditions then it is 
likely that they are bioequivalent. 
For high solubility-high permeability compounds (Class 1) which are formulated in 
immediate release solid oral dosage forms and exhibit rapid dissolution in vitro, the BE 
clinical studies may be replaced by dissolution data under certain conditions (FDA, 
2003). These conditions are; drug stability in the GIT, drug does not have a narrow 
margin of therapeutic index and the formulation does not contain any excipients that 
affect drug absorption. Furthermore, this biowaiver does not include drugs designed to 
be absorbed in the oral cavity. For some cases, considering the in vitro dissolution test 
as a replacement for in vivo studies would decrease the cost and time of clinical studies 
and reduce the unnecessary administration of drugs to healthy human volunteers. 
Research studies were carried out after the inception of this system to classify drugs 
according to the BCS criteria. For example Lindenberg et al. (2004), classified 61 drugs 
from the essential medicines listed by the world health organization (WHO) based on 
data available from literature. Monographs of acetaminophen reported the drug as a 
Class III compound (Kalantzi et al., 2006c) and prednisolone as a Class I (Vogt et al., 
2007). 
Yu et al. (2004) suggested using the IDR instead of solubility to classify drugs since the 
IDR expresses the kinetics of the solubility rather than the equilibrium. Therefore, it 
was believed that IDR might correlate better with the in vivo dissolution. The IDR of a 
set of drugs classified in the BCS were determined and a good relationship between the 
IDR and BCS classification was found where a value of Ming min" cm -2 was 
considered as a class boundary, taking into consideration the dose of the drug was not 
extremely high or low. 
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1.8 In vitro-in vivo correlation (IVIVC) 
In vitro-in vivo correlation relates the in vitro dissolution of the drug with the in vivo 
pharmacokinetic data. Considering the BCS, an IVIVC is unlikely to occur with Class I 
drugs. High solubility means drug is dissolved in gastric media and waiting gastric 
emptying to be transferred to the intestine. Since the gastric site is not the main site for 
absorption then gastric emptying, which is not represented in the dissolution process, is 
the rate-limiting step for absorption rather than dissolution (Lennernas and 
Abrahamsson, 2005). Whereas with Class Il drugs, IVIVC is likely since poor 
dissolution is the rate-limiting step for absorption. Class III correlation is also unlikely 
since the dissolution is high so dissolution is not the rate-limiting step, in fact it is the 
barrier properties of the GI which are controlling the absorption. With class IV drugs 
where both dissolution and permeability are limited, correlation is not expected (Gray et 
al., 2009). 
There are two cases mentioned in the literature where IVIVC may not be achieved with 
Class 11 drugs (Lennernas and Abrahamsson, 2005). Firstly, when poor soluble drugs 
are manipulated in formulations that make them soluble, the drug would fall under the 
characteristics of Class I drugs instead. Thus, it was suggested to create an intermediate 
category, called intermediate Class 11. Secondly, there are some cases where the 
saturation solubility and not the dissolution rate will be rate-limiting for drug absorption 
so the concentration of drug in the GI will be close to the saturation solubility. 
However, the in vitro standard dissolution test does not consider reaching the saturation 
solubility since it requires testing in non-sink conditions, which does not always prevail 
in the GI system. Drugs with extremely poor solubility could be examples for this case. 
Thus, more physiologically relevant media might improve IVIVC even though sink 
conditions are not maintained. 
Dressman et al. (1998) confirmed the importance of the dissolution test as a predictive 
tool of absorption for all four BCS categories and accordingly recommended well- 
designed dissolution experiments where conditions simulate the GIT environment as 
closely as possible. For example, for Class Il drugs dissolution is the limiting-factor for 
absorption for two reasons. Firstly, equilibrium considerations, where the fluid volumes 
are not enough to dissolve the dosage form. Secondly, kinetic considerations, because 
the time the dosage form spends before reaching its absorption window is not long 
enough for complete dissolution. Thus, this showed the importance of gaining 
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information regarding the dissolution in simulating conditions to establish meaningful 
IvivC. 
1.9 Biorelevant dissolution media 
The dissolution media recommended by the pharmacopoeias are simple aqueous buffer 
systems, composed mainly of hydrochloric acid or phosphate buffer with or without 
enzymes (Table 1.1). The pharmacopoeias aim to achieve quality control by using 
simple media, which are easy to prepare and standardize and, moreover, with low costs. 
However, the dissolution test is supposed to evaluate the behaviour of dosage forms in 
vivo and consequently the dissolution media used should reflect the composition of the 
fluids encountered in the GI tract, especially when the test is used for developmental 
purposes. 
Table 1.1 Examples of dissolution media recommended by the BP (2008) 
pH Dissolution media 
pH 1.0 OAM HCI 
pH 1.2 0.05M NaCl, 0.085M HCI 
pH 1.5 0.05M NaCl, 0.041M HCI 
pH 5.5 
0.2M Phosphate buffer or 
0.05M acetate buffer 
pH 6.8 0.2M Phosphate buffer 
pH 7.5 0.33M Phosphate buffer 
One of the early studies that formulated artificial gastric juice (Filleborn, 1948) to assess 
tablet disintegration took into consideration the conditions prevailing in the empty 
stomach and in fed conditions, such as pH, peristalsis, presence of pepsin and gastric 
mucin. Thereafter, efforts have been employed in this direction to develop more 
biorelevant dissolution media. This section gives examples of research studies 
developing media simulating GIT fluids and investigating their effect on drug 
dissolution. 
1.9.1 Gastric simulated media 
1.9.1.1 Simulated fasting gastric fluids 
The composition of simulated gastric fluid (SGF) in the USP (2008) and BP (2008) is 
hydrochloric acid, sodium chloride and it may contain pepsin. However, the gastric 
medium has a lower surface tension (41.9 to 45.7mN m") (Kalantzi et al., 2006a). 
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Therefore, to mimic the surface tension inside the stomach, surfactants were added to 
reduce the surface tension such as SDS (0.25%) (Dressman et al., 1998) and Triton X- 
100 (0.1%) in SGF (Galia et al., 1999). However, media with synthetic surfactants may 
lead to overestimation of the solubility of drugs (Pedersen et al., 2000b). Consequently, 
a formulation containing relevant physiological components was developed: NaTC 
(80gM), lecithin (20gM) and pepsin (0.1mg ml-) in SGF pH 1.6 (Vertzoni et al., 2005). 
Thereafter, it was suggested to perform the dissolution in two media; simple medium of 
HCI (pH 1.6) and the aforementioned physiologically-relevant medium and then 
combine the obtained data to achieve good simulation for drug performance in gastric 
fluid (Vertzoni et al., 2007). 
1.9.1.2 Simulated fed gastric fluids 
The composition of the gastric fluid at postprandial conditions is very variable 
according to the nature of the meal and the time after food ingestion. Initially, the 
composition of the stomach is similar to the composition of the ingested meal in terms 
of pH, surface tension and osmolality. However when the stomach starts the digestion 
process by the secretion of gastric juices followed by gastric emptying, the fasted state 
will be re-established (Kalantzi et al., 2006a; Mullertz, 2007). Therefore, to tackle the 
problem of variability of the gastric composition in fed conditions, some media were 
suggested to standardize simulated stomach fluids in fed conditions. 
1.9. ]. Zl Milk 
The use of milk as a biorelevant medium was suggested since it is a type of nutrient that 
contains the three basic components of fat, protein and carbohydrates in a ratio 
resembling the ratio in a typical diet (Drcssman et al., 1998). Macheras et al. (1990) 
found that the solubility of a range of drugs increased in milk compared to in phosphate 
buffer, pH 6.5 and this increase was proportional to drug lipophilicity, fat content and 
temperature. The solubility of diazepam, a highly lipophilic drug, increased 7 times in 
low fat milk (0.75%) and 14 times in high fat milk (3.5%) compared to the buffer at 
37'C. The solubility of hydrochlorothiazide and chlorothiazide also increased in milk 
compared to the buffer; however, the greatest increase was recorded in skimmed milk 
(fat content less than 0.1 O/o) (Macheras et al., 1989). It was demonstrated that drug 
entities had the ability to bind milk constituents and this binding increased when milk 
had a high fat content (Macheras et al., 1986). Furthermore, binding was independent of 
drug concentration which suggested that the drug binding was non-specific. Binding 
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was correlated to the lipophilicity of the drugs where a linear relationship was found 
between log P and log (bound drug / free drug). Although binding to milk components 
and solubilisation into casein micelles affected the solubility of drugs, this solubilising 
effect was attributed to the entire complex structure of milk (Macheras et al., 1989). 
The dissolution of dosage forms in milk was investigated, for instance, the dissolution 
of mefenamic acid capsules increased in milk. This was explained by the effect of lipids 
in milk since this drug is highly lipophilic and moreover the effect of the milk pH (6-6) 
helped to dissolve the acidic drug (Galia et al., 1998). 
The dissolution of BCS Class I drugs such as paracetamol decreased in milk whereas a 
significant increase was recorded with class 11 drugs such as danazol capsules (Galia et 
al., 1998). The same observations were reported by Nicolaides et al. (1999) where the 
dissolution of the investigated Class II dugs such as atovaquone tablets increased in 
milk compared to water or SIF without enzymes. However, Macheras et al. (1989) 
reported that low fat milk increased the dissolution of Class I drugs represented by 
theophylline in controlled release dosage forms. 
It is worthy of note that milk may interfere with the disintegration process of dosage 
forms. The disintegration time of tested tablets was extended by more than five times in 
milk media compared to simulated gastric media at fasting state. This was attributed to 
the physical characteristics of milk such as high viscosity and low surface tension, 
which led to slow penetration of the fluid into tablets (Anwar et al., 2005). 
Recently, Jantratid et al. (2008b) noticed that gastric post-prandial conditions could be 
represented by the stages of food digestion in the stomach. Subsequently, three 
compositions of simulated media were developed: early medium (pH 6.4) composed of 
milk with NaCl, middle medium (pH 5) composed of milk-acetate buffer (1: 1) and late 
medium (pH 3) composed of milk-phosphate buffer (3: 1). For practical interest, the 
solution that represented the middle stage was suggested as a global medium to reflect 
the composition of FeSSGF. 
Although milk was considered a representative physiologically-relevant medium, in 
particular for the starting point of digestion (Dressman et al., 2007), drawbacks were 
observed with the use of milk as a standard medium where the variability in 
composition from region to region or even throughout the year led to difficulty in 
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standardisation (Klein et al., 2004). Furthermore it has a relatively high pH (6.7) which 
is unrepresentative of the fed gastric state. 
IALZ2 Homogenised breakfast 
Klein et al. (2004) discussed the possibility of using homogenised standard breakfasts as 
biorelevant media. The preparation of these mixtures was a difficult, time-consuming 
process and the composition of standard breakfasts varied among regions. Table 1.2 
shows the composition of one of the standard breakfasts used in that investigation. 
Table 1.2 Composition of a standard breakfast meal, from Klein et al. (2004) 
Composition of standard breakfast meal 
2 Slices of toasted white bread with butter 
2 Eggs fried in butter 
2 Slices of bacon 
2 Ounces of hash browned potatoes 
8 Ounces of whole milk 
Carbohydrate 58g, 232kcal, 24% of calories 
Protein 33g, 132kcal, 14% of calories 
Fat 67g, 603 kcal, 62% of calories 
1.9. ]. Z3 Protein 
Dissolution was investigated in media containing albumin or casein; these proteins were 
chosen to simulate the possible effects of food proteins on drug dissolution. Human 
serum albumin affected the dissolution of drugs through drug binding and casein 
exerted a solubilising effect through the formation of aggregates. For example, the 
dissolution of phenytoin powder increased in the presence of both proteins (Rosen and 
Macheras, 1984). 
Drug solubility increased proportionally to albumin concentration. While in casein 
solutions, the increase in solubility was slow with low concentrations of casein until the 
concentration of the protein exceeded a certain point then a more significant increase in 
drug solubilisation was observed (Macheras and Reppas, 1986). Although both proteins 
affected drug solubility positively, the dissolution rate of dicoumarol was decreased. 
This delay in dissolution was attributed to protein increasing the interfacial barrier and 
formation of a drug-protein complex whose diffusivity was slower than the free drug 
(Macheras and Reppas, 1987). 
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Imai et al. (1989b) noticed that egg albumin increased the solubility of several drugs 
with a more pronounced effect on acidic drugs. For example, the solubility of 
flurbiprofen (acidic drug) in a 0.1% egg albumin solution at 20'C increased 3.2 times 
while the solubility of pindolol (basic drug) increased 1.2 times. The mechanism of this 
increase in solubility was attributed to albumin-drug interactions where two binding 
sites in albumin were found (Imai et al., 1991). The solubility of cc-tocopherol increased 
300-fold in the presence of 0,2% egg albumin at 37'C (Imai et al., 1997). 
The effect of gelatin on drug solubility was investigated because firstly, gelatin as a 
natural polymer was considered a candidate drug carrier and secondly the 
bioavailability of digoxin increased when administrated in gelatin soft capsules 
compared to tablets. This raised the question of whether gelatin was increasing the 
solubility of the drug (Johnson et al., 1986). Gelatin increased the solubility of a range 
of drugs which was explained by the ability of gelatin to enhance the wettability of the 
drug. The maximum increase was recorded with lipophilic and poorly water-soluble 
drugs (Kallinteri and Antimisiaris, 2001). The solubility of the acidic drugs was greater 
when the drugs were not ionised, for example, the solubility of nitrofurantion in 0.5% 
gelatin-containing solution increased by 85% at pH 3.7 and increased only by 15% at 
pH 7. Acarturk et al. (1992) reported that gelatin and egg albumin did not induce a 
marked increase on the solubility of nifedipine. It was previously noticed that the 
solubility of basic drugs was enhanced in 0.0075% gelatin solution but acidic drugs 
were unaffected (Imai et al., 1989a). 
1.9. ]. Z4 Nutrional liquids 
IntralipidTm, NutridrinkTm and NutrisonTm emulsions are artificial nutritional substitutes 
with the same basic composition of purified soya oil, egg phospholipids and glycerol 
and a final pH of 7-8. Ashby et al. (1989) suggested utilizing diluted IntralipidTm 
emulsions to simulate fed gastric fluid since it could be a better standardized solution 
compared to milk or homogenized meals. It was noted that the release profiles of 
tetracycline tablets were altered in IntraliPidTm compared to a solution of HCI (Buckton 
et al., 1989). Junginger et al. (1990) employed NutridrinkTm as a dissolution medium 
and noticed that a decline in the release of theophylline occurred. This was attributed to 
food particles being adsorbed onto the surface of the dosage form preventing the release 
of the drug from the carrier. Abrahamsson et al. (2004) examined the effect of a diluted 
nutritional drink (NutrisonTm) on the disintegration process. Tablet disintegration was 
delayed in the test medium compared to a simple buffer, which was elucidated by a 
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precipitation of components, in particular proteins, that formed a film on the surface of 
tablets. 
Another suggestion for simulating the fed stomach was to use the nutritional drink 
Ensure plUSTM. Klein et al. (2004) noticed that this drink resembled the composition of a 
typical western diet and matched the physiochemical parameters of homogenized 
breakfast when it was mixed with a viscosity enhancer (0.45% pectin). A mixture of 
EnsureTM with buffer or HCI was found to alter the dissolution of theophylline and 
tetracycline dosage forms (Ashby et al., 1989; Buckton et al., 1989) 
1.9. LZ5 Fat 
To mimic a high fat meal, the contents of propranolol capsules were pre-treated with 
peanut oil prior to dissolution which resulted in a decrease in dissolution rate of the 
dosage forms (EI-Arini et al., 1989). Fatty media containing 10% peanut oil were 
utilized to study the dissolution of theophylline controlled release forraulations which 
induced variable effects on the dissolution (EI-Arini et al., 1990). 
1.9.2 Simulated intestinal fluids 
Based on the composition and the physiochemical parameters of the intestinal fluids 
including pH, buffer capacity, surface tension and osmolality, simulated intestinal fluids 
were developed. Two formulae representing fast and fed states were published in the 
International Pharmaceutical Federation (FIP) guidelines (Aiache et al., 1997). 
Thereafter, simulated intestinal fluid in fasting (FaSSIF) and fed states (FeSSIF) were 
further developed (Galia et al., 1998). These media were employed in studying the 
dissolution of dosage forms of Class I drugs, such as acetaminophen and metoprolol 
which did not show a significant difference in their dissolution rate compared to that in 
water. The dissolution of Class II drugs increased in the biorelevant media. For instance, 
dissolution of danazole (Class II) capsules increased 30-fold in FaSSIF and 100-fold in 
FeSSIF, compared to water or SIF. Nicolaides el al. (1999) investigated the dissolution 
of weak acid and non-ionisable lipophilic compounds from BCS Class IL An increase in 
dissolution rate due to the presence of bile salts/lecithin was observed. Good agreements 
were revealed between the in vitro dissolution of the dosage forms and their 
bioavailability at pre- and postprandial conditions. Kostewicz et al. (2002) evaluated the 
dissolution of four poorly soluble basic drugs in these media and found good correlation 
between the dissolution and bioavailability in both fed and fast states. 
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The possibility of using FaSSIF and FeSSIF to forecast the in vivo behaviour of drugs 
was further demonstrated in several studies (Dressman and Reppas, 2000; Dinora et al., 
2005). Wei and Lobenberg (2006) could predict the bioavailability parameters of 
glyburide (Class 11) based on drug dissolution in FaSSIF combined with permeability 
measurements. 
Some modifications to FaSSIF and FeSSIF were considered in order to develop media 
to achieve better IVIVC. Potassium cations were replaced by sodium ions to better 
simulate the physiology, this substitution did not affect the dissolution of the tested 
dosage forms (Vertzoni et al., 2004). Furthermore, the replacement of the expensive 
pure bile salts with cheaper mixtures of crude sodium taurocholate from ox bile and 
lecithin with partially hydrolysed Soybean phosphatidyl choline was suggested 
(Vertzoni et al., 2004). In some cases, such as ketoconazole, where the drug was highly 
lipophilic, using crude bile salts produced profiles more similar to the in vivo 
performance. Nevertheless it was difficult to standardize the crude bile salts due to 
batch to batch variation and the presence of other substances that may indirectly affect 
dissolution. The type of fatty acid affected only the dissolution of highly lipophilic 
compounds, which suggested the possibility of substituting the lecithin with partially 
hydrolysed phosphatidy1choline in the simulated fluids. The use of the crude products 
was also advised by Sunesen et al. (2005) but assaying the bile salt components was 
essential prior to their use in the dissolution media. 
It is important to note that most of the developed simulated intestinal formulations used 
phosphate buffer due to its buffer stability, even though this buffer does not exist in 
natural fluids (Dressman and Reppas, 2000). Bicarbonate buffer is the predominant 
buffer in the upper GI in fasting conditions; however, its use is impractical because it 
has to be freshly prepared, has poor stability and requires a constant Supply Of C02 to 
the dissolution medium. Boni et al. (2007) reported that bicarbonate buffer caused a 
problem with reproducibility of drug release because bubble formation caused 
variations due to mechanical stress and a change in pH. Furthermore, when bicarbonate 
buffer was employed in FaSSIF and FeSSIF, problems of extreme foaming of the 
dissolution media made the use of this buffer impossible. 
Vertzoni et al. (2004) demonstrated that the type of the buffer used in the biorelevant 
medium can affect the dissolution of basic drugs with pKa >5 and extremely lipophilic 
compounds. Moreover, the buffer type may affect the stability of the compounds. It was 
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found that hydrolytic and oxidative reactions were decreased when replacing acetate by 
citrate buffer in FeSSIF. 
Using aspirated human intestinal fluid (HIF) as a natural medium could produce the best 
IVIVC but it is not easily available (Dressman et al., 2007). Therefore, canine intestinal 
medium was studied as an alternative natural fluid. In general, the solubility and 
dissolution in canine fluids did not show good correlation with that in human fluids due 
to the higher bile salt and phospholipid contents in canine fluids (Vertzoni et al., 2007). 
Nevertheless, Persson et al. (2005) found good correlation in respect to solubility and 
intrinsic drug dissolution between fed dog intestinal fluid (DIF) and fed HIF but only 
when subjects were given small meals. Kalantzi et al. (2006b) demonstrated DIF was a 
good surrogate to HIF at fasting conditions with regard to the solubility of two basic 
drugs, dipyridamole and ketoconazole. 
The lack of ingested lipids which originate from lipid digestion in FeSSIF may lead to 
underestimation of dissolution for highly lipophilic drugs (Nicolaides et al., 1999). 
Therefore, fatty acids and monoglycerides were added to FeSSIF to better mimic the 
intestinal fluid (Sunesen et al., 2005) which in turn led to better IVIVC for danazole 
dosage forms compared to FeSSIF. Furthermore, FeSSIF was found to include greater 
amount of bile salts than the human aspirate fluid (Kalantzi et al., 2006b). 
A recent study updated the composition of FeSSIF with the aim to better mimic the 
intestinal fluid at fed state (Jantratid et al., 2008b). Three media were developed to 
reflect changes in the luminal fluids according to the phases of digestion; early, middle 
and late. Thereafter, a new version of FeSSIF, (pH 5.8) containing monoolein and oleic 
acid in addition to bile salts and phospholipids, was recommended as a standard 
simulated intestinal medium for the general assessment of drug dissolution. 
1.10 Azole anti-fungal drugs 
1.10.1 Introduction 
Azole anti-fungal drugs are used in the treatment of a variety of fungal infections. They 
have a fungistatic effect when taken in low concentrations and are fungicidal at higher 
concentrations. A weakly basic imidazole or 1,2,4 triazole moiety substituted at N-1 
with a lipophilic root are essential for the antifungal activity of this group. These 
compounds usually contain five or six membered rings (Thomas, 2000). 
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Ketoconazole was synthesized in 1977 and it possessed a broad spectrum of antifungal 
activity (Frointling, 1988). Thereafter, there was the introduction of the first-generation 
of triazoles, such as itraconazole and fluconazole, which represented a more advanced 
fungal treatment and showed promise as systemic antifungal drugs. In general, the 
triazole compounds exhibited greater potency and less toxicity than the imidazole- 
derivatives. Subsequently, a second-generation of triazoles was developed, to overcome 
problems raised with first generation such as pathogenic resistance. 
Itraconazole and ketoconazole were chosen from the azole antifungal family for the 
present investigation due to their poor water-solubility and good permeability which 
make them BCS Class II drugs (Six et al., 2004). Moreover, they are widely used 
antifungal agents, available for oral administration and, most importantly, their 
bioavailability is food-correlated. Itraconazole previously showed variability in the 
absorption and plasma drug concentrations when taken as capsules which was 
problematic for systematic application (Boogaerts and Maertens, 2001). 
Itraconazole may be given orally or intravenously. It is marketed in the UK as either 
capsules containing 100mg of itraconazolc coated on sugar spheres or as a 10mg ml'l 
oral solution in 40% hydroxypropyl-o-CD. The drug is dosed as 100-400mg and 200mg 
via the oral and parcnteral routes, respectively. Ketoconazolc is available as tablets 
(200mg) and a topical agent (2% cream) with a maximum dose of 7.5mg kg' via the 
oral route (Sweetman, 2009a). 
Although fluconazole and miconazole are widely used azole antifungal agents, they 
were not suitable candidates for the present study. Fluconazole is classified as class I 
because of its high water solubility (8mg ml-1 at 37'C) and good permeability 
(Lindenberg et al., 2004). Its rate and extent of GI absorption are not affected by food or 
changes in the GI environment (Zimmermann et al., 1994). Miconazole, an example of 
an imidazole anti-fungal compound, is slightly soluble in water (I gg ml" at 37C) and 
classified as class 11. Although it is a highly lipophilic compound, it is incompletely 
absorbed after oral administration as the solubility to dose ratio is small (Zhao et al., 
2002) so it is primarily used topically. The main purpose of the study was investigating 
the effect of GI-relevant media on solubility and dissolution of poorly soluble drugs and 
hence miconazole was not a candidate for this study. 
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1.10.2 Physicochemical properties 
Itraconazole 
Itraconazole has the molecular formula C35H38Cl2N804 (Figure 1.8) with a molecular 
weight of 706. It can be characterized as a highly lipophilic compound and a very 
poorly soluble, weak base. Its pKa is 3.6 with an octanol-aqueous buffer (pH 6) 
partition coefficient (log P) >5 and a melting range of 165-169 1C. It is insoluble in 
water, very slightly soluble in alcohols and freely soluble in dichloromethane 
(Sweetman, 2009a). 
Itraconazole is composed of two triazole rings, piperazin, dioxolan, dichlorophenyl and 
two phenyl rings. Four of the nitrogens are potentially ionisable (Peeters et al., 2002). 
As postulated from proton and carbon nuclear magnetic resonance (NMR) analysis of 
itraconazole (dissolved in deuterated chloroform, methanol and water), by adding one 
equivalent of deuterated hydrochloric acid to itraconazole, the nitrogen N26 of the 
piperazine ring (Figure 1.8) was ionised proving that this nitrogen has the highest proton 
affinity. By adding another equivalent of acid, the nitrogen Nil in the triazole ring was 
protonated. Then an excess of the acid was added which resulted in the ionisation of the 
entire triazole ring. Peeters et al. (2002) calculated the pKa values of these groups and 
determined that pKa =4 was associated with the protonation at N26 of the piperazine 
ring. An estimated value of 1.5-2 was assigned to the ionisation constant of Nil in the 
triazole ring. The other two ionisation constants were assigned to Ng and N13 in the 
triazole ring and they are only ionised at very low pH < 2. Consequently, itraconazole is 
only fully ionised under very acidic conditions such as that of gastric fluid in fasting 
conditions. 
CH3 C) 
HSC'ýýN'A 
IN 
N/ 
Figure 1.8 Chemical structure of itraconazole: 4-[4-14-[4-[Icis-2-(2,4-dichlorophenyl)-2-(lH-1,2,4- 
triazol-1-ylmcthyl)- 1,3-d ioxolan-4-yi] methoxyl phenyll piperazin- I -yll phenyll-2-1(1 RS)- I- 
mcthylpropyl]-2,4- dihydro-3H-1,2,4-triazol-3-one 
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1.10.2.2 KetoconazoIe 
Ketoconazole has the molecular formula C26H28C12N404 (Figure 1.9) and a molecular 
weight of 531. It is practically insoluble in water and freely soluble in methanol and 
diluted hydrochloric acid (Sweetman, 2009a). Its melting point is 146*C and log P is 
3.73. 
The drug is a weak dibasic compound as its structure presents two basic groups, a 
piperazine ring and an imidazole ring, with pKa values of 2.94 and 6.5 1, respectively. 
Thus, there are two basic centres for protonation in ketoconazole structure, N26 of the 
piperazine ring and N, I of the imidazole ring. 
The percentage of protonation on the piperazine ring mostly determines drug solubility 
and the in vitro antimicotic activity of the drug (Minagawa et al., 1983). Thus, at pH = 
pKa2= 6.5, the imidazole ring will be 50% ionised while the piperazine ring will be 
virtually unionised. At pH = pKal =3 all the imidazole ring and 50% of the piperazine 
ring will be ionised under acidic conditions. By further acidifying the medium both 
rings will be fully protonated which explains the importance of an acidic gastric 
environment to dissolve the drug. 
9N 
ci 
Figure 1.9 Chemical structure of ketoconazole: 1-acetyl-4-[4-[[(2RS, 4SR)-2-(2,4-dichlorophenyl)-2- 
(IH-imidazol-1-ylmethyl)-l, 3-dioxolan-4 yllmethoxylphenyllpiperazine 
Ketoconazole is not as poorly soluble as itraconazole; however, both compounds exhibit 
strong pH dependent solubility. Due to the poor solubility and good absorption of both 
drugs, they are classified in the BCS as class II drugs (Amidon et al., 1995). The poor 
solubility of the drugs, which is insufficient for the whole dose to be dissolved in the 
gastro-intestinal fluid under normal conditions means the drugs have dissolution-limited 
oral absorption. 
1.10.3 Mechanism of action 
Both categories of the azole drugs, imidazole and triazoles, have the same mechanism 
of action inhibiting the biosynthesis of ergosterol, a major component of the cell 
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membrane of yeast and fungal cells. The free azole nitrogens (position II of imidazole 
and position II of triazole ring) are believed to be the active sites. These nitrogens 
compete for oxygen at the catalytic haern iron atom of cytochrome P-450 enzymes, 
thereby blocking the action of this enzyme (Saag and Dismukes, 1988). Itraconazole has 
a broader spectrum of antifungal activity, more effective and better tolerated than 
ketoconazole. This is due to a higher affinity for fungal cytochrome P-450 than 
ketoconazole, but a low affinity for mammalian cytochrome P-450, and because its 
main metabolite (hydroxy-itraconazole) has also considerable antifungal activity. 
1.10.4 Pharmacokinetics 
Both drugs are highly protein bound (ý! 99%) and widely distributed in the body 
(Hoesley and Dismukes, 1997). The schematic diagram in Figure 1.10 displays the 
pharmacokinetics of itraconazole administered orally. Dissolution takes place in the 
stomach and subsequently the drug is absorbed in the intestine and passes into the blood 
stream. The drug is extensively metabolized in the liver producing a large number of 
different metabolites, the major active metabolite being hydroxyl-itraconazole (De 
Beule, 1996). 
pharmacological 
effect 
Small bowel 
pH 5-7 
faeces 
CYP 3A4 
I 
adive 
metaboli(e 
Hepatic metabolism 
dearance 
Figure 1.10 Dissolution, absorption and metabolism of itraconazole, from Lewis (2002) 
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1.10.4.1 The effect of gastric acidity on bioavailability 
The absorption of itraconazole under fasted conditions is related to gastric acidity. The 
bioavailability of the drug was reduced in individuals suffering from relative or absolute 
achlorhydria. Lohitnavy et al. (2005) demonstrated that when gastric acidity was 
reduced by co-administration of itraconazole capsules with an antacid suspension 
(aluminum hydroxide and magnesium hydroxide) 5min prior to itraconazole 
administration, a decrease in the rate and extent of itraconazole absorption was 
observed. The time to reach the maximum concentration, t. ax, increased from 3 to 5.1 h 
while the peak plasma concentration (Cm. ) was reduced from 146 to 43.6ng ml". Lange 
et al. (1997) noticed that when subjects were pretreated with H2 blockers (ranitidine) to 
increase the pH of the stomach to 5a decline in Cma., and area under curve (AUC) of 
40-50% was estimated. To compensate for the effect of ranitidine on gastric acidity an 
acidic beverage of cola (pH 2.27) was co-administrated with itraconazole. The 
pharmacokinetic parameters were approximately the same as when itraconazole was 
given alone. Finally, hypochlorhydria is a common complication in acquired immune 
deficiency syndrome (AIDS) patients and it was found that the serum concentration of 
itraconazole was less than that recorded in normal subjects (Cartledge et al., 1997). 
The same observations were found with the oral absorption of ketoconazole where the 
drug concentration in plasma was reduced when patients took antacids or H2 blockers. 
Van Der Meer et al. (1980) showed that after pretreatment of volunteers with cimetidine 
or sodium bicarbonate, the plasma levels of ketoconazole were low compared to non- 
treated cases. Blum et al. (1991) found that when volunteers were given parenteral 
cimetidine, to alter the pH of the stomach to 6, and then ketoconazole capsules (400mg) 
were administered, the AUC was reduced from 34 to 1.7h pg ml" and the Cm. declined 
from 7 to 0.48pg ml-1. A marked decrease in absorption was reported in patients with 
AIDS who had hypochlorhydria, which could be corrected by the concurrent oral 
ingestion of 0.1 M hydrochloric acid solution (Lake-Bakaar et al., 1988). 
1.10.4.2 Food influence on the absorption of oral formulation 
The bioavailability of itraconazole increased when taken in the fed state, Van Peer et al. 
(1989) examined the bioavailability of itraconazole capsules in different dosages and in 
solution in the fast and fed states. To simulate the fed condition, the capsules were given 
directly after a meal of standard breakfast comprising bread, ham, cheese, butter, jam 
and coffee. Food increased the C.. by 3.4-fold and the AUC by 2.6-fold. 
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When itraconazole capsules were given after the ingestion of a standard breakfast, an 
increase in the systemic availability of the drug was noticed. The composition of the 
standard breakfast was orange juice, egg, bacon, toast, butter, jam, whole milk and 
banana. The AUC increased under postprandial conditions by 1.6-fold and the C.. 
elevated by 1.7-fold (Barone et al., 1993). 
Zimmermann et al. (1994) conducted a comparative study investigating the effect of 
food on the absorption of itraconazole capsules. The ingested meal was divided into 
different patterns, namely a light meal composed of bread, jam, and decaffeinated 
coffee, and a heavy meal composed of bread, butter, fried eggs, sausages, bacon and 
decaffeinated coffee. Bioavailability increased when drug was administered under 
postprandial conditions. The AUC measured after heavy meal ingestion was the greatest 
where the bioavailability were 54% in fasting conditions and 86% after a light meal, 
considering heavy meal conditions as 100%. This increase in absorption was attributed 
to a long gastric retention time, high fat content of the coadministered meal and the low 
gastric pH that was reported in their investigation. 
Regarding the effect of food on ketoconazole bioavailability, some contradictions 
appear in the literature. When a 200mg dose of ketoconazole was given with a breakfast 
meal to 30 patients, the drug concentration was higher after 1-2h of dose administration 
compared to fasting conditions (Gascoigne et al., 1981). However, Daneshmend et al., 
(1984) reported no significant effect of food on the bioavailability of the ketoconazole 
when given with breakfast food. This study showed that there was an increase in AUC 
upon ingestion with food but that this was not significant. Mannisto et al. (1982) 
performed the test on subjects who were given ketoconazole after a standardized meal 
or 300ml of orange juice. Contrary to others finding, food ingestion led to a decrease in 
AUC and C.., of approximately 1.6. Co-administration with orange juice did not 
significantly change the pharmacokinetic parameters from the fasting state apart from a 
decrease was observed with the t... The authors explained their contradictory results 
by the type of the standard breakfast administered as their meal was rich in carbohydrate 
and low in fat while other studies used a meal with a richer fat content. 
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1.11 Aims and objectives of this study 
It is desirable in drug discovery and formulation development to forecast drug 
dissolution in the gastrointestinal tract since dissolution is a prerequisite for drug 
absorption and subsequent bioavailability. 
Dissolution is an important issue for poorly soluble drugs in particular as it can be the 
rate-limiting step for absorption. Therefore, two poorly soluble drugs (itraconazole and 
ketoconazole) were chosen for this investigation. These two drugs are azole orally 
administered antifungal agents classified as Class II according to the BCS due to their 
poor solubility and good permeability and their bioavailability is affected by food 
ingestion. Furthermore, most of the innovative drugs are poorly soluble basic drugs 
which made the two drugs good candidates to examine the effect of biorelevant media 
on their solubility and dissolution characteristics. 
The main objectives of this thesis were to gain an understanding of the in vitro 
dissolution of poorly soluble drugs in biorelevant media and thereby improve the ability 
to predict the behaviour of the drugs in vivo. To achieve this goal biorelevant media 
were developed based on the fact that in the gastrointestinal tract drugs are exposed to a 
medium of partially digested food, comprising mixtures of fat, protein and 
carbohydrate. Thus, the intentions of this thesis were to: 
Investigate the solubility and intrinsic dissolution behaviour of itraconazole and 
ketoconazole in simple compendial media, with or without enzymes, and 
understand the effect of pH on these properties. 
Study food-induccd effects on drug behaviour in simulated gastric fluids by 
determining the solubility and dissolution (IDR) in the proposed dietary media 
in comparison to compendial media. The dietary additives were: 
1. Milk with different fat contents. 
2. Proteins: albumin, casein, gluten and gelatin. 
3. Carbohydrates: glucose, lactose and starch. 
4. Amino acids: lysine, glycine, alanine and aspartic acid. 
5. Fat emulsions: Soybean oil emulsions. 
Investigate the effect of simulated intestinal fluids containing natural surfactants, 
bile salts and phospholipids (sodium taurocholate and lecithin), representing key 
endogenous digestive materials, on the dissolution of the drugs. 
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Investigate the possibility of utilizing synthetic surfactants to develop simplified 
simulated intestinal fluids which may replace the expensive bile salts media. 
Evaluate the dissolution of the drugs in fasted state-simulated gastric fluids 
containing synthetic and natural surfactants using formulations proposed in 
literature. 
Assess the effect of the viscosity and surface tension of the investigated media 
on the dissolution of the drugs. Furthermore, to evaluate the effect of the 
dissolution media on the wettability of itraconazole and ketoconazole compact 
surfaces. 
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Chapter 2: Materials & General Methods 
2.1 Materials 
A list of the materials used throughout the project is provided below. 
2.1.1 Drug substances 
Itraconazole powder (batch number 20050303) and ketoconazole powder (batch number 
060910) were purchased from Medichem, China Group Company (Shenzhen, 
Guangdong, China). Itraconazole donated by Jansssen Pharmaceutica was used for the 
initial studies. Figure 2.1 shows the chemical structure of the drugs studied. 
N--\\ 
CH3 0 
H3C 
N 'ý 
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N 
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Itraconazole 
Ketoconazole 
Figure 2.1 The chemical structures of itraconazole and ketoconazole 
2.1.2 Dissolution media 
A list of materials used in the preparation of dissolution media and their suppliers is 
given in Table 2.1 
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Table 2.1 Materials used in the preparation of dissolution media 
Material Source Batch number 
Sigma-Aldrich Chemie, 
B-Alanine 1259810 
Steinhcim, Germany 
Fluka, Sigma-Aldrich 
Albumin (from hen egg white) Chemie, Stcinhcim, 1143891 
Germany 
Sigma-Aldrich Chemie, 
DL-Aspartic acid 075KO705 Steinheim, Germany 
Casein from bovine milk Sigma-Aldrich Chemie, 103kO680 
(Technical grade) Steinheim, Germany. 
The fat contents: 
Fresh pasteurised bovine milk Express dairies, Liverpool, Skimmed milk (0.1%) 
containing different fat contents UK semi-Skimmed (1.7%) 
whole fat milk (3.6%) 
Gelatine from bovine skin, Type Sigma-Aldrich Chemie, 
015kO221 
B -75 bloom Steinheim, Germany 
Glacial acetic acid BDH, Poole, UK Anala R, K23898917 
Glucose BDH, Poole, UK Anal R, K33805414 
Sigma-Aldrich Chemie, 
Gluten from wheat 1140077 Steinheim, Germany 
Sigma-Aldrich Chemie, 
Glycine 0340166 
Steinheim, Germany 
Hexadecyltrimethyl ammonium Sigma-Aldrich Chemie, 113kOO92 
bromide (CrAB) Steinheim, Germany. 
Hydrochloric acid BDH Poole UK GPR, (d 1.18,36.5 - 38%) , , K32540451 343 
L-Lysine Sigma-Aldrich Chemie, 1269151 Steinheim, Germany. 
Lactose, monohydrate NX spray Foremost, Baraboo, 
dried Wisconsin, USA 3RF908 
Lecithin 
Lipoid GrnbH Donated by Lipoid Egg phosphatidy1choline , Ludwigshafen Germany GmbH (Lipoid EPC, 96%) , (lot 108024-2) 
DL-Leucine Sigma-Aldrich Chemie, AnalaR A651725 
I Steinheim, Germany , I 
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Table 2.1 continued from previous page: 
Pancreatin powder Acros Organics, New Jersey A014159201 USA 
Pepsin powder Acros Organics, New Jersey A017535901 USA 
Potassium dihydrogen phosphate BDH, Poole, UK AnalaF, 102034B 
Sodium acetate B DH, Poole, UK 
AnalaR, 
K91214705339 
Fluka Analytical- 
Sodium chloride Sigma-Aldrich Chemie, 1360238 
Steinheim, Germany 
Sodium dihydrogen BDH, Poole, UK AnalaR A856721 
orthophosphate 1 -hydrate , 
Sodium hydroxide pellets BDH, Poole, UK B449148 481 
Sodium lauryl phosphate BDH, Poole, UK 30175 
Sodium taurocholate hydrate, Alfa Aesar, Lancaster UK 10111536 97% , 
Soybean oil 
Sigma-Aldrich Chemie, 
ll5k0061 Steinheirn, Germany 
Starch soluble BDH, Poole, UK 1160402 
Triton X- 100 Sigma-Aldrich 
Chemie, 
066KO089 Steinheim, Germany 
Tween 20 
I Sigma-Aldrich Chcmie, 
04SK0082 Steinheim, Germany 
2.1.3 
2.1.4 Solvents 
The solvents used for sample extraction and as mobile phases for HPLC analysis are 
given in Table 2.2. 
Table 2.2 Solvents used in these studies 
Solvent Source Grade 
Acetonitrile BDH, (Chromanorm grade) Prolabo, Poole, UK HPLC 
n-Heptane Poole, BDH, UK HPLC (Hipersolv) 
Isoamyl alcohol Poole, BDH, UK GPR 
Dimethy1formamide Fisons, Loughborough, UK Analytical grade 
I -Cholorobutane 
Fluka, Sigma-Aldrich, 
Steinheim, Germany 
purum2: 99.0%GC 
Water Poole, BDH, UK HPLC (Hipersolv) 
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2.1.5 Filters 
The type and size of filters used in the solubility and dissolution studies and the 
specifications of the dialysis membrane used in the dialysis studies are listed in Table 
2.3. 
Table 2.3 Filters and dialysis membrane used in solubility, dissolution and dialysis experiments 
Filter type and size Source 
0.2pm poly-vinylidene fluoride (PVDF) filters, 
Whatman, Maidstone, UK 
12 mm syringe filter with tube tip 
0.45gm PVDF filters, 25mm syringe, Gelman Sciences, Northampton, UK 
Acrodisc filters 
1.0 prn glass fibre 25mm syringe, Gelman Sciences, Northampton, UK 
Glass Acrodisc filters 
5p acrylic polymer, 25mm syringe filters, 
Gelman Sciences, Northampton, UK 
Acrodisc Versapor 
0.45pm (poly-tetrafluoroethylene) PTFE, 
Millipore Millex LCP, Watford, UK 
25mm syringe filters 
Cannula filters- 20 ýtm, Erweka style, Quality Lab Accessories, New Jersey, 
URMW Polyethylene micron filters USA 
Filter papers, type I and 3 Whatman, Maidstone, UK 
0.2 ýtm polyamide filter Sartorius, Gottingen, Germany 
Dialysis tubing, size 10, diameter 31.7mm, molecular Visking-Medicell International, 
weight cut off 12000-14000 Daltons London, UK 
2.2 Solubility and dissolution determinations 
2.2.1 Media preparation 
Media were prepared according to the method specified in each chapter using deionised 
water which was prepared using a HP 340 water deioniser (Purite, UK). The PH of the 
media was measured and adjusted to the desired value using a digital PH meter (Delta 
350, UK). The PH meter was calibrated prior to use with three standard PH buffer 
solutions (4,7 and 10) (BDH, Poole, UK). Specific procedures for each medium are 
described in the relevant chapters. 
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2.2.2 Solubility determination 
The solubilities of itraconazole and ketoconazole in each dissolution medium were 
determined using a thermodynamic solubility test, the modified 'shake-flask method. 
This method was adopted by Sunesen et al. (2005) for studying the solubility of poorly 
soluble drug in complex biorelevant media. Each experiment was performed at least in 
triplicate. 
Medium (10ml) and drug powder (approximately 30mg for itraconazole and 300mg for 
ketoconazole) were transferred into closed-cap vials and shaken gently for 24h at 37'C 
in a shaking incubator (Model AM89B, Dynex Technologies Ltd, Worthing, UK). 
After this time, the suspension was centrifuged at 4000rev min" (2325xgravity (g)) for 
I Ornin (Centaur 2, MSE, Fisons, England). 
The supernatants were collected and filtered through the appropriate filter with the first 
portion of each filtrate being discarded to circumvent the effect of the initial adsorption 
of the drugs to the filters. Generally, filtration was performed using 0.2ýun PVDF 
syringe filters discarding the first Iml of each filtrate. For particulate biorelevant 
dissolution media, the use of filters with bigger pore size was required (Nicolaides et al., 
1999) and details are specified in the relevant chapters. 
Itraconazole filtrates were then diluted, where appropriate, with the mobile phase used 
for HPLC analysis, which was acetonitrile-0.02M potassium dihydrogen phosphate 
(60: 40, v/v). Collected samples were analysed using HPLC to determine the 
concentration of drug in solutions as described in Section 2.2.6.1. 
Ketoconazole filtrates were diluted as required with a mixture of acetonitrile-water 
(50: 50, v/v). Collected samples were analyzed using HPLC as described in Section 
2.2.6.2 
2.2.3 Disk preparation 
Intrinsic Dissolution Rate (IDR) testing was performed using the stationary disk 
apparatus. The equipment was manufactured by the Engineering workshop in Liverpool 
John Moores University (Liverpool, UK). A hardened polished steel plate was attached 
to the steel die. Drug powder (150mg of itraconazole or 200mg of ketoconazole) was 
inserted into the cavity of the steel die (9.5mm diameter) (Figure 2.2). A hardened-steel 
punch was inserted into the die cavity and then the whole arrangement was transferred 
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to a hydraulic compressor (Model M-30, Research and Industrial Instrument Company, 
London, England) (Figure 2.3). Drug substance was compressed at 1000p. s. i. 
(6.89Mpa) for 30s forming a smooth face with a circular surface area of 70 . 9MM2 . The 
steel plate was detached and the die containing the compressed powder was blown with 
compressed air to remove any loose particles. 
Punch 
Die -4 
Base plate A-'-- 
Screws 
14 
A- 
II 
Figure 2.2 Schematic diagram of intrinsic dissolution disk assembly used for the preparation of 
drug compact disks 
2.2.4 Intrinsic dissolution studies 
Dissolution studies were carried out using USP apparatus 11 (paddle) (Pharmatest PTW 
S3C, Pharmatest GmbH, Hainburg, Germany). The die, containing the compressed drug 
powder was positioned disk-up at the bottom of a flat-bottom dissolution vessel 
containing 500ml of the dissolution medium (Figure 2.4). The temperature was set at 
37 ± 0.5'C and a rotation speed of I 00rev min-' was used. The paddles were lowered to 
a position where the distance of the bottom of the paddles from the die upper surface 
was approximately 1.7cm. The vessels were covered with plastic lids to reduce 
evaporation. 
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Samples (3ml) were withdrawn periodically from the dissolution vessels through filters 
with the first 1.5ml being discarded. Itraconazole samples were filtered using 5gm 
Versapor filters and ketoconazole samples were filtered using 0.45gin PVDF filters. 
Unless particulate complex dissolution media were used, itraconazole and ketoconazole 
samples were withdrawn through 20gm Cannula filters. 
Compressed 
drug powder 
Figure 2.3 Schematic diagram of the settings used to prepare intrinsic dissolution disks; it shows 
the disks assembly and hydraulic compressor 
52 
IRýotating Sha 
133.6mm 
104mm 
Dissolution Vessel 
with Flat-bottom 
0, Rotating Shall 
150.2mm 
7 14 
4 2mm 
Dic Containing 
Compresscd Drug 
Figure 2.4 Schematic diagram shows the dimensions of die and the flat-bottoin dissolution vessel 
used in the intrinsic dissolution studies 
2.2.5 Extraction of drugs from complex dissolution media 
The drugs were extracted from the complex dissolution media by liquid-liquid 
extraction at alkaline pI I. 
2.2.5.1 Itraconazole 
Samples (Iml) of the aliquots withdrawn from the dissolution vessels were adjusted to 
pH 9.5 with IM phosphate buffer then shaken mechanically (Model AM8913, Dynex 
Technologies) for 10min. Then, 5ml of heptane-Isoamylalcohol (98.5: 1.5, v/v) 
(Woestenborghs et al., 1987) was added and samples were shaken manually for Imin 
and centrifuged at 4000rev min-' for 10min. Portions (2ml) were removed from the 
upper organic layer and dried under a stream of nitrogen at 60'C. Thereafter, 2ml of 
eluent (mobile phase used for itraconazole HPLC analysis, Section 2.2.6.1) was added 
to reconstitute the dried residue and sonication was applied for 2min (Kerry Ultrasonics, 
UK). Subsequently, the resultant samples were transferred to 2ml glass autosampler 
vials and submitted to HPLC analysis. 
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2.2.5.2 Ketoconazole 
Aliquots (Iml) withdrawn from the dissolution vessels were alkalinised with Iml of 
sodium hydroxide (NaOH) (0.05M) and shaken mechanically for 10min. 5ml of a 
mixture of acetonitrile-n-butyl chloride (1: 4, v/v) was added (De Bruijn et al., 2001), 
shaken for I min and then centrifuged at 4000rev min" for I Omin. Portions (2ml) were 
collected from the upper layer and evaporated to dryness with nitrogen at 60'C. The 
residues were reconstituted in 2ml of eluent (mobile phase used for HPLC analysis, 
Section 2.2.6.2) by sonication for 2min. Subsequently, the resultant samples were 
transferred to 2ml glass autosampler vials and submitted to HPLC analysis. 
2.2.6 Drug assay 
Drug quantitation in the solubility and dissolution samples was performed using reverse 
phase-High Performance Liquid Chromatography (HPLC) 
2.2.6.1 Itraconazole 
Itraconazole was assayed with a modified HPLC method proposed by Wong et al. 
(2003). The same method was applied for itraconazole dissolution and solubility 
studies. 
The column used was a LUNAO C18 (2) (250 x 4.60nim, 5ýtm) (Phenomenex, USA) 
and the mobile phase was a mixture of acetonitrile and 0.02M potassium dihydrogen 
phosphate (60: 40, v/v) adjusted to pH 3.0 with 5M HCL This mixture was vacuum 
filtered using 0.2pm polyamide filters in a Millipore vacuum filtration assembly and 
then degassed with helium-sparging. Chromatography was performed at a flow rate of 
1.3ml min" held at ambient temperature. The injection volume was 50ýtl and the 
injection needle was washed with acetonitrile between injections to prevent any carry 
over. Eluting peaks were detected using a Waters 474 fluorescence detector (Waters, 
UK) with the gain set at 100 and the attenuation at 32. The equipment was controlled 
and the data were handled using Millennium software (Version 3.05). 
Due to the extremely poor solubility of itraconazole, a stock solution (100ýLg ml-1) was 
prepared by dissolving 10mg of itraconazole in 3ml of dimethylformamide then the 
volume was taken up to 100ml with the mobile phase. Subsequent standard solutions 
were prepared in a range from 0.025 to 5pg ml" by diluting the stock solution with the 
mobile phase as appropriate. The method of external standards was used to convert the 
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measured peak areas to concentration units. The data acquired following the HPLC 
analysis were transferred to Excel (Microsoft Office) for subsequent data analysis. 
2.2.6.2 Ketoconazole 
Drug quantitation was carried out using a HPLC separation module Waters Alliance 
2695 chrornatograph (Waters, UK). The same method was applied for ketoconazole 
dissolution and solubility studies. Detection and quantitation were carried out using a 
Waters 996 Photodiode Array Detector (PAD) (Waters, UK). 
Ketoconazole samples (20-30pl) were eluted using a mobile phase consisting of 
acetonitrile, water and triethylamine (50: 50: 0.1 v/v), with a flow rate of L Iml min". A 
5gm. Hypersil BDS (Base Deactivated Silica) C18 column (150 x 4.6mm) (Thermo 
Electron Corporation, USA) fitted with a Phenomenex C18 guard cartridge (4mm. x 
3mm) was used and eluting peaks were detected at a wavelength of 254nm. In spite of 
using the BDS column, which has hydroxylated silanol in the stationary phase, the 
addition of triethylamine was necessary for peak symmetry to compensate for the 
acidity of the silanol groups which led to tailing of the peak and a longer retention time 
(Vertzoni et al., 2006). 
A Fluorescence detector (Waters 474, UK) operating at 251Mn for the excitation 
wavelength and at 376nm for the emission wavelength was employed when the 
dissolution media had a pH Z!: 5. 
2.3 Method validation 
2.3.1 Filter tests 
2.3.1.1 Introduction 
Filtration was essential in the solubility studies to remove the residual undissolved drug 
particles. Moreover, filtration was required for samples collected from the dissolution 
media to avoid any potential transference of undissolved particles from the media to the 
sample. Therefore, it was important to choose the appropriate type of filter to avoid 
adsorption of drug on the filters. 
A set of filters of different materials and pore sizes were tested for possible adsorption. 
The amount of each drug retained by the filter was determined by assaying a drug 
solution with and without passage through the filters and consequently the adsorptive 
losses to filters were calculated (Lindenberg et al., 2005). 
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2.3.1.2 Procedures 
A stock solution of itraconazole (1.5lig ml") was prepared in simulated gastric fluid 
(SGF) pH 1.2. A stock solution of ketoconazole (30[tg ml"') was prepared in SGF pH 3. 
SGF solutions were prepared as described in Section 3.2.3.1. 
Three samples of each drug stock solution were drawn up into a 5ml plastic syringe 
(concentric luer tip syringes, Becton Dickinson) and filtered immediately. The drug 
concentration in the filtrate was determined by HPLC analysis (Section 2.2.6). The 
experiments were conducted in triplicate and a new filter was used for each experiment. 
As a reference, the stock solutions of the drugs were withdrawn through the syringes 
without filters and the concentration of the drug was determined using HPLC. Drug 
recovery was calculated by comparing the concentrations of the corresponding filtrates 
and references using Eq. (2-1) (Lindenberg et al., 2005). 
Recovery = (Concentration of filtrate / Concentration of reference) x 100 Eq. (2.1) 
Additionally, the effect of discarding the first portion of the filtrate was evaluated by 
determining the recovery after the first 1.5ml of the filtrate was discarded. Iml was 
discarded only when using PVDF filters of smaller diameter (13mm). 
2.3.2 Assay validation 
Analytical parameters used in the validation of the drug assay methods were: linearity, 
precision, limit of detection (L. O. D) and limit of quantification (L. O. Q). 
Calibration curves were obtained for standard solutions of both drugs. The solutions 
were injected to the HPLC system according to the chromatographic conditions in 
Section 2.2.6. The linearity was evaluated by the least square regression method. 
The L. O. Q was defined as the lowest concentration determined with acceptable 
precision and accuracy (ICH, 2005). L. O. Q of the analyte in the sample was calculated 
as the concentration yielding a signal-to-noise (S/N) ratio of 10: 1. 
The L. O. D referred to the lowest amount of the analyte that could be reliably detected 
and not necessarily quantified in an exact amount (ICH, 2005). It was calculated in the 
present investigation as S/N of 3: 1. 
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The precision of the assay (repeatability) was computed as the percent relevant standard 
deviation (0/oR. S. D) over a range of concentrations greater than L. O. Q (ICH, 2005). The 
average of triplicate analysis of each sample was evaluated. 
To compare the sensitivity of UV absorbance detection with fluorescence detection, 
L. O. Q of itraconazole was evaluated in both cases as described above. 
2.3.3 Stability tests 
The stability of itraconazole and ketoconazole was assessed in the dissolution media 
under dissolution testing conditions. The drugs were evaluated for their stability over 
12h in acidic medium (pH 3) under dissolution testing conditions. Itraconazole 
(0.016pg ml-1) and ketoconazole (0.10mg ml-) solutions in SGF were incubated at 
37'C and injected onto the HPLC system at certain time points over 12h. The 
chromatograms obtained by the HPLC were verified with regard to peak area and 
possible formation of degradation products. 
2.3.4 Disk surface morphology 
Scanning electron microscopy SEM (Model JSM-840, Jeol Technics Ltd, Tokyo, Japan) 
was employed to investigate the morphology of itraconazole compact surfaces. The 
surface of the sample needed to be conductive to reduce electric charge build-up on the 
surface that might change its morphology. Therefore, itraconazole disks were coated 
with a thin layer of gold (sputter coating) (Crowder et al., 2003). Images were obtained 
for fresh disks of itraconazole substance to check the smoothness of the surface. Simple 
techniques were applied to enhance the smoothness of the surface, re-polishing the plate 
surface by surface finishing processes (fine grinding) and covering the plate with 
aluminium. foil. Images of the produced disks were taken thereafter. Furthermore, 
images were taken of itraconazole disks after they had been through the dissolution 
process in chosen media and details are specified in the relevant chapter. 
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2.4 Results of method validation 
2.4.1 Filter tests 
2.4.1.1 Itraconazole 
Table 2.4 shows the percentage recovery after the filtration of itraconazole solutions, 
including the first and second aliquots. The second aliquot always had a higher drug 
recovery. PVDF filters (0.2ýtm, l3mm) gave the highest recovery for itraconazole 
second aliquot, which was greater than 95%. Since the criterion for filter acceptance is 
95% drug recovery in the filtrate (Lindenberg et al., 2005), this type of filter material 
was used for most of the solubility studies with the first aliquot (Iml) being discarded. 
The Acrylic polymer also gave acceptable results so it was used for most of itraconazole 
dissolution studies. 
Table 2.4 Itraconazole recovery after filtration for two aliquots. Each data point represents the 
mean: h standard deviation (S. D. ) of 3 measurements 
Product name Material 
Millipore 
Whatman 
Gelman 
Gelman 
Acrodise Versapor 
Nalgen 
Whatman, mini- 
filters-centrifuge 
2.4.1.2 Ketoconazole 
Mesh width 
Itraconazole recovery (%) 
(Prn) V aliquot 2 nd aliquot 
PTFE 0.45 81.4 1.9 92.1 2.2 
PVDF (13mm) 0.2 72.9 1.6 99.6 0.9 
PVDF (25mm) 0.45 73.9 1.6 94.1 3.7 
Glass fibre 1 64.7 4.7 93.1 2.7 
Acrylic polymer 5 83.2 ± 1.1 97.4 0.8 
Cellulose acetate 0.45 75.2 ± 3.1 79.1 ± 5.4 
Regenerated 
0.45 64.2-11.6 65.9 ± 2.8 
cellulose 
The highest recovery of ketoconazole was from filters with PVDF membrane 
(0.2prn -0.45pm) where the recovery in the second aliquot was within the accepted 
value (>95%) (Table 2.5). Therefore, filters with PVDF membranes were used for most 
of the solubility and dissolution studies. 
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Table 2.5 Ketoconazole recovery after filtration for two aliquots. Each data point represents the 
mean± S. D. of 3 measurements 
Mesh Ketoconazole recovery (%) 
Product name Material width 
1" aliquot 2 nd aliquot (AM) 
Millipore PTFE 0.45 60.9 ± 3.0 91.2 ± 2.8 
Whatman PVDF (13mm) 0.2 88.1 ± 3.2 97.2± 1.9 
Gelman PVDF (25mm) 0.45 91.6 ± 2.1 96.7 ± 2.1 
Gelman Glass fibre 1 72.5 ± 5.3 94.6± 2.5 
Acrodisc Versapor Acrylic polymer 5 91.9 ± 3.4 95.3 ± 1.0 
In general, discarding the first portion of filtrate allowed saturation of the filters and so 
produced better recovery agreeing with the findings of Kiehm and Dressman (2008). 
Filters which gave the highest recovery were used thereafter except when the 
dissolution media were complex biorelevant particulate media. The composition of 
which did not allow the use of these filters which had a small pore size so a compromise 
between filtering recovery and pore size was considered. 
2.4.2 Assay validation 
Validation of the analytical methods was necessary to demonstrate the methods were 
suitable for the required analysis. 
2.4.2.1 Itraconazole 
Since the solubility of itraconazole was very low, it was necessary to apply a sensitive 
method that could detect and quantify it at very low concentrations so fluorescence 
spectroscopy was chosen as the detection method. The triazole and piperazine rings 
provide itraconazole with the capacity for fluorescence emission. The excitation and 
emission peaks were determined using a fluorescence spectrophotometer, Varian Cary 
Eclipse (Varian, USA), operated via the Cary Eclipse Advanced Reads Application 
Version 1.1 (132) software. The maximum excitation and emission wavelengths were 
recorded at 252nm and 360nm, respectively, for itraconazole dissolved in the mobile 
phase (Figure 2.5). 
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Figure 2.5 Emission and excitation wavelength scans for IýLg ml-' itraconazole solution: emission 
wavelength scans generated by excitation at 252nm and excitation wavelength scans generated by 
emission at 360nm 
The calibration curve was linear over the range of concentrations studied with a high 
correlation coefficient (Figure 2.6). 
0 1 2 34 
Concentration of itraconazole (pg ml*') 
5 
Figure 2.6 Calibration curve of itraconazole obtained by HPLC analysis using fluorescence 
detection, range from 0.03 to 5pg ml-, r 2ý,. 0.99 equation is y=291.5x -6.0. Each data point 
represents the mean ± S. D. of 3 measurements 
The L. O. Q of itraconazole was 6ng ml- I and the L. O. D was 1.8ng ml-1, whereas the 
L-O. Q of itraconazole using UV detection at 254nm was found to be 30ng ml-1. This 
indicated that using fluorescence detection increased the sensitivity of the analysis 5 
times compared to UV detection (Figure 2.7). 
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Figure 2.7 Comparison of fluorescence (F) and UV spectra obtained by HPLC analysis of 0.5gg ml- 
itraconazole solution 
The precision of the assay, calculated as the average value of the %R. S. D of seven 
triplicates of various concentrations, yielded a precision parameter of 1.9%. 
2.4.2.2 Ketoconazole 
Figure 2.8 shows a typical chromatograrn of ketoconazole where the retention time of 
the drug was 6.8min. A linear calibration curve was obtained throughout the 
concentration range studied with a high correlation coefficient (Figure 2.9). 
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Figure 2.8 Typical HPLC Chromatogram of ketoconazole solution in mobile phase using UV 
detection at 254nm, injection volume 20pl 
The LOD was 0.03ýig ml-1 and the L. O. Q was 0.1ýtg ml-1. The precision parameter of 
the assay, calculated as %R. S. D. of seven triplicates of various concentrations, was 
2.4%. 
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When optimising the UV wavelength of absorbance of ketoconazole, it was noticed that 
the peak area at 213rim was greater than that at 254nm; however, the S/N ratio was 
smaller at 213nm and so detection wavelength employed was 254nm. 
0 20 40 
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Figure 2.9 Calibration curve of ketoconazole obtained by HPLC analysis using UV detection, 
concentrations range from 1 to 100ýLg ml-1, r2> 0.99, equation is y=2.08x - 2.07. Each data point 
represents the mean ± S. D. of 3 measurements 
2.4.3 Stability testing 
Most of the investigations of the current research were carried out at pH 3, hence it was 
important to assess the stability of the drugs under acidic conditions. Furthermore, the 
drugs were reported to being prone to degradation by acid catalysis through oxidation 
and hydrolysis (Skiba et al., 2000). 
2.4.3.1 Itraconazole 
Itraconazole solutions did not show a detectable loss in drug concentration after 5h 
(Figure 2.10). Hence, during the normal time period for the dissolution test in this 
investigation (5h), it was apparent that itraconazole was stable in SGF (pH 3). A slight 
decrease in itraconazole concentration was observed after 12h where the recovery was 
97.9 ± 1.7% but no degradation peaks were observed. 
62 
110 
100 W fj Iifi 
50 
90 
80 
70 
60 
I 068 10 12 
Time (h) 
Figure 2.10 Stability profile of 0.016gg ml-1 itraconazole solution in SGF (pH 3) over 12h. Each data 
point represents the mean ± S. D. of 2 measurements 
2.4.3.2 Ketoconazole 
The concentration of ketoconazole (0.1 Omg ml- 1) did not drop significantly over 12h as 
drug recovery measured 98.6 ± 1.7%, n=2. This indicated that the ketoconazole solution 
in SGF (pH 3) was stable at the experimental conditions throughout this period. 
2.4.4 Disk morphology 
A principal requirement for determining the IDR of a drug is that dissolution takes place 
from a compressed sample of the drug having a constant surface area (USP, 2008). Any 
unevenness in the disk surface arising from cracks, produced during the compression 
process, may be exacerbated as the test proceeds leading to a gradually changing surface 
area (Levy, 1963). Therefore, it was necessary to confirm that the IDR disk surface was 
intact and so ensure dissolution would take place evenly across the entire surface. The 
surfaces of a number of disks were evaluated prior to perfon-ning the dissolution to 
check the smoothness of the drug compact surface. 
Micrographs of freshly-compressed disks (Figure 2.11) exhibited a striated surface with 
regular, raised ridges which arose from a roughness of the base-plate against which the 
drug powder had been compacted and were due to the fabrication procedure of the base- 
plate itself. 
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Figure 2.11 SEM photomicrographs of itraconazole disks obtained when the steel plate was un- 
polished, taken at two magnifications 500x and 2000x, scale bars: 63.2pm and 15.8pm 
These striations can affect the dissolution process by increasing the surface area of drug 
disk. Therefore, two approaches were taken to try to eliminate the formation of the 
ridges during production of the drug disks; firstly, the surface of the plate was polished 
in an attempt to make it smoother. Secondly, aluminium foil was placed onto the surface 
of the plate in order to present a smoother surface against which to compress the drug. 
L-J6-A-. &-&-J 
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Figure 2.12 SEM photornicrographs of itraconazole disk obtained after polishing the steel plate, 
taken at two magnifications 500x and 2000x, scale bars: 63.2pm and 15.8pin 
Micrographs produced by polishing (Figure 2.12) indicated that re-polishing the plate 
was seen to reduce the striations. However, covering the plate with aluminium foil 
produced an even smoother surface (Figure 2.13). 
I .*. -. I IS W 63.2 pm 590 X 
Figure 2.13 SEM photomicrographs of itraconazole disk obtained after covering the steel plate with 
aluminium foil, taken at two magnifications 500x and 2000x, scale bars: 63.21im and 15.8pm 
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Consequently, the simple technique of covering the steel plate with aluminium foil was 
adopted for the preparation of all the IDR disks, and furthermore, the plates were re- 
polished occasionally. 
2.5 Media characterisation & wettability assessment 
The investigated media were characterised in term of viscosity and surface tension in 
order to evaluate the influence of these parameters on the dissolution of the drugs. 
2.5.1 Viscosity 
2.5.1.1 Introduction 
The viscosity of a fluid is described as its resistance to flow. Viscosity can be 
demonstrated by suspending two horizontal, parallel plates in a liquid, keeping the 
bottom plate stationary whilst setting the upper plate in motion at constant velocity 
without changing the distance to the stationary plate. The difference in velocity between 
adjacent layers, i. e. the velocity gradient is termed shear rate and the force per unit area 
required to create the flow is the shearing stress. The unit of viscosity, poise 
(I OOmpascal. second), is defined according to the Newtonian liquid concept as the 
shearing force required to produce a velocity of lcm s-1 between two parallel flat 
surfaces of liquid each with an area of I CM2 and separated by I cm (Martin, 1993b). 
The viscosity of the dissolution media can affect drug dissolution; therefore, it was an 
important parameter to consider and to investigate its influence on dissolution (Section 
1.6.1.3). 
A rotational rheometer was initially employed to measure the viscosity of deionised 
water but it did not provide values consistent with the literature value and demonstrated 
poor repeatability. Thus, this indicated that this apparatus was not appropriate for 
measuring the viscosity of aqueous media. Thereafter, the viscosity of the dissolution 
media was measured using a vibrational rheometer which allowed the deten-nination of 
the viscosity of Newtonian and non-Newtonian fluids with good repeatability (2.1%, 
measured as average of % RSD). 
The rotational viscometer allowed the determination of the rheological behaviour of the 
media and their classification as Newtonian or non-Newtonian by plotting the viscosity 
versus shear rate, (more details are given in Section 4.3.1.1). Obtaining such 
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information gives an insight into the change of viscosity of the fluid according to 
change in the shear rate, which is produced by the stirring in the dissolution tester. 
Furthermore, the viscosity of non-Newtonian fluids will be different in different 
positions in the dissolution vessels according to the shear rate which in turn may affect 
the flow of the fluid (Kukura et al., 2004). 
2.5.1.2 Vibrational rheometer 
A Viscolite VL700-TI5 viscometer (Hydramotion, UK), a vibrational or resonant 
viscometer, was used for measurements of media whose viscosity was similar to water 
(Hydramotion, Viscolite VL700). This type of viscometer works by creating waves and 
only shear waves are utilized for measurements. When the sensor is immersed in fluids, 
high frequency waves (3200 - 3300 Hertz) emanating from its surface shear through the 
fluid and the energy is lost in the fluid. This loss in energy is measured by 
microprocessor-contro I led electronics and is expressed as viscosity through 
programmed calculations. The dissipated energy is related to liquid viscosity as high 
viscous solutions cause more loss in energy (Kress-Rogers and Brimelow, 200 1). 
The apparatus creates a high shear rate and so forces the viscosity measurement to a flat 
part of the viscosity versus shear rate curve, allowing the determination of the viscosity 
of both Newtonian and non-Newtonian fluids. 
Procedures 
Samples were wan-ned to 37'C prior to measurement using a water bath (Clifton, UK) 
and this temperature was maintained during the measurements by putting the samples 
on a holder placed over a heating plate. The solid stainless steel sensor of the rheometer 
was immersed into the fluid (approximately 25ml). The measured viscosity was 
displayed on the read-out unit as soon as the probe was immersed in the sample. The 
sensor was washed with deionised water and wiped between measurements to prevent 
carryover. 
2.5.1.3 Rotational rheometer 
The rotational rheometer measures fluid viscosity under controlled stress conditions. 
The test fluid is sheared between rotating cones, plates or cylinders. The system consists 
of four parts: (i) a measurement tool with a well-defined geometry, (ii) a device to 
produce a constant rotation speed to the tool, (iii) a device to measure the stress or shear 
rate response and (iv) a means of temperature control. 
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A CarriMed CSL2 100 rheometer (TA Instruments Ltd., USA) was used in the current 
investigation, employing a cone/plate geometry system with a6 cm diameter and cone 
angle of approximately V (Figure 2.14). A large diameter-geometry was chosen for its 
sensitivity to stress changes, being more suitable for the investigated fluids which were 
not highly viscous. 
Stationary Plate 1, 
Figure 2.14 Schematic diagram of a cone and plate viscometer 
Procedures 
The procedure was composed of three steps; prc-experimental where solutions were 
pre-sheared for Imin and the temperature equilibrated at 37T; then a flow step where 
the shear rate was increased over 3mm from 0 to 500 s 1; Finally, the shear rate was 
decrcascd from 500 to 0s1 over 3min. The sample was placed at the centre of the plate 
which was raised up to the correct position. Data were transl'errcd to software where a 
plot of shear rate versus shear stress was obtained. The rheological behaviour of' media 
containing milk or proteins was determined using this technique. 
2.5.2 Surface tension 
2.5.2.1 Introduction 
The surface tension of all dissolution media was measured to determine its influence on 
drug dissolution. Although the values of surface tension for some of' the media used 
already exist in literature, it was still necessary to determine the surface tension using 
the starting materials utilized in the current investigations, because of the possible 
existence of impurities in these materials which may have an impact on the surface 
tension (Crison et al., 1997). Furthermore, measuring the surface tension of all media 
using the same technique and conditions would be more appropriate for comparative 
purposes. 
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2.5.2.2 Method 
The surface tension of the dissolution media was measured using a Wilhelmy plate 
tensiometer Camtel CDCA model 100 (Camtel Ltd. UK). The method utilized the 
interaction of a platinum plate with the liquid interface being tested using the static 
mode. The length, width and thickness of the platinum plate were 40.4,20 and 0.2 mm, 
respectively. 
The medium (100ml) was wan-ned in a water bath to approximately 37' and then poured 
into a Pyrex glass. The glass containing the fluid was placed on the motorized stage of 
the tensiometer. The temperature of the medium was maintained at 37 ± 0.50C by the 
use of a circulating water bath and samples left for I Omin before starting the experiment 
for the temperature to equilibrate. The stage was lifted up automatically towards the 
Withelmy plate at a speed of 0.2mm s-1 until the plate was 0.2mm immersed in the fluid. 
Then, the plate perimeter was wetted and its total mass increased to a maximum, 
proportional to the surface tension of the fluid. The apparatus was interfaced by a 
computer for control and data acquisition. 
The contact angle between the plate and the lower liquid must be zero and hence 
cos 0 =1 (Figure 2.15). Therefore, the surface of the plate was carefully cleaned with 
distilled water and roughened by flaming using a Bunson bumer. 
Figure 2.15 Schematic diagram of Wilhelmy plate method, from Moules (1998) 
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Extra care was taken to avoid any carry over. All glassware used for the surface tension 
measurements was thoroughly cleaned by soaking with ammonium persulphate in 
sulphuric acid, washed with distilled water and then dried in hot air oven. 
2.5.3 Wettability assessment 
2.5.3.1 Introduction 
The contact angle describes the shape of a liquid droplet resting on a solid surface and it 
is defined as the angle between the tangent line that the drop forms with the solid 
surface (Fell, 2002). The ability of a liquid to wet the surface and displace the air phase 
from that surface leads to an increase in the effective surface area subjected to the 
dissolution fluid. 
2.5.3.2 Method 
The Sessile drop method was adopted for measuring the contact angle on drug compacts 
prepared following same procedures for IDR disks, Section 2.2.3. The contact angle 
between the disk and the dissolution medium was determined by placing one drop (4ýd) 
of each medium onto the surface of an intact compact using a IOPI glass syringe 
(Hamilton co., Nevada, USA) (Crowder et al., 2003). Photos were taken immediately 
after the medium was placed on the compact and every 5s for 5min at room temperature 
using a digital camera (AF Micro Nikkor 60 mm 1: 2.8, Nikon, p LUNIX TM-6CN, 
Japan) (Figure 2.16). 
The images were transferred to a computer with IDL software Version 6.0 win 32 
(x 86). The angle between the baseline of the drop and the tangent at the drop boundary 
was determined using the Adobe Photoshop CS2. Contact angles were determined twice 
at least for each of the dissolution media. 
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Digital camera 
Figure 2.16 Images of arrangement used for contact angle determination 
The measured parameters of viscosity, surface tension of the dissolution media and the 
contact angle formed between the dissolution media and the compact surfaces of the 
drugs are reported and discussed in the relevant chapters. 
2.6 Data analysis 
Differences in solubility, dissolution data and physical parameters of various media 
compared to corresponding blank solutions were statistically evaluated using a t-test at 
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the probability level of 0.05. A one-way analysis of variance (ANOVA) was employed 
with Microsoft Excel 2003 when comparing the data acquired in several media, 
differences were considered significant at the 0.05 level (Miller and Miller, 1993). 
I 
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Chapter 3: Initial studies: characterisation of itraconazole 
and ketoconazole 
3.1 Introduction 
The dissolution tests of itraconazole and ketoconazole were performed using the 
intrinsic dissolution rate technique which required compaction of the drug powder. 
Therefore, characterisation of the solid-state forrn of itraconazole and ketoconazole 
compressed disks was performed prior to the dissolution studies to detect if any solid- 
state changes occurred due to compression. 
Initial studies were performed to evaluate the dissolution and solubility of itraconazole 
and ketoconazole in compendial media at various pHs, with or without enzymes. Thus, 
the aim was to explore the behaviour of both the drugs at physiologically relevant pH 
values. Therefore, the pH of the media was varied over the range typically encountered 
in the GIT; pH 1.2 was considered a simulation for the fasted stomach (pH: 1.2), pH 3a 
simulation for the fed stomach (pH: 3-5) and pH 6.8 a simulation for the small intestine 
fluid (pH: 5 -7.5), (Section 1.6.2.2). These data were then employed for the subsequent 
comparison with the dissolution profiles in more complex media. 
3.2 Materials and methods 
3.2.1 Materials 
Details of all materials used in the thermal analysis, preparation of the dissolution media 
and in performing the experiments are listed in Section 2.1. 
3.2.2 Solid phase characterisation 
In the present investigation, studies were carried out to determine whether compression 
of the drug led to any polymorphic changes using differential scanning calorimetry, 
infra-red spectroscopy and powder x-ray diffractometry (Brittain, 1999c). 
3.2.2.1 Principles of solid phase analysis 
IZZLI Differential scanning calorimetry 
Differential scanning calorimetry (DSC) measures the amount of energy absorbed or 
evolved by a sample when heated, cooled or kept at constant temperature. This energy 
represents the heat flow required to maintain equal temperature in the sample and a 
reference. Thus, by scanning through a range of temperatures, while heating and/or 
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cooling, phase transitions such as melting, crystallization or glass transition can be 
determined (Brittain, 1999c). 
If the drug is present in the crystalline form, an endothermic peak in the plot 
corresPonding to the melting point (m. p. ) of the crystals will be usually observed. If the 
sample is transformed to a less stable crystalline form or it is composed of mixture of 
polymorphs, three possible DSC curves could characterise this phenomena (Figure 3.1), 
as reported by Giron (1995): 
m. p. of A M. P. of B 
11 
IL-i 
- (c) 
m. p. of A 
L6 
(b) 
Solid transition of A 
(a) 
10 
Temperature 
M. P. of 
A and 8 
Figure 3.1 Examples of DSC curves obtained for two polymorphs A and B, 8) Solid transition of A 
then one melting peak, b) Melting of A then recrystallisation and subsequent melting of B and c) 
Two crystalline forms, each has its own m. p. 
a) A solid-solid transition occurs before the melting point of the high m. p. form. By this 
transition the less stable form is converted to the stable one which then melts at the 
characteristic m. p. 
b) After the melting of the form with the lower m. p., another melting peak appears in 
the DSC curve attributed to the formation of crystals that grow from the melt of the first 
form (recrystallisation). Thus, the DSC graph shows two melting peaks. 
c) Each form has a melting peak and no transformation occurs between the forms. 
M. P. of B 
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If the drug is present in an amorphous state, it may undergo a glass transition 
corresponding to a decrease in heat capacity, followed by crystallisation and melting. 
Previous DSC studies described the thermal behaviour of amorphous itraconazole and 
ketoconazole. When amorphous itraconazole was heated, it showed the following 
possible stages: transition at 59T, 74 T and 90'C and then a possible re-crystallization 
at 120T (Six et al., 2001). Amorphous ketoconazole went through a glass transition at 
44.51C, followed by a possible exothermic crystallization at 120T (Van den Mooter et 
al., 2001). 
3. ZZI. 2 PowderX-ray Diffraction 
Powder X-ray diffraction (PXRD) is one of the most reliable techniques for solid phase 
differentiation (Rodriguez-Spong et al., 2004). A beam of X-rays passed through a 
sample of randomly-oriented microcrystals produces a diffraction pattern of rings on a 
distant screen (Brittain, 1999c). The position of the peaks corresponds to the periodic 
spacing between the atoms. Polymorphs usually have different diffraction patterns 
because different lattice constants lead to different peak positions (Rodriguez-Spong et 
al., 2004). The amorphous compound often does not show a pattern, or possibly shows 
only one or two broad peaks. 
3.2. Z1.3 Infrared spectroscopy 
Infrared spectroscopy provides information about the structure and conformation of the 
solid state and allows the distinction between polymorphs by probing the vibration of 
the atoms. A change in crystal morphology and a lack of crystallinity often affects 
hydrogen bonding and weak interactions between functional groups in polymorphs. 
Consequently, a change in the vibration of the atoms occurs leading to a shift in the IR 
absorbance of these bands (Rodriguez-Spong et al., 2004). 
3.2.2.2 Sample handling 
Itraconazole and ketoconazole disks were prepared as detailed in Section 2.2.3. The 
disks were broken by knocking the disks smoothly using a small stainless steel spatula 
and the pieces were collected on a weighing boat. Samples of the compressed materials 
analysed were not fine powder but pieces of compressed disk. The reason for not 
grinding the compressed samples was to avoid applying energy through the grinding 
process that could possibly change the lattice structure of the drug and so form a 
different solid form. Grinding may also convert the crystal form to an amorphous 
substance (Brittain, 1999b). 
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3.2.2.3 Differential scanning calorimetry 
Then-nal analysis of itraconazole and ketoconazole samples was performed using a 
Perkin-Elmer Pyris DSC calorimeter (Norwalk, USA). The calorimeter was calibrated 
for temperature against the melting point of pure indium (158.6'C and the onset 157.4'C 
when heated at IO'C min-). Samples (2-3mg) were placed in aluminium pans and 
crimped in position; a similar empty pan was used as a reference. Samples were heated 
at 1,10 and I OO'C min-' from 20'C to 200'C. 
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Figure 3.2 DSC scan for itraconazole at IOOC min-' showing the positions of onset temperature, 
extrapolated onset temperature and peak temperature 
The DSC data were presented as curves of the heat flow as a function of temperature 
where the area under a DSC peak was proportional to the heat absorbed by the thermal 
event. The peak temperature was defined as the temperature corresponding to the 
maximum of the endothen-n (Ford and Timmins, 1989b). The extrapolated onset 
temperature represented the intersection of the extrapolated leading edge of the peak to 
the baseline. The onset temperature represented the temperature where the transition 
started, i. e. just left the baseline. Figure 3.2 shows an illustration of a typical DSC scan. 
The parameters: extrapolated onset peak, enthalpy values (AM and peak area were 
determined using the provided software (Pyris ITm DSC). 
3.2.2.4 Powder X-ray diffraction 
X-ray diffraction patterns for each of the un-compressed and compressed itraconazole 
and ketoconazole samples were recorded using an X-ray diffractometer (Miniflex, 
Rigaku Corporation, Tokyo, Japan) with a kb-filtered Cu/Ka line as the source of 
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radiation, operated at 30kV voltages and a current of 15mA. The angular range 5-60' 20 
was scanned at a speed of 5' min*' at room temperature. 
3.2.2.5 FT-IR spectroscopy 
Infrared spectra for compressed and non-compressed samples were recorded using a 
Perkin Elmer BX FT-IR system (Perkin-Elmer Corporation, UK). Samples did not 
require any pre-treatment as a MIRacle attenuated total reflectance (ATR) accessory 
was used which allowed powder and small piece of compressed sample to be analysed 
directly. Spectra were recorded and analysed using a Spectrum Soflware Version 5.0.1 
(Perkin Elmer). Spectra were obtained, after subtracting the spectrum of the 
background, over the range of mid-infrared (4000cm" to 600cm") 16 scans were 
acquired to produce each spectrum. 
3.2.3 Evaluation of itraconazole and ketoconazole behaviour in compendial 
media 
3.2.3.1 The composition of the dissolution media 
Simulated Fluids were prepared in accordance with the United States Pharmacopoeia 
(USP, 2008). 
The Simulated gastric fluid (SaF) contained 2g sodium chloride (NaCl), 7ml HCI to 
make the pH 1.2 and deionised water up to IL 
SGF with enzyme contained 2g NaCl and 3.2g pepsin in 7ml HCI and volume was 
taken to IL by deionised water, the pH of the media was 1.2. 
SGF (pH 3) contained 2g NaCI and OAM HCI (to make the pH) and the volume was 
taken to IL by deionised water. 
SGF (PH 3) with enzymes had same composition as SGF (pH 3) but with the addition of 
3.2g pepsin. 
Simulated intestinal fluid (SIF) with enzymes contained lOg of pancreatin, 6.8g of 
monobasic potassium phosphate (KH2P04), 0.2M sodium hydroxide (NaOH) and 
deionised water up to IL. Potassium phosphate was dissolved in 250ml of water then 
77ml of 0.2M NaOH and pancreatin were added. The solution was mixed, the volume 
was completed to 1L with water and the final pH was adjusted with either 0.2M NaOH 
or 0.2M HCI to 6.8. 
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SIF (pH 6. n was prepared as for SIF with enzymes but without the addition of 
pancreatin. 
Phosphate buffer 0.05M (pH 7.5) contained 27.2g of KH2PO4,40ml of 30%, W/V of 
potassium hydroxide solution and deionised water up toIL (BP, 2008). 
Acetate buffer (pH 5) contained 13.6g of sodium acetate, 6ml of glacial acetic acid and 
sufficient deionised water up to IL (13P, 2008). 
3.2.3.2 Characterisation of the media 
The viscosity and surface tension have important effects on drug dissolution (Section 
1.6.1). Therefore, it was essential to evaluate and consider these parameters when 
comparing the effect of different media on drug dissolution. 
3. Z3. ZI Viscosity 
The viscosities of the media were evaluated using the vibrational viscometer (Section 
2.5.1.2). The probe of the apparatus was immersed in the media and measurements were 
taken directly from the read-out unit of the apparatus. Measurements were taken in 
triplicate. 
3. Z3. Z2 Surface tension 
The surface tension was measured using the Wilhelmy plate technique in the static 
mode (Section 2.5.2). The liquid was raised up and allowed to touch the plate and so the 
force acting on the plate was measured automatically and transferred to the interfaced 
computer. Measurements were taken at 37 ± 0.5C in triplicate. 
3.2.3.3 Solubility studies in compendial media 
The solubility of itraconazole and ketoconazole was determined as a function of the pH 
in the following media: SGF (pH 1.2), SGF (pH 3), acetate buffer (PH 5), SIF (PH 6-8) 
and phosphate buffer (pH 7.5). 
The modified shake-flask method was applied (Section 2.2.2). Drug substances 
(approximately 30mg for itraconazole and 300mg for ketoconazole) were added in 
excess to closed vials containing 10ml of dissolution medium and shaken for 24h at 
37'C. The amount of ketoconazole was increased to 400mg when studying the 
solubility in SGF (pH 1.2). Undissolved material was separated by centrifugation 
followed by filtration and the resultant filtrates were quantified using HPLC. 
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Prior to analysis itraconazole samples in highly acidic media were diluted two-fold with 
the mobile phase used for HPLC analysis (acetonitrile and 0.02M potassium dihydrogen 
phosphate (60: 40, v/v) adjusted to pH 3.0 with 5M HCI). No dilution was applied to 
other samples due to the low concentration of the drug in these fluids. The temperature 
of the samples in the HPLC compartments was maintained at 35 ± 2'C, to avoid any 
possible precipitation in the HPLC vials. 
Filtrates of ketoconazole were diluted, if required, with a mixture of water: acetonitrile 
(50: 50). Samples in SGF (pH 1.2) were diluted 10-fold. 
3.2.3.4 Dissolution tests in compendial media 
Dissolution studies were carried out using the stationary disk method (Section 2.2.3). 
Itraconazole and ketoconazole powders were compressed to form circular compacts. 
The dies containing the drug compacts were then placed in the dissolution vessels with a 
single face exposed to 500ml of dissolution media (37'C). Samples were withdrawn at 
different time points through syringe filters (5grn Versapor filters for itraconazole and 
0.45prn PVDF filters for ketoconazole). The dissolution tests were performed for 5h, 
except the dissolution of itraconazole in, SGF (pH 1.2) which was further monitored for 
a longer period of 2 days. 
Collected samples of itraconazole and ketoconazole aliquots were injected onto the 
HPLC system via autosampler without pre-treatment. Only when SGF (pH 1.2) with 
enzymes was used as dissolution medium for itraconazole, the collected samples were 
diluted 50: 50 with the mobile phase. Ketoconazole samples collected from media 
containing enzymes were diluted 50: 50 with acetonitrile-water (50: 50). 
3.2.3.5 Drug Analysis 
HPLC was used for the analysis of solubility and dissolution samples of both drugs, 
(Section 2.2.6). For itraconazole analysis, a fluorescence detector was used with an 
injection volume of 50pl. 
For ketoconazole analysis, the UV detector wavelength was set at 254nm with an 
injection volume of 20pl. However, for samples collected from SIF media, the 
fluorescence detector (XEx, =25lnm, XE. =376nm) was employed instead. 
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3.2.3.6 Disk surface morphology 
The change in the morphology of itraconazole disks during the dissolution process was 
monitored using SEM according to the method described in Section 2.4.4. SEM images 
were taken for itraconazole disks after exposure to the dissolution process in SGF (PH 
1.2) after 5,24 and 48h and in SIF after 5h. 
3.3 Results and discussion 
3.3.1 Solid phase characterisation 
The morphology of solids can affect the solubility and dissolution rate of materials 
(Section 1.6.1.1). Polymorphs behave differently when they are in the solid state but 
once in solution behave the same. Compression is a high energy process which may 
affect the crystallinity of drugs by inducing dislocational strains in crystal which 
facilitate nucleation. Chan and Doelker (1985) reported that compression of drugs, 
which exist in different polymorphic states, induced polymorphic transformations 
towards the more stable forms. In addition, the compaction process can destroy the 
crystal structure leading to the formation of amorphous material which usually has 
higher solubility (Connors, 2002). Therefore, an assessment of solid state is a pre- 
requisite for IDR studies from disks of compact drug powder. For example, if the 
dissolution experiment was carried out on a metastable form which has higher solubility 
compared to the stable form, then the liquid will be supersaturated with respect to 
metastable form leading to possible precipitation. The production of amorphism was 
reported by Persson et al. (2005) whilst preparing IDR disks of griseofulvin and 
cyclosporine, where signs of minor amorphism were observed on the surface of the 
disks. 
3.3.1.1 Differential scanning calorimetry 
3.3.1.1.1 Itraconazole 
DSC scans taken before and after compression showed one single endothermic peak 
corresponding to the melting point of itraconazole (169-170.40C) and did not exhibit 
any thermal event before melting (Figure 3.3). This suggests that the drug did not 
undergo any solid-state alterations indicating the samples contained only one crystal 
form of itraconazole. However, the compressed sample displayed a decrease in peak 
parameters, approximately computed as: the extrapolated onset m. p. (1.7'C), the onset 
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m. p. (2.90C), AH (6.5J g-1) and the peak area (16m J), compared to non-compressed 
itraconazole powder (Table 3.1). 
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Figure 3.3 DSC scan of uncompressed (solid line) and compressed (dotted line) itraconazole at a 
heating rate of 100C min-' 
To find out the reason for the decrease in these values, different heating rates were 
applied with the aim of differentiating any thermal transition events that occurred 
(Giron, 1995). Consequently, samples were scanned at slow (I IC min7l) and fast heating 
rates (100*C min-1). One endothermic peak appeared in each DSC scan and the same 
observations were found regarding the decrease in the onset peak (Table 1.1). 
A decrease in the extrapolated onset, peak area and AH was recorded also but was not 
significant (t-test at 0.05 level). An increase in the onset interval, defined as 
extrapolated onset minus onset peak, was noticed. 
Table 3.1 DSC data for itraconazole compressed and un-compressed, the values presented are 
average of two experiments: k S. D. 
Heating rate 
(*C min-I ) 
Extrapolated 
onset peak (OC) 
Onset peak (OC) 
Peak area (m J) 
AH (J g") 
Itraconazole 1 10 100 
Non-comprcsscd 164.0 ± 0.6 167.6 ± 0.5 172.1 ± 0.2 
Compressed 163.4 ± 0.7 165.9 ± 0.6 169.8 ± 1.3 
Non-compressed 161.8 ± 0.3 165.6 ± 0.2 166.7 ± 1.1 
Compressed 160.2 ± 0.2 162.7 ± 0.5 162.9 ± 1.5 
Non-compressed 204.9 ± 9.4 227.5 ± 2.2 218.7 ± 7.4 
Compressed 173.4 13.3 211.5 13.5 203.9112.8 
Non-compressed 81.7 6.1 83.1 ± 0.3 87.6 ± 5.7 
Compressed 71.0 5.6 76.6 ± 0.9 77.6 ± 3.8 
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3.3.1.1.2 Keloconazole 
One endothcrm peak appeared in the DSC scan at 146.1-148.5'C representing the 
melting point of ketoconazole with no other transitions observed (Figure 3.4). This 
suggested the presence of ketoconazole in one crystal form. 
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Figure 3.4 DSC scan of uncompressed (solid line) and compressed (dotted line) ketoconazole at a 
heating rate of 100C min-' 
However, there was a decrease in the peak parameters of the compressed samples. 
When samples were heated at I O'C min-', the decrease was computed as approximately: 
the onset peak (3'C), extrapolated onset peak (1.6'C), AH (12.8J g-1) and peak area 
(25m J), compared to non-compressed sample (Table 3.2). Similar observations were 
found with slow (IOC min-') and fast heating rates (100'C min7l) where a reduction in 
DSC peak parameters of the compressed samples was apparent although not all the 
differences observed, such as the peak areas, were significant. An increase in the peak 
onset interval (extrapolated onset minus onset) was also noted. 
The decrease in peak parameters could be attributed to the size and the shape of the 
samples. Uncompressed samples were powder composed of fine particles, whereas the 
compressed samples were small pieces of broken disks of the compact drug powder 
which had a larger particle size. It was reported previously that the size and shape of 
particle can have an important effect on thermal properties (Ford and Timmins, 1989a). 
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Table 3.2 DSC data for ketoconazole compressed and un-compressed, the values presented are 
average of two experiments ± S. D. 
Heating rate 
Ketoconazole 1 10 100 
('C min-I ) 
Extrapolated onset Non-compressed 146.7:: L 0.2 146.0 ± 0.2 147.9 ± 0.1 
peak ('C) Compressed 145.1 ± 0.1 144.5 ± 0.1 146.6 ± 0.2 
Onset peak ('C) 
Non-compressed 143.8 ± 1.3 143.8 ± 0.9 144.1 ± 0.9 
Compressed 142.1 ± 1.5 140.9 ± 0.9 142.1 ± 1.1 
Peak area (m J) 
Non-compressed 208.7 ± 8.9 235.5 ± 2.1 213.8 ± 3.5 
Compressed 195.1 ± 8.6 210.5 ± 6.4 195.8 ± 7.7 
AH (J g-) 
Non-compressed 90.1 ± 3.2 102.4 ± 0.9 87.4 ± 2.5 
Compressed 82.3 ± 1.0 89.6 ± 2.8 85.7 ± 5.2 
Van Dooren (1982) found that larger particles of adipic acid have a lower onset melting 
peak, lower AH and greater peak onset interval than the smaller particles. This shift in 
the values was ascribed to less heat transfer occurring between the bigger particles so 
the hotter parts of the particles may reach a higher temperature and melt before 
releasing the energy to the colder parts. This resulted in a decrease in the thermal effect 
and a smaller peak area with an earlier melting onset. 
3.3.1.2 Powder X-ray diffraction 
The representative X-ray diffraction patterns for compressed and non-compressed 
itraconazole (Figure 3.5) exhibited the characteristic crystalline peaks which were at the 
same position for both samples (12.71', 14.78', 19.16' and 20.250). This represented a 
slight shift from literature values recorded for both samples (Lee et al., 2005). 
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Figure 3.5 Powder X-ray diffraction patterns of compressed and non-compressed itraconazole 
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The same observations were recorded for ketoconazole as the characteristic diffraction 
peaks (6.8' and 22.3') were apparent at the same position for uncompressed and 
compressed samples (Figure 3.6). 
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Figure 3.6 Powder X-ray diffraction patterns of compressed and non-compressed ketoconazole 
Thus, the results did not show any evidence of crystal lattice modification of 
itraconazole and ketoconazole with compression. However, the diffraction patterns of 
the compressed sample of both drugs had a noisier baseline and wider and distorted 
peaks. It is believed that this change in peak shape was due to differences in sample 
particle size. 
3.3.1.3 FT-IR analysis 
The IR spectra (Figure 3.7) of itraconazole did not show any differences between the 
compressed and uncompressed samples. For example, peaks at 2963,1697,1609,15 10, 
1425cm-1 assigned to C-H, C=O, C=N, C=C (aromatic) and C-N bonds, respectively, 
appeared in both spectra (Nesseem, 2001). 
Similar observations were found with ketoconazole (Figure 3.8) where characteristic 
peaks of ketoconazole remained unchanged after compression. For example the bands at 
1643 and 1507cm-1 assigned as C=O (arnide) and C=C (aromatic), respectively, 
appeared at same position for both ketoconazole samples. The provided software 
indicated a correlation of 0.9931 for itraconazole and 0.9991 for ketoconazole, when 
spectra of compressed and non-compressed samples were overlaid. Thus, this indicated 
that no polymorphic transformation occurred. 
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3.3.2 Evaluation of itraconazole and ketoconazole behaviour in compendial 
media 
3.3.2.1 Characterisation of the media 
3.3.2. LI Viscosity 
The viscosity of the deionised water was 0.702 ± 0.007millipascal. seconds (mPa. s) 
which was similar to the value obtained from literature (extrapolated as 0.697mPa. s 
(ESDU, 1980)). Statistical analysis of the results obtained for media not containing 
enzymes (SGF pH 1.2, SGF pH 3 and SIF) using ANOVA (0.05) showed no significant 
difference between the viscosities of these media (Table 3.3). 
Table 3.3 Viscosity and surface tension of compendia[ media and water at 370C. Each data point 
represents mean ± S. D. of three measurements 
Medium Viscosity (mPa. s) Surface tension (mN m 
Deionised water 
SGF pH 1.2 without pepsin 
SGF pH 1.2 with pepsin 
SGF pH 3 
SIF pH 6.8 without pancreatin 
SIF pH 6.8 with pancreatin 
0.702 ± 0.007 68.4 ± 0.3 
0.719 ± 0.009 67.4 ± 0.7 
0.731 ± 0.014 57.5 ± 1.4 
0.714 ± 0.010 66.4± 1.6 
0.724: E 0.010 67.6 ± 0.7 
0.747 ± 0.015 56.2 ± 2.8 
The viscosity of SGF increased with the addition of pepsin by approximately 0.0 1 mPa. s 
and the viscosity of SIF increased with addition of pancreatin by 0.02mPa. s, but these 
increases were not significantly different (t-test, 0.05 significant level) (Table 3.3). 
3.3.21.2 Surface tension 
The measured surface tension of the deionised water at 370C was 68.4 ± 0.3mN m-1 
whereas the literature value was extrapolated as 70. ImN in-' (ESDU, 1980). This 
difference could be attributed to impurities in the water used. Despite the use of purified 
water, impurities could have passed through the filtration system used for purification 
and induced a slight reduction in water surface tension (Shah, 2006). A negligible 
difference was observed between the surface tension values determined for water and 
the aqueous media (SGF pH 1.2, SGF pH 3 and SIF pH 6.8). However the additions of 
pepsin or pancreatin resulted in a significant decrease in the surface tension of SGF and 
SIF by approximately I OmN in-', (Table 3.3). 
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3.3.2.2 Solubility determinations 
The solubility of both drugs was assessed in various media of different compositions 
over a pH range from 1.2 to 7.5, the composition of the media and the solubility method 
were described in Sections 3.2.3.1 and 3.2.3.3. Evidence of the poor aqueous solubility 
of the two drugs is presented in Table 3.4. Itraconazole proved to be approximately 
2700 times less soluble than ketoconazole. These results also indicated that the 
solubility of both drugs is highly pH dependent and requires an acidic environment for 
maximum solubility. 
Table 3.4 Solubility of itraconazole and ketoconazole at 371C in SGF (with and without pepsin), SIF 
(with and without pancreatin), acetate buffer, phosphate buffer and deionised water. Each data 
point represents the mean ± SD of 3 measurements 
Medium 
Deionised water 
SGF (pH 1.2) 
SGF (pH 1.2) with pepsin 
SGF (pH 3) 
Acetate buffer (pH 5) 
SIF (pH 6.8) 
SIF (pH 6.8) with pancreatin 
Phosphate buffer (pH 7.5) 
3.3.221 Itraconazole 
Itraconazole Ketoconazole 
Solubility (pg ml-1) Solubility (mg ml") 
-0.002 
3.9 0.7 
8.1 1.15 
0.035 0.003 
0.011 0.004 
-0.003 
0.076 ± 0.01 
-0.003 
0.0054 0.0005 
20.33 3.26 
23.42 2.41 
0.43 0.05 
0.1 ± 0.009 
0.007 ± 0.001 
0.010 ± 0.003 
0.006 ± 0.001 
The solubility of itraconazole in water and SIF was extremely low, less than the limit of 
quantification of the analysis method (6ng ml- 1) (Section 2.4.2.1). The values obtained 
for aqueous solubility were in accordance with the solubility (0.00 152 gg ml-1) reported 
by Glomme et al. (2005), which was calculated based on log P and the melting point of 
the drug. 
Approximately a 100-fold decrease in itraconazole solubility was noticed when the pH 
of the medium increased from 1.2 to 3 (Table 3.4). The solubility of the free base is 
much less than that of the protonated forms. Itraconazole is weakly-basic drug with a 
pKa of 3.6 and four ionisable nitrogens in its structure, full protonation of the four 
nitrogens occurs only at low pH of less than 2 (Peeters et al., 2002) (Section 1.10.2). 
This explains the drop in solubility noticed between pH 1.2 and 3. 
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3.3.2.2.2 Ketoconazole 
The aqueous solubility of ketoconazole was 5.4ýtg ml-1, which was in accordance with 
the literature values of 4.5ýtg ml-1 (Galia et al., 1998) and 5.98ýtg ml-I (Glomme et al., 
2005). Ketoconazole solubility was also highly dependent on the pH of the medium. 
Table 3.4 shows that solubility dramatically decreased 47 times when the pH of SGF 
increased from 1.2 to 3 and further dropped 62 times in SIF compared to SGF pH 3. 
Ketoconazole is a dibasic drug with two ionisable species, the imidazole and piperazine 
(Section 1.10.2). At pH 3 all imidazole moieties were ionised (pKaj = 6.5) and nearly 
50% of piperazine moieties (pKa2 = 2.9) were protonated. So by lowering the pH further 
to 1.2, both base moieties were protonated leading to an increase in its solubility under 
more acidic conditions. 
3.3.2.2.3 The effect of enzymes on solubility 
The media containing enzymes were turbid and developed signs of precipitation during 
the solubility and dissolution experiments. This was observed in particular with 
ketoconazole samples in SIF-pancreatin where the solubility recorded was higher than 
the solubility in SIF but the difference was not significant. Qazi et al. (2003) studied the 
solubility of the antiviral drug (stampidine) in SIF with enzyme; however the drug could 
not be detected on HPLC after performing the solubility test and filtrations. Authors 
presumed that the association of the drug with the precipitated enzymes led to 
separation of the drug upon filtration. 
The presence of pepsin in the SGF medium led to a 2-fold increase in itraconazole 
solubility however, a less pronounced effect was seen with ketoconazole. The effect of 
enzymes is believed to be due to their solubilising effect as indicated by the low surface 
tension of their media compared to the corresponding media without enzymes (Table 
3.3). 
3.3.2.3 Intrinsic dissolution studies 
The dissolution of itraconazole and ketoconazole was evaluated at 37'C in compendial 
media with and without enzymes (SGF and SIF) using the IDR method (Section 2.2.4). 
3.3.23.1 Itraconazole 
Due to the low solubility of itraconazole, all the dissolution experiments were 
performed under non-sink conditions. The accumulation of the drug in the media soon 
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affected the dissolution process so the linear portion of each curve was brief as 
saturation solubility was quickly approached. The initial dissolution was considered 
during the first 15min. A plot of the amount dissolved per unit area versus time was 
constructed and the slope of the fitted linear regression represented the IDR. The zero 
point was considered to be when samples were taken from dissolution vessels before 
immersing the disks. Thereafter, for comparative purposes and in addition to the initial 
IDR, data for the amounts dissolved per unit area after one hour was also utilized. 
It was evident that dissolution was proportional to the pH of the media (Figure 3.9), as 
under the more acidic conditions (pH 1.2) a greater extent and rate of dissolution was 
observed. The initial dissolution rate was 12 times greater than that at pH 3. 
Figure 3.9 Intrinsic dissolution profile of itraconazole at 371C in SGF at pH 1.2 (with and without 
pepsin) (n=3) and in SGF pH 3 (n=6). Each data point represents the mean ± S. D. 
The dissolution in SGF (pH 3) reached a plateau by 3h since the amount dissolved 
reached the saturation solubility. The dissolution of itraconazole in the more acidic 
media (pH 1.2) still increased gradually after 5h. Consequently, the dissolution at pH 
1.2 was further monitored for a longer period of 48h (Figure 3.10). This profile 
exhibited a steady rise throughout the course of the experiment. The amount of 
itraconazole dissolved after 48h was approximately the same as the solubility indicating 
an equilibrium state had been reached in the dissolution medium. 
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Figure 3.10 Intrinsic dissolution profile of itraconazole at 370C in SGF at pH 1.2 over 48h. Each 
data point represents the mean of 3 measurements: k S. D. 
The inclusion of pepsin in the medium increased the dissolution rate significantly with 
an initial burst at the beginning. The initial IDR was three times higher than the value in 
the non-enzyme solution (Table 3.5). Hence, this increase mirrored the trend in 
solubility and was attributed to the solubilisation effect of the enzymes that enhanced 
the dissolution of itraconazole. 
Table 3.5 IDR data of itraconazole at 370C in SGF (pH 1.2) with and without pepsin (n=3) and in 
SGF (pH 3) (n=6). Each data point represents the mean 4: S. D. 
Medium 
Initial IDR (0-15min) 
(pg min-' CM-2) 
SGF pH 1.2 12.1 ±2.5 
SGF pH 1.2 with pepsin 34.3 d: 5.2 
SGFpH3 1.1 ± 0.3 
3.3. Z3.2 Keloconazole 
The dissolution of ketoconazole could not be performed at pH 1.2 due to its high 
solubility at that pH whereby the disks entirely dissolved within 15min. Dissolution of 
ketoconazole was performed in SGF (pH 3) over a period of 4h. A change in the disk 
surface was observed after 4h indicating that disk integrity was not maintained after this 
period which made the IDR determination invalid after that time point. 
The dissolution profiles displayed in Figure 3.11 show the profound effect of the pH of 
the medium on the rate and extent of drug dissolution. The amount dissolved in SGF 
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(pH 3) was 10 times greater than in SIF (pH 6.8) within one hour, and became 26 times 
greater within 4h. - 
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Figure 3.11 The intrinsic dissolution profiles of ketoconazole at 370C in SGF pH 3 (with and 
without pepsin) and SIF pH 6.8 (with and without pancreatin). Each data point represents the 
mean ± S. D. of 3 measurements 
The dissolution profiles of ketoconazole were divided into two stages, the initial 
dissolution profile from time zero to 15min and the subsequent stage up to 240min. The 
profiles in SGF with and without enzymes were well fitted by a linear function 
(coefficient of determination, r2 > 0.99). In all cases, the initial dissolution stage 
(0-15min) was steeper than the final segment indicating a more rapid dissolution in the 
first 15min (Table 3.6). The addition of pepsin to SGF enhanced the rate of dissolution 
by 1.4 and 1.7 during the two stages, respectively. 
Table 3.6 IDR data of ketoconazole at 370C in SGF (pH 3) with and without pepsin. Each data 
point represents the mean ± S. D., n=3 
Medium 
Initial IDR (0-15min) IDR (15-240min) 
(pg mid' cm -2 ) (pg mid' CM-2) 
SGFpH3 187.5 ± 27.3 75.4 3.5 
SGF pH 3 with pepsin 266.4 ± 13.0 124.3 4.1 
On the other hand, the dissolution profiles in the simulated intestinal media were not 
linear. This non-linearity could be attributed to approaching sink conditions which led 
to a slowing of the dissolution process. The dissolution in the enzyme-containing 
medium appeared slightly higher than in the medium without enzyme. However, by 
applying a West (at significance level of 0.05) for the cumulative amounts dissolved at 
each time point no significant difference between the two graphs was observed. 
Furthermore, for comparing the dissolution profiles in SIF with and without enzymes 
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the similarity factor f2 (Eq. (3.1)) was calculated where Tj and T2 are the percentage of 
accumulative amount dissolved in each dissolution media at each of the sampling time 
points (n). 
0.5 
f2=50. log 
[1+(Iln)E(Ti-T2)2 
Eq. (3.1) 
I- 
. 
100 
t=l 
This factor was originally employed for comparing the dissolution profiles of solid 
dosage forms however it was used by Viegas (2001) for comparing IDR profiles. If 
dissolution profiles were equivalent, thef2 value would lie between 50 and 100 (Shah et 
al., 1998). In the current investigation, when comparing the dissolution in SIFs, the 
calculated f2 value was 99 which indicated a similarity between these two profiles. 
Although SIF with pancreatin had a solubilisation activity and was expected to increase 
drug dissolution this was not observed probably due to the precipitation which led to 
lower dissolution rates. 
3.3.2.4 Surface morphology of itraconazole disks 
To gain a deeper understanding of the dissolution process of itraconazole, the surface 
morphology of the disks was monitored using SEM as a visualizing method. Images 
were taken after exposure to SGF pH 1.2 at three time points 5,24 and 48h, and in SIF 
only after Sh as the IDR dissolution did not show any change after that time point. The 
displayed images were taken at 500,1000 and 200OX magnifications. 
Although it was expected that dissolution would take place evenly across the surface of 
the disks, the signs of superficial disintegration started to appear after 5h as if gradual 
erosion was occurring (Figure 3.12). These observations were more pronounced after 
24h (Figure 3.13) where the smoothness of the disk started to diminish. After 48h 
(Figure 3.14) a marked change was noticed as if a plume was being formed over the 
disk surface during the dissolution process and the surface appeared to become more 
porous. 
t=l 
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Figure 3.14 SEM photomicrographs for itraconazole disks after exposure to SGF for 48h, taken at 
three magnifications 500x, 100ox and 2000x, scale bars: 63.2pm, 31.6jAm and 15.8pm 
This irregularity in the dissolution ol'the disk could be attributed to the hydrodynamics 
ol'the fluid and the direction of fluid flow on the dissolution surface. Previous studies 
showed that when using the static disk configuration, the fluid flows from the surface of 
the disk radially and sweeps inwards to the centre oC the disk. Then fluid moves axially 
upwards towards the centre of the paddles, forming a plume ot'the dissolved material 
ý -1-i , ro 'n . -, - 
"  "" 
 
92 
over the disk. Consequently, this suggested that not all the disk surface was equally 
accessible to dissolution (Smith and Colton, 1972; Mauger et al., 2003). 
Another possibility behind the irregularity in the surface of' the disks is that although 
Much effort was applied to smooth the surface of the disk some striations, resulting 
from the compression of the surface, may still exist leading to this unevenness. 
Finally, although investigations to eharacterise the solid phase of the drug did not show 
any evidence of amorphism, minor transformations may have occurred which were less 
than the detection of the applied procedures. Such trans fortnations Could create localiscd 
spots that were more soluble than the remaining crystalline material (I lancock and 
Parks, 2000). 
In SIF, there was a minimal change in the surlace morphology (Figure 3.15), with tile 
Surface remaining relatively flat throughout the 5h. This reflects the dissolution profile 
acquired in that medium where the amount of itraconazoic dissolved was less than tile 
limit of quantification of the analytical method. 
Figure 3.15 SEM photornicrographs for itraconazole disks after exposure to SIF for 5h, taken at 
two magnifications 500 x and 2000x, scale bars: 63.2pm and 15.8pm 
3.4 General discussion 
Due to the low solubility of itraconazole, it was difficult to maintain sink conditions in 
the dissolution experiments. Although it is desirable to keep sink conditions throughout 
the dissolution process (CDER/FDA, 1997), these conditions may not prevail in the 
GIT. Attaining these conditions in vivo depends upon the pcrineability, volurne and 
composition of luminal fluids (Dressman and Reppas, 2000). Since itraconazole has a 
solubility of less than Iýtg ml-1, the volume of' the GI fluids is not large enough to 
dissolve a typical dose Of IOOMg, unless the mucosa permeability is high enough to 
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compensate for this poor solubility. In vivo, the basic drug is expected to be dissolved 
mostly in the stomach, which acts as reservoir, while the main site for absorption is the 
intestinal mucosa (Dressman et al., 1998). So it is more probable that sink conditions 
are not maintained in gastric fluids and so better IVIVC would be achieved under non- 
sink conditions for this drug. 
The acquired dissolution profiles of ketoconazole were compared to the literature data 
on ketoconazole dissolution from various formulations. For example, Galia et al. (1998) 
studied the dissolution of ketoconazole tablets (Nizoral Tm, 200 mg) in 500ml SGF (pH 
1.2) in USP 11 apparatus stiffed at 100rpm and found that all tablets dissolved within 
30min. Zhou et al. (2005) found that 90% of ketoconazole dissolved from ketoconazole 
USP tablets (200 mg) within 20min in 0. IN HCI (pH 1.2) stiffed at 50rpm. While at pH 
6.8 only 4% of ketoconazole dissolved within one hour. This provides an approximation 
for drug behaviour from intrinsic disks and dosage forms with a slightly slower release 
from the formulations that could be attributed to interactions from formulation 
constituents and different experimental conditions. 
The same comparison was not valid in the evaluation of the dissolution of itraconazole 
marketed capsules (SporanoXTm) as in this dosage form the drug exists in an amorphous 
form while in the present investigation the itraconazole powder was crystalline and it is 
known that the solid state affects the dissolution and the solubility of the entities. 
Upon dissolving the ionisable basic drugs an increase in the pH of the dissolving media 
was expected, however, a final pH adjustment was not performed. Some investigators 
previously recommended adjusting the final pH when determining the solubility of 
ionised compounds (Alsenz and Kansy, 2007). However, this procedure might be 
physiologically irrelevant (Vertzoni et al., 2007). With highly dosed drugs, such as in 
the present case, where doses are 100-200mg a pH shift may also occur during 
dissolution in the GIT, and this is more likely at fasting conditions where the buffer 
capacity is at its lowest level (Kalantzi et al., 2006a). Hence, this suggests that to 
achieve a better IVIVC there is no need to alter the final pH of the media. 
3.5 Conclusion 
The data acquired from the techniques employed to detect changes in the solid state of 
itraconazole and ketoconazole did not provide any clear evidence of polymorphism 
changes due to compression. The decrease in the thermal parameters observed in the 
DSC scans and the noisier PXRD patterns of the compressed samples compared to the 
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uncompressed samples were probably due to the bigger particle size of the compressed 
material. Consequently, drug compact disks were prepared and employed in the current 
investigation to assess the intrinsic dissolution of the drugs. 
To predict the in vivo performance of a drug, it is important to run the in vitro 
dissolution test under conditions that are likely to simulate in vivo fluids. This initial 
dissolution investigation was concerned with mimicking the pH values of the GIT in the 
fed and fasting states. The two drugs showed a strongly pH dependent solubility which 
increased markedly when the pH dropped to 1.2. The dissolution profiles mirrored the 
solubility studies. This clearly underpins the importance of elevated gastric acidity on 
the dissolution of those two basic drugs in vivo. 
Studies concerned with the influence of gastric p1l on the bioavailability of itraconazole 
(Section 1.10.4) showed that when the drug was co-administrated to subjects with an 
antacid suspension or subjects were pre-treated with H2 blockers, itraconazole 
bioavailability decreased (Lange et al., 1997; Lohitnavy et al., 2005). The same 
observations were found with ketoconazole as when it was administered in acidified 
solution its bioavailability increased compared to administering the drug alone, whereas 
it decreased when ketoconazole was giving with H2 blockers (Van Der Meer et al., 
1980). 
Food components have a buffering effect which increases the gastric pH, this is 
supposed to suppress the bioavailability of itraconazole and ketoconazole, however, an 
increase in the bioavailability of the drugs was reported. This raised the question of 
whether food is affecting the dissolution and so improving the bioavailability of the 
examined drugs. Consequently, further investigations of the dissolution of itraconazole 
and ketoconazole in the presence of dietary constituents were carried out. 
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Chapter 4: The effect of food components on the dissolution 
of itraconazole and ketoconazole 
4.1 Introduction 
Drugs in the gastrointestinal tract are exposed to a medium of partially digested food, 
comprising mixtures of fat, protein and carbohydrate. The effect of food on the 
bioavailability of drugs can be determined and predicted by studying the dissolution of 
drugs in simulated in vivo conditions. The dissolution behaviours of itraconazole and 
ketoconazole were evaluated in biorelevant media which were developed to take the 
effect of food into account. Consequently, the objective of this work was to understand 
the impact of food on the solubility and dissolution of itraconazole and ketoconazole. 
Since the composition of the fed stomach is variable according to the type of the meal 
consumed, a milk mixture was used as an example of a balanced diet. Furthermore, 
dissolution was also studied in less complex media composed of specific food types; 
protein (albumin, casein, gluten and gelatin), carbohydrates (glucose, lactose and starch) 
and amino acids (lysine, glycine, alanine, leucin and aspartic acid) to mimic a digested 
meal. 
4.2 Materials and methods 
4.2.1 Materials 
Details of all materials used in the preparation of the dissolution media and in 
performing the experiments are listed in Section 2.1. 
Materials used for the protein assay were Bradford reagent obtained from Sigma-aldrich 
Chemie (Steinheim, Germany) batch number 046K4374 and bovine serum albumin 
obtained from BDH (Poole, UK) with a batch number BAH62-630 
4.2.2 Preparation of dissolution media 
Simulated gastric fluids SGF (pH 1.2) and SGF (pH 3) were prepared as described in 
3.2.3.1. Generally, the dissolution media were prepared by dissolving or dispersing food 
substances in SGF pH 3 and then the final pH was adjusted to 3 with diluted HCI. 
Specific procedures for each medium are described below: 
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4.2.2.1 Milk-containing media 
Media containing milk were prepared by mixing an equal volume of the specified milk 
with SGF pH 1.2. The pH of the resulting solutions were variable (pH 2 to 4) depending 
on the type of the milk added and batch to batch variations. Therefore, for consistency, 
the final pH was adjusted to 3 using either OAM HCI or OAM NaOH. This allowed 
investigation of the effect of one variable; fat content, on the dissolution of the drugs. 
4.2.2.2 Album in-containing media 
Albumin from hen egg white was used at concentrations of 0.1,1,2,3 and 4%, w/v and 
for the phase solubility studies additional dilutions were prepared. Addition of albumin 
to SGF raised the pH because of the buffering effect of albumin. For instance, 1%, w/v 
albumin in SGF had a pH of 5.3. Therefore, the pH of the solutions and dispersions 
were all adjusted to 3 using 1M HCI as required. 
4.2.2.3 Gelatin-containing media 
Gelatin from bovine skin was dissolved in SGF at concentrations of 0.5,1, and 2%, w/v- 
For solubility determinations further dilutions were prepared. An increase in pH was 
also observed due to adding gelatin. For instance, 1%, w/v gelatin solution had a pH of 
4.9. Therefore, the final pH was reduced to 3 with 0.1 M HCL 
4.2.2.4 Casein- and gluten-containing media 
Casein from bovine milk (2%, w/v) and gluten from wheat (2%, w/v) were dispersed in 
SGF. Saturated solutions of the two proteins were prepared as follows: an excess 
amount of the protein was added to water and the resulting dispersion was stirred 
overnight and then filtered under vacuum using the Buchner apparatus and filter paper 
(Whatman, type 1). Sodium chloride (2g L-1) was added and the pH of the resultant 
solution was adjusted to pH 3 with 0.1 M HCI. 
4.2.2.5 Amino acid-containing media 
The amino acids lysine (LYS), glycine (GLY), leucin (LEU) and alanine (ALA) (1%, 
w/v) were dissolved in SGF and the final pH was taken to 3 with IM HCI. 
Media containing the same molar concentrations (133mM) of the amino acids GLY, 
LYS and ALA were prepared by dissolving the appropriate amount of the amino acid in 
SGF. The final pH was taken to 3 with IM HCl. 
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SIF containing 1%, w/v GLY was prepared by dissolving GLY in SIF (SIF composition 
is listed in Section 3.2.3.1). The final pH was checked as 6.8. 
When aspartic acid (ASP) was added to SGF, it formed a dispersion rather than a 
solution due to the low solubility of the acidic ASP in SGF. Therefore, the suspension 
was filtered through Whatman filter paper type I and then the final pH was checked. 
The concentration of ASP in the aqueous saturated solution (pH 3) was extrapolated 
theoretically using the Henderson-Hasselbalch equation for ampholyte compounds (Eq. 
(4.1)) (Avdeef, 2007). S denotes the solubility of ASP at pH 3 and So the intrinsic 
solubility (minimum solubility) which was computed as 1.5x 10'5 M. 
logs = log So + log(, 
0-pKa3-pKa2+2pH + 10-plCaa+pH + lo+pKai-pH + 1) Eq. (4.1) 
pKal=1.9, pKa2=3.7, pKa3=9.6 (The Merck Index, 2006). 
4.2.2.6 Sugar-containing media 
Sugar solutions, composed of glucose, lactose and starch in SGF pH 3 (1%, w/v), were 
prepared by dissolving the appropriate amount of the sugar in SGF pH 3 and the final 
pH was adjusted to 3 with a few drops of 0.1 M HC1. 
4.2.3 Media characterisation 
4.2.3.1 Viscosity 
The viscosity of each medium was measured in triplicate using a Hydramotion 
vibrational sensor viscometer (Viscolite VL700-T 15) (Section 2.5.1.2). The sensor was 
immersed in 30ml of the medium and measurements were recorded. 
Another technique, controlled stress rheometery (Carri-Med model CSL2-100) was 
employed to investigate the flow behaviour of media containing milk, albumin, casein, 
gluten and gelatin, using the method described in Section 2.5.1.3. The flow properties of 
the fluids were measured in a shear stress range of 0 to 500s" in up and down curves. 
Accordingly, the results were represented as shear rate versus shear stress using 
Rheology Advantage Data Analysis Software (TA Instruments Ltd. ). 
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4.2.3.2 Surface tension 
Surface tension was determined in triplicate using a Wilhelmy plate tensiometer, static 
mode, at 37T (Section 2.5.2). Data points for each medium were collected by an 
interfaced computer every 7s up to 600s. 
4.2.4 Contact angle measurements 
The wettability of itraconazole and ketoconazole compact surfaces with the media 
containing proteins and milk were assessed in triplicate using the Sessile drop method. 
Photographs were taken immediately after placing a drop of fluid on drug surface and 
every 5s thereafter for a total period of 5min (Section 2.5.3). 
4.2.5 Solubility studies 
Solubility studies were perfonned according to the phase solubility studies reported by 
Higuchi and Connors (1965) to investigate the effect of the additives on the solubility of 
the drugs. 
Excess amounts of itraconazole or ketoconazole (30mg or 300mg, respectively) were 
added to screw capped vials containing l0ml of media (SGF) containing various 
quantities of food constituents. The vials were shaken at 37*C for 24h. The suspensions 
were centrifuged and filtered through 0.2ýtrn PVDF syringe filters (Section 2.2.2). 
Media which contained particulate matter (milk and albumin containing-media) clogged 
these filters which required the use of filters with a bigger pore size (Nicolaides et al., 
1999). For the albumin-containing samples, IýLrn glass filters (Gelman Sciences) were 
used and 5pni Acrodisc Versapor filters (Gelman Sciences, medium: acrylic polymer) 
were used for the milk-containing samples. Filter validation was performed as described 
in Section 2.4.1. 
Itraconazole samples were diluted 2-fold with the mobile phase which was a mixture of 
acetonitrile-0.02M potassium dihydrogen phosphate (60: 40, v/v) except samples 
collected from media containing carbohydrates or amino acids. All ketoconazole 
samples were diluted as appropriate (from 2 to 16-fold) with water-acetonitrile (50: 50). 
4.2.6 Dissolution tests 
In parallel, intrinsic dissolution studies in the media were performed using the stationary 
disk method under the same conditions described in Section 2.2.4. Samples collected 
from complex dissolution media containing milk and protein were pre-treated by 
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extraction (Section 2.2.5). No extraction was performed with samples collected from 
media containing carbohydrates or amino acids where ketoconazole samples were 
diluted with a mixture of water-acetonitrile (50: 50) as appropriate and itraconazole 
samples were not diluted due to the low solubility of the drug in these media. 
4.2.7 Drug analysis 
Assays were preformed by HPLC using fluorescence detection for itraconazole and UV 
detection for ketoconazole (Section 2.2.6). 
4.2.8 Casein solutions quantitation: Bradford assay 
The concentration of casein in the filtered saturated solution was determined using the 
Bradford protein assay (Bradford, 1976). The principle of the assay is when an acidic 
solution of Coomassie Brilliant Blue G-250 binds to arginine and aromatic residues 
present in the protein, a shift in the UV absorbance occurs. The anionic (bound form) 
has absorbance maximum at 595nm whereas the cationic form (unbound form) has and 
absorbance maximum at 470nm. The increase of absorbance at 595run is proportional to 
the amount of bound dye and so to the amount of the protein in the sample. 
Standard solutions of bovine serum albumin ranging from 100 to 200ýtg ml"' (5 points) 
were prepared by dissolving the protein in 5OmM tris-buffer (hydroxymethyl) 
aminomethane-HCI (pH 8). Each standard solution (O. Iml) was added into a plastic 
cuvette containing 3ml of Bradford reagent. Cuvettes were covered with paraffin film, 
gently inverted a few times to mix and then incubated for 5min prior to taking the 
measurements. The same procedures were followed with casein solutions which were 
diluted with tris-HCI buffer. Casein solutions (O. Iml) were added to 3ml of Bradford 
reagent in plastic cuvettes with parafilm, inverted and incubated for 5min. The 
absorbance of all casein samples and albumin standards were measured at 595nm using 
a Thermo Electron spectrophotometer. 
4.3 Results 
4.3.1 Media characterisation 
4.3.1.1 Viscosity 
4.3.1.1.1 Rotational rheometer 
The rheological behaviour of the media containing milk and protein was determined 
using the provided data analysis software and the type of flow was based on minimizing 
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the standard error of the fitting model. SGF and SGF containing gelatin exhibited 
Newtonian behaviour (Figure 4.1) whereas milk and the other protein-containing media 
were non-Newtonian. 
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Figure 4.1 Shear stress versus shear rate of SGF containing gelatin (a) 0.5%, (b) I %, (c) 2% and (d) 
4%, w/v (red: up curve and blue: down curve). Measurements were taken at 3TIC using a cone 
/plate geometry with a 6-cm diameter and cone angle of - 10 
In Newtonian fluids the viscosity (q ) does not change with the shear rate (7 
denotes the shear stress, while the viscosity of non-Newtonian fluids varies with shear 
rate, (Figure 4.2). 
4 Non-Newtonian fluid 
0 
C. ) 
(I, 4 Newtonian fluid 
[c = 17. YI 
Shear rate (y) 
Figure 4.2 Example of the flow behaviour of Newtonian and non-Newtonian fluids demonstrating 
the relationship of viscosity to shear rate 
AI%, w/v albumin in SGF demonstrated non-Newtonian behaviour, whereas the flow 
of 0.1%, w/v albumin in SGF was near-Newtonian. The media containing the three 
types of milk, casein or gluten exhibited non-Newtonian behaviour throughout the 
applied conditions (Figure 4.3). 
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Figure 4.3 An example of the flow curves of milk-containing media (SGF-whole fat milk) 
representing shear stress versus shear rate (red: up curve and blue: down curve). Measurements 
were taken at 371C using a cone/plate geometry with a 6-cm diameter and cone angle of - 11 
4.3.1.1.2 Vibration rheometer 
The viscosities of the media were also evaluated using the vibration rheometer which 
allowed the determination of the viscosity of both Newtonian and non-Newtonian 
fluids. Table 4.1 shows the mean viscosities of media containing milk or protein. The 
viscosity of the media increased in the presence of food additives and the more viscous 
media were milk and gelatin-containing media. 
Table 4.1 Viscosity and surface tension of SGIF containing milk, albumin, casein or gelatin. Each 
data point represents the mean of 3 measurements :LS. D. 
Medium Viscosity (mpa. s) Surface tension (mN m-1) 
SCiFpH3 0.71 ± 0.01 66.4± 1.6 
Whole fat milk-SGF pH 1.2 (1: 1) 1.72 ± 0.07 49.7 ± 1.3 
Semi-skimmed milk-SGF pll 1.2 (1: 1) 1.66 ± 0.05 50.4 ± 1.2 
Skimmed milk-SGF pH 1.2 (1: 1) 1.56 ± 0.05 50.9 ± 0.7 
Albumin 0.01% in SGF 0.72 ± 0.01 60.3 ± 0.5 
Albumin 0.1% in SGF 0.82 ± 0.01 55.5 ± 0.7 
Albumin I% in SGF 1.15 ± 0.04 51.9 ± 1.1 
Albumin 2% in SGF 1.28 ± 0.03 49.6 ± 1.2 
Casein filtered solution in SGF 1.04 ± 0.03 48.4 ± 0.6 
Casein solution-SGF (3: 1) 1.01 ± 0.01 50.0 ± 1.0 
Casein diluted solution-SGF (1: 1) 0.94 ± 0.01 50.2 ± 0.7 
Casein diluted solution-SGF (1: 3) 0.90 ± 0.04 51.4 ± 1.0 
Gluten filtered solution in SGF 0.84 ± 0.02 50.2 ± 1.1 
Gelatin 0.5% in SGF 0.87 ± 0.01 51.9 ± 0.5 
Gelatin 1% in SGF 1.15 ± 0.01 50.5 ± 0.9 
Gelatin 2% in SGF 1.43 ± 0.04 45.2 ± 0.6 
Gelatin 4% in SGF 1.98 ± 0.05 45.1 ± 0.9 
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The media containing 1%, w/v glucose or lactose had a greater viscosity than SGF 
(Table 4.2), however this increase was statically insignificant (t-test at significance level 
of 0.05). Starch-containing media had a significantly greater viscosity compared to 
SGF. The addition of amino acids (GLY, LYS or ASP) to the media did not induce a 
significant difference in SGF viscosity. 
Table 4.2 Viscosity and surface tension of SGIF containing sugars or amino acids. Each data point 
represents the mean of 3 measurements ± S. D. 
Media 
Viscosity 
(mpa. s) 
Surface tension 
(mN m-1) 
1% glucose in SGF 0.72 ± 0.01 68.5 ± 0.5 
1% lactose in SGF 0.73 ± 0.01 61.1± 0.8 
1% starch in SGF 0.76 ± 0.01 67.7± 0.6 
1% GLY in SGF 0.73 4: 0.02 65.6 ± 1.7 
1% LYS in SGF 0.70 ± 0.03 60.2 ± 1.0 
ASP saturated solution in SGF 0.71 ± 0.01 65.0 ± 1.1 
4.3.1.2 Surface tension 
The media containing milk or proteins had significantly lower surface tensions 
compared to SGF (Table 4.1). Only slight variations were observed between the media 
containing sugars or amino acids (Table 4.2). 
4.3.1.3 Casein quantitation 
The concentration of casein in the diluted casein-containing media was determined in 
duplicate; variations were not more than 2%. The concentrations of casein in the media 
were 0.005,0.0038,0.0025 and 0.0013%, w/v. 
4.3.2 Contact angle measurements 
Since wetting is the first step for dissolution, it was important to assess the wettability 
of drug disks with the biorelevant media. 
4.3.2.1 Itraconazole 
For comparison, the contact angle formed between a drop of the dissolution medium 
and an itraconazole disk surface at 300s was considered. The contact angles formed 
between the itraconazole surface and the majority of the tested biorelevant media were 
smaller than those observed with SGF (Figure 4.4). This indicated that the media tested 
had the ability to enhance the wetting of the drug. 
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Figure 4.4 shows the mean contact angles of protein- and milk-containing media on 
itraconazole disks. SGF formed a contact angle of 65' and with the inclusion of food 
additives the angle was reduced by approximately 11'. Slight differences were observed 
among the contact angles of the different biorelevant media with the itraconazole 
surface. Contact angles for milk-containing media decreased by about 100, compared to 
SGF. This indicated that addition of milk increased the wettability of the drug but the 
difference was not significant between the three types of milk. The inclusion of gelatin 
in the media decreased the contact angle by 12' but with no marked variations observed 
with an increase in the concentration of gelatin in the media. Similar observations were 
found with gluten-containing medium where the contact angle was reduced by 13'. 
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Figure 4.4 Contact angles for milk- and proteins-containing media with itraconazole disks. Each 
data point represents the mean of 3 measurements ± S. D. 
The enhancement in the wettability was more pronounced with the inclusion of albumin 
in the media, where a 1%, w/v albumin-containing medium reduced the contact angle 
by approximately 15'. Three of the casein-containing solutions induced a decrease in 
the contact angle of approximately 10' while the more diluted casein solution (0.0013% 
w/v) did not markedly affect the wetting. 
4.3.2.2 Ketoconazole 
To compare the contact angles formed on ketoconazole surfaces, it was more 
appropriate to consider the measurements taken after 150s of placing the liquid drop on 
the drug surface since most of the contact angles at 300s were small and variable 
(S. D >- 5 0). 
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Milk-containing media also resulted in a decrease in the contact angle with 
ketoconazole of approximately 14' compared to SGF (Figure 4.5) with no significant 
variations between the milk-containing media (ANOVA at 0.05 level of significance). 
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Figure 4.5 Contact angles for milk and protein-containing media with ketoconazole disks. Each 
data point represents the average of measurements ± S. D. 
Albumin also enhanced the wettability of the ketoconazole surface but to a lesser extent; 
a 1%, w/v solution decreased the contact angle by IV whereas lower concentrations did 
not. A slight enhancement in the wettability of ketoconazole surfaces was noticed with 
gelatin-containing solutions. However, this effect was not significant with solutions 
containing a high amount (t-test, 0.05), most likely due to the high viscosity of gelatin- 
containing media which led to poor spreading and penetration. Gluten and casein- 
containing solutions at the higher concentrations (0.0038,0.005%. w/v) lowered the 
contact angle by 70-100, compared to SGF- 
4.3.3 Solubility and dissolution studies in dietary media 
4.3.3.1 Milk-containing media 
Milk contains the three basic nutritious constituents; proteins, carbohydrates and fat so 
milk mixtures were considered a physiologically relevant dissolution media to 
investigate the dissolution of the drugs in vitro. 
4.3.3.1.1 Itraconazole 
The saturation solubilities for itraconazole media containing whole fat, semi-skimmed 
and skimmed milk increased approximately 24 times from that in SGF (Figure 4.6). 
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Figure 4.6 Solubility of itraconazole at 371C in SGF, SGF containing 50% milk (semi-skimmed, 
skimmed, whole fat) and SGF containing different concentrations of albumin, cascin, gelatin and 
gluten. Each data point represents the mean J: S. D. of 3 measurements 
Statistical analysis of the results indicated that there was no significant difference in 
solubility between the different types of milk (ANOVA at 0.05 level of significance). 
An increase in dissolution was apparent in milk-containing media compared to SGF 
(Figure 4.7). By comparing the amount of itraconazole dissolved in the three milk- 
containing media, it was noticed that the amount dissolved in whole fat milk-containing 
media within one hour was the greatest, whilst after 3h the amount dissolved into semi- 
skimmed milk-containing medium exceeded the corresponding value in whole fat milk- 
containing medium. ANOVA analysis of the IDR data at one and three hours indicated 
a significant difference among the three media. 
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Figure 4.7 The intrinsic dissolution profile of itraconazole at 371C in SGF containing 50 % milk 
(whole fat, semi-skimmed or skimmed). Each data point represents the mean ± S. D. of (at least 4) 
measurements 
The initial IDR (Table 4.3) in whole fat milk-containing medium was the highest, 
probably due to the greater amount of lipid (3.5%) which could have affected the 
dissolution of the lipophilic drug. However, with time, the dissolution in the whole fat 
milk-containing medium started to slow down. The relative decline in the dissolution in 
that medium could be due to stability problems of the milk which were more 
pronounced in the whole fat milk. 
These results provided clear evidence of an increase in both dissolution rate and 
solubility in milk containing-media. The increase in the initial dissolution rate was up to 
6 times greater whereas the solubility increased 24 times, compared to SGF. 
Consequently, the increase in solubility was greater than the increase in dissolution. 
4.3.3.1.2 Keloconazole 
The solubility of ketoconazole in milk-containing media was approximately 6 times 
greater than the solubility in SGF with no significant difference between the solubility 
values for the three different milk-containing media (Figure 4.8). 
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Figure 4.8 Solubility of ketoconazole at 371C in SGF, SGF containing 50% milk (semi-skimmed, 
skimmed, whole fat) and (SGF) containing different concentrations of albumin, casein, gelatin and 
gluten. Each data point represents the mean ± S. D. of 3 measurements 
The initial IDR in whole fat milk-containing medium was 1.3-fold greater than that in 
SGF and it was slightly higher than in the two milk-containing media (Table 4.3). A 
greater increase was observed in the IDR representing the subsequent time period (15- 
240min), of around 5.4-fold compared to SGF (Figure 4.9). 
150 
cc 41, 
C 
100 
0 
50 
0 
0 50 100 150 
Time (minutes) 
200 250 
Figure 4.9 The intrinsic dissolution profile of ketoconazole at 371C in SGF containing 50 % milk 
(whole fat semi-skimmed or skimmed). Each data point represents the mean ± S. D. of 3 
measurements 
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The three dissolution profiles were not significantly different although the dissolution in 
semi-skimmed milk-containing medium appeared slightly greater. The only point that 
was significantly lower was the A time point in skimmed milk containing-media. Thus, 
it was deduced that the fat content did not affect the dissolution of this lipophilic drug in 
the expected manner. 
Table 4.3 IDR data for itraconazole and ketoconazole at 37'C in SGF containing 50% milk (semi- 
skimmed, skimmed, whole fat) 
Medium 
Itraconazole Ketoconazole 
Initial IDR Initial IDR 
(0-15min) (0-15min) 
q, g Min-1 CM-2) (ýLg Min-1 CM-2 
SGFpH3 1.1 ± 0.2 187.3 ± 27.3 
SGF-Whole fat milk 5.5 ± 1.1 247.7 ± 40.5 
SGF-Semi-skimmed milk 3.3 ± 1.1 242.7 ± 39.8 
SGF-Skimmed milk 3.0 ± 0.4 206.4 ± 13.7 
4.3.3.2 Albumin-containing media 
IDR 
(15-240min) 
(pLg min-'cm-2) 
75.4 3.5 
407.7 37.5 
433.7 58.5 
309.5 6.8 
4.3.3.2.1 Itraconazole 
The inclusion of albumin in SGF increased the solubility and dissolution of itraconazole 
with a quantitative relationship between concentration and solubility. The solubility of 
the drug was linear up to concentrations of 2%, w/v of albumin with a coefficient of 
determination r2=0.99, calculated using data analysis from Microsoft Excel software. 
Above 3%, w/v of albumin a plateau level of solubility was reached (Figure 4.10). 
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Figure 4.10 Effect of egg albumin on the solubility of itraconazole at 37C in SGF. The amount of 
albumin added varied from 0.0 1% to 4%, w/v. Each data point represents the mean ± S. D. of 3 
measurements 
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The dissolution of the drug increased with an increase in albumin concentration (Figure 
4.11). For example, in media containing 1,2 and 4%, w/v of albumin the amount 
dissolved per unit area after one hour were 5.1-, 6.7- and 7.8-fold (respectively) greater 
than that recorded in SGF. 
The solubility in 1%, w/v albumin-containing medium was 20-fold greater than that in 
SGF whereas the initial IDR increased only 4 times. At a low concentration of albumin 
(0.5%, w/v) the increase in solubility was II times and the initial IDR was 1.7 times 
greater than in SGF. Accordingly, the increase in the solubility was greater than the 
increase in the dissolution. 
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Figure 4.11 The intrinsic dissolution profile of itraconazole at 370C in SGF containing egg albumin 
in concentrations of 0.5,1,2,3 and 4 %, w/v. Each data point represents the mean ± S. D. of 5 
measurements, in SGF (n=6) 
4.3.3.2.2 Keloconazole 
The solubility of ketoconazole in albumin-containing media displayed clear evidence of 
an increase in the presence of albumin (Figure 4.12). A strong correlation was observed 
between the concentration of albumin and ketoconazole solubility, up to 1%, w/v of 
albumin with a squared coefficient of correlation r2=0.99 (Figure 4.12). Above this 
concentration the increase in solubility declined. 
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Figure 4.12 Effect of egg albumin on the solubility of ketoconazole at 371C in SGF. The amount of 
albumin added varied from 0.01% to 1%, w/v. Each data point represents the mean ± S. D. of 3 
measurements 
An increase in drug dissolution was apparent in media containing albumin (Figure 
4.13). The dissolution rate in the first 15min was faster than for the subsequent time 
period (Table 4.4). There was a decline in the initial IDR with the inclusion of low 
concentrations of albumin, compared to SGF, whereas a slight increase was observed 
with higher concentrations of albumin (I and 3 %, w/v). 
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Figure 4.13 The intrinsic dissolution profile of ketoconazole at 371C in SGF containing egg albumin 
in a concentrations of 0.01,0.1,0.5,1 and 3%, w/v. Each data point represents the mean ± S. D. of 3 
measurements 
The solubility increased 3-fold in 1%, w/v albumin-containing medium compared to 
SGF but the initial dissolution of the drug only increased by a factor of 1.2 and the IDR 
for the subsequent step (15-240min) increased by a factor of 2.6. 
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Table 4.4 IDR of ketoconazole at 37"C in SGF containing various amounts of albumin. Each data 
represents the mean of 3 measurements ± S. D. 
Albumin concentrations in SGF Initial IDR IDR (15-240min) 
(W/V) (gg Min-1 CM-2) (ttg min-' CM-2) 
0 187.3 ± 27.3 75.4 3.5 
0.01% 175.1 ± 23.8 80.5 8.6 
0.1% 136.1 ± 27.2 101.1 6.7 
0.5% 200.0 ± 37.8 133 ± 17.0 
1% 2 17.6 6.3 194.8 9.3 
3% 381.0 32.8 248.1 14.7 
4.3.3.3 Casein-and gluten- containing media 
4.3.3.3.1 Itraconazole 
Suspensions of casein and gluten (2%, w/v) in SGF did not appear to greatly enhance 
the dissolution of itraconazole as the profiles observed were not markedly improved 
over that using SGF alone (Figure 4.14). This could be attributed to undissolved protein 
forming an occlusive layer on the surface of the disks, hence limiting the effect of the 
protein. This hypothesis was tested by increasing the casein concentration to 4%, w/v. 
At this concentration, it was found that virtually no drug dissolved. To avoid this 
'blinding' of the disk, saturated filtered solutions (rather than suspensions) of casein and 
of gluten were prepared. A marked increase in the dissolution was observed in the 
filtered media, confin-ning the effect of undissolved protein. 
To study the relationship between casein concentration and the solubility of 
itraconazole, three diluted casein-containing media were prepared from a filtered casein 
saturated solution. It was found that the addition of casein increased the solubility 
approximately 1.6-fold (Figure 4.6) and a statistical evaluation of these data (ANOVA, 
0.05) showed no significant difference between the solubilities observed with the four 
different casein solutions. Similar observations were found with the dissolution studies 
where no obvious differences were apparent between the dissolution profiles in the 
casein-containing media. Hence, there was no quantitative relationship observed 
between casein concentration and solubility over the range tested. The initial IDR was 
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enhanced 2.4-fold in 0.005% casein and the amount dissolved increased 5-fold 
compared to SGF. 
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Figure 4.14 The Intrinsic dissolution profile of itraconazole at 370C in 2%, w/v casein in SCF, 
casein saturated filtered solution, 2%, w/v gluten in SCF and gluten saturated filtered solution. 
Each data point represents the mean ± S. D. of 3 measurements, SCF (n=6) 
Although the gluten-containing solution appeared to increase the dissolution rate, this 
increase was not statistically significant compared to the SGF because the data were 
widely distributed. 
4.3.3.3.2 Ketoconazole 
The solubility studies indicated that there was an enhancement of ketoconazole 
solubility of approximately 1.2-fold in 0.0038 and 0.005%, w/v casein solutions 
whereas the more diluted solutions of casein did not induce a significant effect (Figure 
4.8). The data presented in Figure 4.15 shows that there was an increase in dissolution 
of ketoconazole in casein saturated solution compared to the SGF. The IDR increased 
by a factor of 1.2 to 1.5 in the presence of casein. 
The inclusion of gluten in the media did not induce a discernible effect on either the 
solubility or the dissolution of ketoconazole. 
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Figure 4.15 The Intrinsic dissolution profile of ketoconazole at 37*C in SGF containing cascin and 
gluten filtered solutions. Each data point represents the mean of 3 measurements ± S. D. 
4.3.3.4 Gelatin-containing media 
4.3.3.4.1 Itraconazole 
The solubility of itraconazole in gelatin containing media depicted an increase in 
itraconazole solubility (2- to 4-fold) with an increase in the concentration of gelatin 
(Figure 4.6). 
The solubility and the amount dissolved in one hour per unit area in 0.5%, w/v gelatin 
media did not increase significantly from that in SGF but with media containing higher 
concentrations of gelatin a marked increase was recorded (Figure 4.16). 
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Figure 4.16 The intrinsic dissolution profile of itraconazole at 370C in SGF (pH 3) containing 
gelatin in concentrations of 0.5,1 and 2 %, w/v. Each data point represents the mean ± S. D of 3 
measurements, in SGF (n=6) 
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4.3.3.4.2 Ketoconazole 
Both solubility and IDR increased significantly in the presence of gelatin in SGF. The 
solubility increased linearly with gelatin concentration where 1,2 and 4%, w/v gelatin 
in SGF recorded a 2.5-, 3.5- and 5.2-fold increase in solubility respectively, compared 
to SGF (Figure 4.8). 
The gelatin-containing media showed similar initial dissolution patterns. However, 
within 3h there was clear evidence that the increase in the dissolution rate was 
proportional to gelatin concentration (Figure 4.17). The increase in the dissolution rate 
and the solubility was approximately equivalent in gelatin-containing media. 
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Figure 4.17 The intrinsic dissolution profile of ketoconazole at 370C in SGF containing gelatin in 
concentrations of 1,2 and 4 %, w/v. Each data point represents the mean ± S. D. of 3 measurements 
4.3.3.5 Amino acid-containing media 
Three amino acids (ASP, LYS and GLY) were chosen for this investigation as 
representative of acidic, basic and neutral amino acids. Thereafter, the study was 
expanded to include two further neutral amino acids: ALA and LEU. Table 4.5 gives 
their structures and isoelectric points. 
Table 4.5 The linear structure and the isoelectric point of the assessed amino acids 
Amino acids Structure Isoelectric point 
GLY NH2CH2COOH 6.1 
ASP HOOCCH(N I 12)CH2COOH 2.9 
LYS HOOCCH(NH2)(CH2)4NH2 9.6 
ALA CH3CH(NH2)COOH 6.0 
LEU HOOCCH(NH2)CH2CH(CH3)2 6.0 
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4.3.3.5.1 Itraconazole 
Media containing amino acids showed a slight increase in both dissolution and 
saturation solubility (Table 4.6). The solubility was greater in GLY, ALA and LEU- 
containing media. LYS-containing medium induced an enhancement in the solubility 
but this was not significant. ASP did not affect the solubility which could be explained 
by its low concentration in the medium. The solubility of ASP at pH 3 was computed as 
0.0003 %, based on its aqueous solubility which is 0.4%, w/v. 
The amount of itraconazole dissolved within Ih was slightly higher in media-containing 
GLY, ALA and LEU and increased further by 3h. LYS and ASP inclusion did not affect 
significantly the dissolution of itraconazole (Mest, 0.05 significance level). 
Table 4.6 Solubility and intrinsic dissolution of itraconazole at 370C in SC IF containing I%, w/v 
amino acid. Each data point represents the mean ± S. D. of 3 measurements 
Medium 
SGF 
GLY I% in SGF 
ALA I% in SGF 
LEU I% in SGF 
LYSI%inSGF 
ASP saturated solution in SGF 
4.3.3.5.2 Ketoconazole 
Solubility Amount dissolved per unit 
(Ag ml-') area within 60min (pg cm-2) 
0.035 ± 0.003 22.7 ± 1.8 
0.060 ± 0.008 35.7 ± 1.5 
0.073 ± 0.014 37.1 ± 4.1 
0.075 ± 0.008 35.0 ± 2.5 
0.056 ± 0.012 32.0 ± 6.8 
0.040 ± 0.004 23.5 ± 3.4 
GLY inclusion in the medium increased the solubility 11 -fold whereas LYS increased 
the solubility 6-fold. ASP did not induce a discernible effect. Consequently, the effect of 
further neutral amino acids was investigated. Media containing ALA and LEU were 
assessed. Each neutral amino acid-containing media showed considerable solubility 
enhancement of ketoconazole (Figure 4.18). A parallel increase in the dissolution rate of 
ketoconazole was also observed in these media (Figure 4.19). 
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Figure 4.18 Solubility and [DR of ketoconazole at 37*C in amino acid-containing SGF (pH 3). Each 
data point represents the mean ± S. D. of 3 measurements 
Visual observations of the disks during the dissolution process showed that holes 
formed at the surface of the disks after 3h. Therefore the results after this time point 
were invalid for IDR calculations due to the change in the disk surface area. This 
phenomenon was due to the high solubility of the drug in these media which led to fast 
dissolution. 
The IDR (15-180min) increased by approximately 4.8-fold in solutions containing 1%, 
w/v GLY and 5.6-fold in 1%, w/v ALA, whereas a greater increase of 6.6-fold was 
observed in media containing I%, w/v LEU. 
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Figure 4.19 The intrinsic dissolution profile of ketoconazole at 371C in SC F containing I%, w/v 
amino acids (LYS, GLY, ALA and LEU). Each data point represents the mean ± S. D. of 3 
measurements 
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To evaluate the effect of the pH of the medium on the amino acid-solubilising effect, 
dissolution was further investigated in simulated intestinal fluid (SIF) pH 6.8 containing 
1%, w/v GLY. Poor enhancement was observed with the inclusion of GLY in the 
medium as the dissolution only increased 1.8-fold and the solubility 1.3-fold, compared 
to SIR This indicated that the solubilising effect of GLY in SIF (pH 6.8) was less than 
that in SGF (pH 3). 
A comparison of the effect of the different amino acids on the solubility of ketoconazole 
was achieved by considering the molarity instead of weight concentration. 1%, w/v 
GLY was equivalent to 133mM so equimolar solutions of LYS (1.9%, w/v) and ALA 
(1.2%, w/v) were prepared. It was found that ALA induced the greatest enhancement in 
solubility of 11.6-fold whereas the increase in LYS-containing media was 7.8-fold. 
4.3.3.6 Sugar-containing media 
4.3.3.6.1 Itraconazole 
Three different carbohydrates were chosen to represent examples of mono-saccharides 
(glucose), disaccharides (lactose) and polysaccharides (starch). The solubility and 
dissolution values of itraconazole in these media exhibited a slight increase compared to 
SGF. However, statistical studies for the amount dissolved in one hour showed this 
increase was insignificant (Nest, 0.05 significant level) (Table 4.7). 
Table 4.7. Solubility and intrinsic dissolution of itraconazole at 370C in SG F containing I%, w/v 
carbohydrate. Each data point represents the mean ± S. D. of 3 measurements, IDR in SGIF (n=6) 
Medium 
Solubility Amount dissolved per unit 
(ILg Ml-, ) area within 60min (Ag CM-2 ) 
SGF (pH 3) 0.035 ± 0.003 22.7 ± 1.8 
Glucose 1% in SGF 0.039 ± 0.002 31.4 ± 3.8 
Lactose 1% in SGF 0.044 ± 0.006 35.2 ± 8.1 
Starch 1% in SGF 0.042 ± 0.004 36.3 ± 11.0 
4.3.3.6.2 Ketoconazole 
Glucose and starch inclusion did not induce an effect on ketoconazole solubility or 
dissolution (Figure 4.20). A slight increase in dissolution was seen with lactose- 
containing medium. 
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Figure 4.20 The intrinsic dissolution profile of ketoconazole at 371C in SGF containing 1%, w/v 
carbohydrate (glucose, lactose and starch). Each data point represents the mean ± S. D. of 3 
measurements 
4.4 Discussions 
4.4.1 Viscosity 
4.4.1.1 Rheology studies 
The purpose of studying the rheology of the media was to investigate probable changes 
in viscosity due to the rotation of the paddle in the dissolution tester. This creates a 
shear rate in the liquid inside the dissolution vessels and the shear rate will vary 
according to the position in the USP 11 dissolution vessels (Kukura et al., 2004). 
It was found that viscosity of gelatin-containing media was independent of the shear 
rate. This Newtonian behaviour was consistent in the four gelatin-containing solutions 
(0.5,1,2,4%, w/v) (Figure 4.1) and was in agreement with previous findings (Marcotte 
et al., 2001). 
On the other hand, milk- and casein-containing media were non-Newtonian. Skimmed 
and whole fat milk were previously found to be non-Newtonian (Kristensen et al., 
1997). Medium with a higher concentration of albumin (1%, w/v) was non-Newtonian 
whereas the more diluted solution was Newtonian (Singh et al., 2005). 
Gluten is composed of two proteins, glutenins and gliadins. The former contributes to 
the elasticity and the latter to the viscosity. Gluten flow was fitted to the power law 
model suggesting non-Newtonian behaviour, which comes in agreement with previous 
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findings regarding the rheology of gliadins solution (Sun et al., 2008). Consequently, 
the viscosity in these media is shear rate-dependant. 
For the non-Newtonian fluids it was expected that during the dissolution experiment the 
change in the shear rate, due to the stirring of the paddles and according to the location 
in the vessel of USP dissolution tester Apparatus 11, may affect the viscosity of the these 
media. These findings may be more interesting when studying the dissolution of the 
dosage forms, which was found to vary according to the position of the dosage form. 
This position-dependent viscosity may also affect the flow hydrodynamics of the 
dissolution medium and in turn affect the dissolution rate of the dosage forms. 
4.4.1.2 Vibration rheometer 
The viscosity of a protein-containing solution depends on its intrinsic properties, such as 
molecular weight, size, volume, surface charge and protein-protein interactions (Nandi, 
1997). Viscosity is also influenced by environmental factors such as pH, temperature 
and ionic strength. Protein molecules absorb water and swell affecting the flow 
behaviour of their solution. The viscosity of albumin and gelatin-containing media 
showed an increase proportional to the concentration of the protein. Less increase in the 
viscosity was noticed in gluten-containing medium. 
Milk-SGF media had a higher viscosity than SGF and the greater the fat content of milk 
the higher the viscosity (Table 4.1). Casein is the main protein in milk as it represents 
about 80% of milk protein. Casein molecules do not exist as monomers at physiological 
conditions as they tend to associate with each other and with calcium phosphate to form 
spherical structures called casein micelles. The hydrophobic fractions are mainly in the 
core and the hydrophilic fractions are on the surface of the micelle (Liu and Guo, 2008). 
These micelles are the main contributors to the viscosity of milk (Walstra et al., 2006b). 
The fat content also contributes to the viscosity but to a lesser extent. An increase in the 
viscosity of SGF containing casein was observed, compared to SGF. This was attributed 
to the flexible open structure of casein and the relatively high capacity to bind water 
which led to the elevation in viscosity of the media (Fox and McSweeney, 1998a). 
Carbohydrates have numerous hydroxyl groups which enable them to bind water 
molecules through hydrogen bindings and which lead to an increase in the viscosity of 
their aqueous solutions. Glucose or lactose solution induced a slight increase in the 
viscosity, compared to SGF (Table 4.2) which is in accordance with literature values 
120 
obtained at 201C. A 1%, w/v glucose or lactose solution in water had a viscosity of 
1.021 and 1.026mPa. s, respectively, whereas the viscosity of water was 1.002 mPa. s 
(Lide, 2002). The presence of starch in the medium induced more increase in viscosity. 
It is composed of two components; amylose and amylopectin, the fon-ner is a straight 
chain molecule which has the ability to bind water and swell, and in turn increase the 
viscosity of starch-containing media (Niba, 2006). 
Although amino acids form hydrogen bonds with water molecules through their 
carboxylic acid and amino groups, the viscosity of media containing amino acids did not 
change considerably (Table 4.2). 
4.4.2 Surface tension 
In general, protein molecules exhibit surface tension activity due to their amphiphilic 
nature. Proteins are adsorbed to the interface between two phases: liquid/gas or 
oil/water, causing a distinct reduction in interfacial tension. Differences in surface 
activity among proteins arise mainly from differences in their structures, size, stability 
and hydrophobicity (Magdassi and Kamyshny, 1996). 
The surface tension of the milk-containing media was relatively low due to the surface 
active components of milk which are proteins, casein micelles and whey protein, 
phospholipids, free fatty acids and monoglycerides (Walstra et al., 2006a). These 
components can adsorb on the air/liquid interfacial surface and reduce the surface 
tension. The milk media with a higher fat content had slightly lower surface tension. 
The mean values observed for the whole fat milk-containing medium were in good 
agreement with data for simulated fed gastric fluid composed of milk and buffer (1: 1), 
obtained by Jantratid et al. (2008b). 
The presence of albumin lowered the surface tension of the media proportionally up to a 
concentration of 2% albumin. The medium of pH 3 led to denaturing of the protein 
which was shifted from its isoelectric point (PI: 4.8). Egg albumin exhibits a surface 
activity; the denaturing phenomena combined with the probable effect of salts resulted 
in a further drop in the surface tension of albumin-containing media (Koseki et at., 
1988). A 1%, w/v solution of albumin in SGF exhibited a 15mN m-1 decrease in the 
surface tension, relative to SGF. 
Gelatin-containing solutions also had a mild surface activity which was proportional to 
protein concentration (Sato and Ueberreiter, 1979). However, the acidity of the media 
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combined with the presence of an electrolyte (NaCl) in the media led to a marked 
decrease in the surface tension of gelatin media. The inclusion of 1%, w/v gelatin in 
SGF lowered the surface tension by 16mN m-1, compared to SGF. 
Casein containing solutions also had low surface tensions. The values dropped with an 
increase in casein concentration suggesting casein micelles were not formed. However, 
the drop in surface tension was not significant. If casein micelles were formed, then no 
further drop in the surface tension would be expected by increasing the concentration of 
the protein, i. e. the surface tension would remain constant after reaching the CMC. 
Thus, these results suggested that CMC for casein was not reached but because the 
variations were not significant this could not be confirmed. 
The inclusion of gluten in the SGF resulted in a l6mN m-1 drop in the surface tension. 
This protein is composed of glutenins and gliadins and the latter is responsible for the 
surface activity. This agrees with a previous report that gluten solutions had low surface 
tensions under acidic conditions (Takeda et al., 200 1). 
Sugars can cause an increase in the surface tension of water due to an increase in the 
hydrogen bond driven cohesion among the sugar solute molecules (Docoslis et al., 
2000). The measured surface tension of glucose-containing medium increased compared 
to SGF (2mN m-1). However, the lactose solution had a significantly lower surface 
tension than SGF. This was probably due to the presence of impurities in lactose which 
led to these lower surface tension measurements (Table 4.2). 
In a similar way amino acids were expected to induce a rise in the surface tension due to 
an increase in the cohesive forces due to hydrogen bonding combined with electrostatic 
attractions among the solute molecules (Docoslis et al., 2000). However this was not 
observed. 
4.4.3 Dissolution and solubility 
The two azole compounds had a significantly higher solubility and dissolution rate in 
the presence of most of the assessed food components, compared to the reference that 
did not contain these additives, which was SGF. 
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4.4.3.1 Milk-containing media 
Although itraconazole and ketoconazole are lipophilic molecules, the increased fat 
content of milk was expected to aid solubility but the different fat content of the three 
types of milk did not show the expected systematic effect on drug behaviour. 
The composition of the three types of milk was identical, except for the fat content 
(according to supplier information). Furthermore, only minor variations in the surface 
tension of the three types of milk containing-media were noticed. A slight difference in 
viscosity was noted, however such small variations were not expected to significantly 
affect the dissolution (Macheras and Reppas, 1987). Although it was expected that a 
higher fat content would induce more dissolution, this did not occur. 
It is possible that some disruption of the milk emulsion occurred during the dissolution 
experiment which led to separation of the fat, which would then float to the surface (Fox 
and McSweeney, 1998b), making it unavailable to the drug disk at the bottom of the 
vessel. Emulsions are known to be broken by extremes of pH, as was seen upon the 
addition of SGF to milk. Steps were taken to minimize this disruption, by adding acid to 
the milk rather than vice versa, but even this process still caused some visible change to 
the appearance of the milk. This destabilizing effect of acid on milk-containing media 
could also explain why the itraconazole results acquired were variable. 
With ketoconazole, which is a relatively less lipophilic drug, variations in the 
dissolution behaviour in the three types of milk containing-media were not obvious and 
the three profiles were nearly identical, except at the later time point. In a previous 
study about drug dissolution in milk mixtures (Shah, 2006), the author reported that the 
dissolution of ibuprofen did not vary according to the fat content of the milk-containing 
media and this was attributed to the structure of the lipids in milk. Nearly all of the fat 
in milk exists in separate small globules coated with a globule membrane which acts as 
a barrier between the fat and the milk plasma and prevents fat globules from 
coalescence (Walstra et al., 2006a). Thus, the composition of the membrane may 
physically hinder the fat solubilising effect onto the lipopholic drugs. However, the 
membrane is fragile and the stability of the fat globules decreases linearly with 
increasing fat content in milk. Thus, the mechanical effect of the stirring during the 
dissolution experiment may affect the stability of milk fat globules and release the fat to 
the media causing variable effects, particularly with the whole fat milk-containing 
medium (Fox and McSweeney, 1998b). 
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Milk-containing media had a lower surface tension, higher viscosity and relatively 
smaller contact angle with both drug surfaces than SGF. The mechanism by which milk 
enhanced the dissolution of the drugs was through solubilisation effect in addition to 
enhancing the wettability of drug surfaces. 
From the Noyes and Whitney equation (Eq. (1-3)) the dissolution increased through 
increasing the saturation solubility. Furthermore, drug-milk complex formation led to a 
decline in the concentration of free drug in the dissolution medium which in turn 
increased the gradient of the concentration (Cs-Q leading to an increase in the 
dissolution rate. Consequently, more diffusion of the drug from the disk into the bulk 
solution occurred. Thus, the additives to the dissolution media played the role of a 
carrier by transporting the solutes from the solid surface to the liquid phase. Thus, 
although milk-containing media had a higher viscosity compared to SGF, which is 
normally expected to slow the dissolution process (Section 1.6.1.3. ), this effect was not 
seen as the complexation effect was more dominant. 
Macheras et al., (1990) reported that the log P value is the most important predictor for 
the effect of milk on drug dissolution as the higher the log P value, the more distinct the 
increase in solubility. These present findings support this since itraconazole was more 
solubilised by milk components than ketoconazole due to its higher lipophilicity. 
4.4.3.2 Albumin-containing media 
The presence of albumin in the media induced an increase in the solubility and the 
dissolution of the two drugs but the effect was more pronounced with itraconazole (6 
times greater) than with ketoconazole. The increase in solubility was greater than the 
increase in the dissolution throughout the time of the experiment. 
Albumin-containing media had a relatively low surface tension, high viscosity and 
achieved better wettability for drugs' surfaces. The mechanism affecting drug behaviour 
in albumin-containing media is believed to be protein-drug binding. 
Egg albumin induced an interesting solubilising effect which was proportional to the 
concentration of the protein and this effect was more apparent with itraconazole than 
ketoconazole. This interaction is probably through hydrophobic, electrostatic 
interactions and hydrogen bonding. This is similar to the case with human serum 
albumin where itraconazole and ketoconazole exhibited high protein binding in vivo, 
99.8% and 99%, respectively (Heykants et al., 1989). 
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Previous studies based on thermodynamic and spectroscopic studies also found that the 
mechanisms of the interaction between ketoconazole and serum albumin were 
electrostatic interaction and hydrophobic interactions (Guo et al., 2008). Figure 4.21 
illustrates possible types of interaction between drug and protein on the molecular level. 
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Figure 4.21 Possible interactions between protein and drug molecules 
The hydrophobic interaction seems to contribute essentially to the association of the 
drug with protein molecules. The possible sites of hydrophobic interactions on 
itraconazole are the two phenyl rings, 2,4-dichloro-phenyl ring and 2-butyl moieties of 
itraconazole. While the hydrophobic sites on ketoconazole are the aromatic ring and 2, 
4-dichloro-phenyl ring. Ketoconazole held more positive charges than itraconazole at 
the pH of the investigation (pH 3); and so the more ionised moieties had less affinity to 
!. 
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the protein hydrophobic cavities. Therefore, this may explain the more profound 
solubilising effect of albumin on itraconazole compared to its effect on ketoconazole. 
The possible multi-hydrogen bonding sites in the drug molecules were: the unionised 
nitrogens, carbonyl groups attached to the triazole ring in itraconazole and the carbonyl 
groups adjacent to piperazine ring in ketoconazole. 
A slight increase or even a decrease in the dissolution onsets were observed with low 
concentrations of albumin (less than 1%, w/v), compared to SGF. A speculation for this 
phenomenon could be due to albumin film formation on the surface of the disks that 
occurred at the beginning of the experiment. This film may have acted as an interfacial 
barrier and so impeded the dissolution of the drug. However, with higher concentrations 
of the protein two effects contradicted each other: film formation and more drug 
solubilisation through complexation with the protein, thus the sum was a slight increase 
in the dissolution onset. 
The observed enhancement in the overall dissolution and solubility of both drugs makes 
egg albumin a potential carrier for itraconazole and ketoconazole as a safe alternative 
for synthetic polymers as suggested previously by Imai et al. (1989). 
4.4.3.3 Casein-and gluten-containing media 
Due to the effect seen with milk, it was investigated whether the predominant protein in 
milk, casein, was responsible for these enhancements. However, casein with its poor 
solubility under the experimental conditions made it difficult to achieve the same 
concentration of casein in solution as in milk which was reported as 1.7-3.5%, w/v 
(Walstra et al., 2006c). The assessed solutions of casein showed a poor solubilising 
effect on itraconazole and ketoconazole. It was reported previously that the mechanism 
by which casein affected drug dissolution was via micelle formation (Macheras and 
Reppas, 1987). 
Cascin molecules have a strong tendency to self-assemble into micelles because of their 
amphiphilic nature in aqueous solution. Various models of the assembly and structure of 
the casein have been suggested in the literature of which sub-unit model for casein 
aggregation was the most widely accepted. This model suggests that 15-20 molecules 
of casein aggregate via hydrophobic interactions and form sub-units where the 
hydrophobic core is surrounded by a polar portion. These sub-units form the building 
units of the micelles (McMahon and Rodney, 1984). Casein monomers and sub-units 
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exist in the solution when the casein concentration is below the CMC, whereas above 
the CNIC casein micelles are combined with monomers and sub-micelles. 
Based on this structure, casein is able to encapsulate hydrophobic compounds into the 
hydrophobic core even at the sub-micellar level. Consequently, itraconazole and 
ketoconazole could be solubiliscd through these sub-units and the position of the drug 
would vary according to the polarity of the drug. 
Previous studies showed that the CNIC of casein solution at pH 7 was 0.1%, w/v (Liu 
and Guo, 2008), however, the existence of salt and the pH of the solution can affect the 
micelle formation. Considering casein is like a surfactant, if the CMC was exceeded, a 
linear increase in the solubility of the drug would be expected as more micelle 
formation leads to more drug solubilisation. An increase in the solubility of both drugs 
was observed with an increase in casein concentration suggesting micelles were likely 
fon-ned but because the increase was not significant this phenomenon could not proved. 
The surface tension measurements of casein solutions (Table 4.1) suggested that the 
CMC was not reached but this also could not be confirmed because the variations were 
not significant. Consequently, it is uncertain whether micelles were formed under the 
present experimental conditions or not, however, casein with its pre-micellar 
aggregation demonstrated the ability of casein to solubilise the drugs. 
Although gluten-containing media had a low surface tension, it did not affect the 
solubility or the dissolution of the drugs significantly indicating this protein could not 
solubilise the investigated drugs. 
4.4.3.4 Gelatin-containing media 
Gelatin inclusion in the media increased the solubility and dissolution of both drugs. 
The effect of gelatin may be attributed to the surface activity of gelatin (Acarturk et al., 
1992) and the ability of gelatin-containing solutions to enhance the wettability of the 
drug compact surfaces. This would allow the gelatin solutions to penetrate faster into 
the drug particles and so induce more solubilising influence. Despite an increase in the 
viscosity of gelatin solutions, the solubilising effect increased proportionally with 
protein concentration. A slightly higher effect was seen with ketoconazole suggesting 
the effect of gelatin increased with the less lipophilic drug. 
Kallinteri and Antimisiaris (2001) found that gelatin increased the solubility of drugs 
and this effect was more pronounced with drugs of high lipophilicity and low aqueous 
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solubility (Kallinteri and Antimisiaris, 2001). Since both drugs investigated here fall 
into this category, the present results support their findings. 
4.4.3.5 Amino acid-containing media 
The presence of neutral amino acids enhanced both the dissolution and solubility of 
both drugs. The effect was greater on ketoconazole than itraconazole. Although the 
differences in the dissolution profiles of ketoconazole with the type of the neutral amino 
acids were not very large, it could be said that the greatest effect was seen with LEU- 
then ALA- and finally GLY-containing media. Since these amino acids have identical 
isoelectric points, this suggested the increase in solubility and dissolution was 
proportional to the length of side chain of the amino acids and consequently their 
hydrophobicity. 
Ketoconazole is a dibasic drug with two pKa values: 6.51 and 2.94. At pH 3, 
ketoconazole molecules coexist in the two ionised forms: H2(keto)' 2 and H(keto) , 1. 
Itraconazole has four pKa values: 4,1.5-2 and two other pKa values which are lower 
than I (not precisely specified) (Peeters et al., 2002). Consequently, itraconazole exists 
mainly in the mono-ionised forrn H(itra)+ I at pH 3, since the other protonated species 
exist at low pH (< 2). The acidic group of the amino acids has a pKal of 2.3 and 
consequently at pH 3,83% of these acidic moieties are deprotonated. Consequently, 
ionic interactions may occur between the negatively charged carboxylic acid of the 
amino acid and the positively charged drug molecules. This interaction could lead to the 
formation of a soluble complex. 
The limited effect of GLY on the dissolution of ketoconazole at pH 6.8 supported this 
assumption as the drug has lost most of its positive charge at this pH. Furthermore, 
hydrogen bonding could occur between the uncharged nitrogen and carbonyl groups of 
the drugs and the carboxylic acid group of the amino acid. 
In addition, since the solubility of the drugs increased with the increase in the 
hydrophobic character of the amino acid in the dissolution medium; this suggested that 
hydrophobic interactions could be an important force in this association. 
The effect of the basic amino acid LYS on the behaviour of itraconazole was not 
significant (t-test, 0.05 significant level). However, the inclusion of LYS in the medium 
induced a marked increase in ketoconazole dissolution and solubility. 
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The solubilising effect of LYS was less than that of the neutral amino acids, probably 
because the side chain of LYS, amine group with pKa= 10.5, was protonated at pH 3 and 
so it acted as a competitive binding site to the cationic drug entities. 
ASP has an isoelectric point of 2.9. Thus at pH 3 its solubility was at a minimum level. 
In addition, ASP molecules have a net charge of zero at this pH which may have limited 
the effect of possible interaction between ASP molecules and the drugs. 
The effect of amino acid was an interesting phenomenon with a marked increase in the 
solubility and dissolution of ketoconazole. So contrary to the albumin solubilisation 
effect, ketoconazole was more solubilised in these media than itraconazole. The 
suggested mechanism was via the formation of soluble complexes through ionic 
interactions and since ketoconazole was highly ionised at pll 3, a more pronounced 
effect was seen with ketoconazole. 
4.4.3.6 Sugar-containing media 
A mechanism by which carbohydrates increased the dissolution of the drug could also 
be through soluble complex formation. Hydrogen bonds can be formed between 
hydroxyl groups in sugars and nitrogen or carbonyl groups in drug entities leading to 
solubilisation of the drugs. 
4.5 Conclusion 
The increase in itraconazole solubility varied with a maximum increase of 
approximately 24-fold in milk and 20-fold in albumin (1%, w/v) containing media. The 
maximum solubilising effect of ketoconazole was seen in media containing 1%, w/v 
neutral amino acid and milk where an approximate increase of a factor of 14 and 6, 
respectively, was recorded. The dissolution rate also increased but not to the same 
extent as the solubility. This relatively slow dissolution could be ascribed to the 
formation of larger complexes or micelles which made their diffusion to the bulk 
solution slower than the free drug (Macheras and Reppas, 1987). 
It is evident from this study that changes in media composition significantly influenced 
the behaviours of the assessed azole antifungal drugs. Since food additives had a 
significant impact on the dissolution, this revealed the importance of simulating gastric 
fluids at fed state in order to develop a more predictive IVIVC model. Thus, the study 
indicated that itraconazole and ketoconazole co-ingestion with food can increase the 
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bioavailability of the drugs and the extent of this effect may vary according to the type 
of the meal. Accordingly, it would be interesting to investigate how these components 
affected drug dissolution and in particular in the media that induced the maximum 
effect, namely; milk- and albumin-containing media. 
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Chapter 5: Itraconazole and ketoconazole binding to milk 
and proteins 
5.1 Introduction 
Media containing milk, egg albumin, casein and gelatin enhanced the solubility and 
dissolution of itraconazole and ketoconazole (Chapter 4). The mechanism of how these 
components could possibly affect the behaviour of the drugs was investigated. It is 
believed that this effect was through the interactions of the drugs with proteins or milk 
components in the media. Therefore, a conventional method for detecting protein-ligand 
interaction was employed, namely, the dynamic dialysis method (Martin, 1993a). 
Ketoconazole binding to egg albumin was further explored using spectroscopic 
techniques. 
5.2 Materials and methods 
5.2.1 Materials 
Details of all materials used for the dialysis and spectroscopy studies are listed in 2.1. 
5.2.2 Dialysis studies 
5.2.2.1 Preparation of drug sample 
A stock solution (0.5mg ml-1) of itraconazole was prepared by dissolving the drug 
powder in dimethylformamide because of its poor aqueous solubility. Appropriate 
dilutions of the stock solution with simulated gastric fluid (SGF) pH 1.2, were made to 
generate drug solutions in concentrations of 5-1 Oýtg ml- 1. 
Ketoconazole was dissolved directly in SGF pH 3 in concentrations of 100-200pg ml-1. 
SGF at pH 1.2 and SGF at pH 3 were prepared as described in 3.3.1.1. 
5.2.2.2 Preparation of drug-protein and drug-milk mixtures 
10ml of drug solution (itraconazole 10ýtg ml-1, ketoconazole 200ýtg ml-) was added to 
10ml of whole fat milk, skimmed and semi-skimmed milk and saturated filtered casein 
solution. 
Albumin or gelatin powders were added in quantities of 0.02-0.4g to 20ml to the drug 
solutions (itraconazole 5gg ml", ketoconazole 100ýig ml-1). The concentrations of the 
albumin in the resultant mixtures were 0.1 and 1%, w/v. The concentrations of the 
131 
gelatin in the resultant mixtures were I and 2%, w/v. The mixtures of drug-protein or 
drug-milk were stirred for I Omin and warmed up to around 3 7'C. 
5.2.2.3 Preparation of the reference solutions 
Reference solutions were prepared in the same manner without the addition of protein 
or milk to the drug solutions. Thus, for milk and casein experiments, drug solutions 
(itraconazole 10ýig ml-1, ketoconazole 200ýtg ml-1) were diluted 50: 50 with SGF. For 
gelatin and albumin experiments, the reference solution was drug solution in SGF 
(itraconazole 5ýtg ml-1, ketoconazole I 00ýtg ml-1). 
5.2.2.4 Dialysis settings 
Visking cellouse tubing with a molecular weight cut-off of 3500 Daltons was cut into 
10cm long strips (5cm width) and soaked in distilled water. 10ml of drug-protein or 
drug-milk mixture was transferred accurately into a piece of the tubing which had been 
tied at one end. The amount of itraconazole and ketoconazole in the bags were 50gg and 
I mg, respectively. 
Figure 5.1 Schematic diagram illustrating the dialysis experiment, it shows the USP 11 dissolution 
tester and dialysis bag attached to the shaft (contained milk-drug, protein-drug mixtures or only 
drug solutions) 
The dissolution tester USP 11 (Pharmatest Type PTW S3Q was employed to simulate 
the conditions of the dissolution test, in term of temperature and rotation. The tubes 
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were tied and attached to the flat, wide part of the paddles (Figure 5.1). The vessels of 
the dissolution tester were filled with SGF (250ml for itraconazole and 500ml for 
ketoconazole studies) and warmed to 37 ± 0.5'C. Stirring of the paddles was applied at 
100 rpm and so the dialysis bags were also rotated. 
5.2.2.5 Sampling and analysis 
Aliquots of the external solution (2ml) were collected from the vessels periodically 
through sampling Cannulae and subsequently transferred to HPLC glass vials. The drug 
concentrations were quantified using the previously described UIPLC method (Section 
2.2.6). The binding of the drugs to the different protein and milk-containing media was 
estimated from the difference in the concentration of free drug released from the 
dialysis bag of the reference (in the absence of milk or protein) and the drug released 
from dialysis bags containing drug-protein or drug-milk mixtures. 
5.2.3 Spectroscopic studies of albumin- ketoconazole mixtures 
5.2.3.1 Preparation of ketoconazole-albumin mixtures 
Ketoconazole was dissolved in SGF (pH 3) (10,50,100 and 200ýLg ml-1). A fixed 
amount of egg albumin (0.1%, w/v) was added to each drug solution. Albumin (0.1%, 
w/v) in SGF was also prepared in the absence of the drug. The mixtures were sonicated 
(Kerry Ultrasonics, UK) for 5min and then incubated at room temperature for 30min 
prior to taking the measurements. All measurements were taken at room temperature. 
5.2.3.2 Fluorescence studies 
Fluorescence measurements were carried out using a Varian Spectrophotometer Cary 
Eclipse (Varian, USA). The fluorescence emission spectra of albumin in the absence 
and presence of different amounts of ketoconazole were recorded in the range of 
300-500nm upon excitation at 296nm. SGF (pH 3) was used as a blank. 
5.2.3.3 UV spectroscopy 
The ultraviolet (UV) absorbance was measured using a Thermo Electron 
spectrophotometer operated via the Vision-pro Software v3.0. Measurements were 
taken for egg albumin in the presence and absence of ketoconazole in the range of 
240-350 nm. 
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5.3 Results 
5.3.1 Dynamic dialysis 
Dynamic dialysis was performed to assess protein-drug binding. This is based on the 
determination of the drug disappearance from a dialysis bag which contained a mixture 
of drug-protein or drug-milk by quantifying the amount of the unbound drug that passed 
through the membrane (Martin, 1993a). The amount of the drug in the bulk medium, 
outside of the dialysis bag, was divided by the total initial amount of drug that was in 
the dialysis bag at the beginning of the experiment and expressed as percentage. 
5.3.1.1 Milk-containing media 
5.3.1.1.1 Itraconazole 
The release of itraconazole from the dialysis bags containing milk-drug mixtures was 
less, in rate and extent, than the release from the reference solution that did not include 
milk (Figure 5.2). 
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Figure 5.2 Percentage of itraconazole released from dialysis bags which contained mixtures of 
itraconazole in SGF and milk of different fat contents. Each data point represents the mean ± S. D. 
of 3 measurements 
No obvious difference between the release profiles of itraconazole from the dialysis 
bags containing whole fat milk, semi-skimmed milk and skimmed milk were observed 
throughout the first 4h of the dialysis experiment. However, within 24h, the skimmed 
milk-containing media showed a higher release of itraconazole (22.4 ± 1.3 %) and the 
minimum release (12.9 ± 0.9 %) was observed in the whole fat milk-containing 
medium. 
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5.3.1.1.2 Keloconazole 
Ketoconazole dialysis in milk-containing media against SGF was carried out for 5h 
(Figure 5.3). The concentration of the released drug from the dialysis bag containing 
milk into the bulk media was less than that when the dialysis bag contained the 
reference solution. At the end of the run, 31.2 ± 0.3 %, 36.6 ± 1.4 % and 37.2 ± 0.3 % of 
the drug was released from the dialysis bags that contained mixtures of SGF and milk: 
whole fat milk, semi-skimmed milk and skimmed milk, respectively. 
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Figure 5.3 Percentage of ketoconazole released from dialysis bags which contained mixtures of 
ketoconazole in SGF and milk of different fat contents. Each data point represents the mean ± S. D. 
of 2 measurements 
5.3.1.2 Albumin-containing media 
5.3.1.2.1 Itraconazole 
When albumin was included in the dialysis bag, a slow release for itraconazole was 
apparent and a higher concentration of albumin led to even slower release. The 
percentage of itraconazole that passed across the membrane over 5h was 65.1 ± 3.4 % 
with albumin 1%, w/v whereas with the reference solution an average of 100.7 ± 2.9 % 
was released (Figure 5.4). 
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Figure 5.4 Percentage of itraconazole released from dialysis bag which contained drug-albumin 
mixtures. Each data point represents the mean ± S. D. of 3 measurements 
5.3.1.2.2 Ketoconazole 
A slow release of ketoconazole was observed when egg albumin was included in the 
dialysis bag. 88.5 ± 3.2% and 71.9 ± 2.1 % passed through the membrane in the 
presence of 0.1 and 1%, w/v albumin, respectively, whereas 98.2 ± 4.3 % passed from 
the reference samples (Figure 5.5). 
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Figure 5.5 Percentage of ketoconazole released from dialysis bags which contained drug-albumin 
mixtures. Each data point represents the mean ± S. D. of 2 measurements 
5.3-1.3 Casein-and gluten-containing media 
Casein inclusion with itraconazole solutions inside the dialysis bag did not lead to a 
significant change (t-test, significance level 0.05) in drug release, which was 
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87.0 ± 3.7 % after 5h whereas the release from the reference was 85.1 ± 2.2 %. Gluten 
inclusion in the media did not induce any discernible effect and only an insignificant 
increase in the percentage of the transported drug was found. 
Similar observations were found with ketoconazole where casein and gluten did not 
affect the dialysis of the drug. 
5.3.1.4 Gelatin-containing media 
Gelatin addition to itraconazole and ketoconazole solutions in concentrations of I and 
2%, w/v did not alter the dialysis of the either drug compared to the corresponding 
reference solutions which did not contain gelatin. 
5.3.2 Spectroscopic studies of albumin- ketoconazole mixtures 
5.3.2.1 Fluorescence studies 
The fluorescence spectra of albumin in the presence of different concentrations of 
ketoconazole are displayed in Figure 5.6. Egg albumin had a strong fluorescence 
emission with a peak at 340nm upon excitation at 296nm. The fluorescence intensity of 
albumin decreased slightly in the presence of increasing amounts of ketoconazole 
without changing the emission maximum wavelength. 
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Figure 5.6 Emission spectra of 0.1 %, w/v albumin in the presence of ketoconazole, a-e: 0,10,50, 
100,200 pg ml-" N: emission spectra of ketoconazole 10,50,100,200 tig ml-1, emission at 340nm 
and excitation at 296nm 
5.3.2.2 UV spectroscopy 
The UV absorbance intensity of the albumin increased in the range between 240nm and 
340nm with the increasing ketoconazole concentrations (Figure 5.7). Furthen-nore, a 
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very slight red shift (towards longer wavelength) of the maximum peak position was 
noticed indicating possible interactions between ketoconazole and egg albumin. 
Wavelength (nm) 
Figure 5.7 UV absorbance of albumin (0.1%, w/v) in the presence of ketoconazole, a-C: 0,10,50, 
100,200 pg ml-, f. an example of ketoconazole solution (50 gg ml-') 
5.4 Discussion 
5.4.1 Dynamic dialysis 
In the present investigation, preliminary studies were performed for the purpose of 
monitoring possible changes in drug transport due to the presence of additives compared 
to a reference. When milk was included in the media a slower rate of drug release from 
the dialysis bags was observed, compared to a reference that did not contain milk. Thus, 
this indicated that drug entities may be entrapped within milk particles due to binding to 
milk components. The fat content of the milk did not affect drug binding throughout 5h. 
The dialysis data indicated that casein did not bind to the drugs. However, this did not 
exclude the possibility of protein binding. Macheras and Reppas (1987) stated that 
during the dialysis studies when casein was included in the media no transport change 
was noticed. This was attributed to the ability of casein to form micelles and so it acted 
as a reservoir for the drug. Hence, the micelles were delivering the free drug to be 
transported which kept the dialysis rate unaltered (Figure 5.8). Furthermore, casein 
micelles or sub-units had porous structures which allowed the release of the entrapped 
drug molecules. 
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Figure 5.8 Schematic diagram for the transport of drug from the dialysis bag containing albumin- 
or casein-drug mixtures to the bulk solution, modified from Macheras and Reppas (1987) 
The solubility and dissolution of itraconazole and ketoconazole increased in the 
presence of milk in the media (Section 4.3.3.1) and the dialysis results indicated there 
was drug binding to the milk. Since casein is the major protein in milk and it did not 
show any evidence of the ability to bind the drugs, the solubilization of itraconazole and 
ketoconazole in milk was not due to specific protein binding but to the entire complex 
structure of milk. This included binding to milk components, casein micelles, ionic 
interactions with the amino acids and partitioning into the lipid contents. This agrees 
with the finding of Macheras et al. (1989) who also attributed drug solubilisation to the 
whole structure of milk. 
The presence of egg albumin in the dialysis bags also slowed the release of itraconazole 
and ketoconazole, which suggests that albumin had the ability to form complexes with 
the drugs (Figure 5.8). The binding is possibly through interaction on the molecular 
level such as hydrogen bonding and hydrophobic interaction or physical entrapment 
through van der Waals forces. Thus, protein binding and complex formation appears 
responsible for drug solubilisation effect (Section 4.3.3.2). 
119 
The presence of gluten and gelatin in the media did not affect the dialysis process of 
itraconazole and ketoconazole which indicated poor binding of the drugs to these 
proteins. 
5.4.2 Spectroscopic studies of albumin- ketoconazole mixtures 
The fluorescence intensity of a compound can be decreased by molecular interactions 
and conformational, changes. Such changes may occur upon complex formation because 
the intramolecular forces involved in keeping the secondary structure are altered. This 
decrease in fluorescence intensity is called quenching. Tryptophan residues are mainly 
responsible for the fluorescence of albumin and this fluorescence is very sensitive to 
changes such as ligand binding leading to a change in the emission intensity (M61ler and 
Denicola, 2002). 
It was reported that human and bovine serum albumin had the ability to form complexes 
with ketoconazole and such interaction led to fluorescence quenching of albumin (Guo 
et al., 2008). UV absorption measurements also allowed the investigation of structural 
changes and complex formation between ketoconazole and serum albumin (Guo et al., 
2008). Consequently, the current findings of the fluorescence quenching and slight shift 
in the UV spectra indicated complex formation between ketoconazole and egg albumin. 
5.5 Conclusion 
The solubilising effect of itraconazole and ketoconazole by proteins and milk was 
attributed to different types of interactions. These in vitro findings can provide a useful 
insight into the effect of food proteins on the bioavailability of itraconazole and 
ketoconazole. Thus, it was found that food components increased the dissolution of the 
investigated drugs through various mechanisms such as drug binding, solubilisation into 
sub-micelles units or wetting enhancement. However, further studies need to be carried 
out to further explain these interactions on the molecular level using techniques such as 
Circular Dichroism and to monitor heat changes that accompany the interactions using 
microcalorimetry method. In addition, food ingestion can also induce important 
physiological changes that may affect drug dissolution such as change in the pH of the 
intraluminal fluids and stimulation of bile and lipid secretions. Accordingly, the impact 
of the bile salts and phospholipids on the dissolution of both drugs was investigated. 
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Chapter 6: The effect of synthetic and natural surfactants on 
the dissolution of itraconazole and ketoconazole 
6.1 Introduction 
In the gastrointestinal fluid, various surfactants are present such as bile salts, lecithin, 
cholesterol and its esters, so luminal fluids have a low surface tension that varies 
according to the prandial state (Kalantzi et al., 2006a) (Section 1.6.2.1). Despite this, the 
compendial dissolution media used for dissolution testing (SGF, SIF and water) do not 
contain surfactants and therefore fail to estimate the possibility of solubilisation and the 
wetting effects of the luminal fluids. Simulated gastric and intestinal media containing 
relevant surfactants have been suggested. For example, Galia et al. (1999) developed 
media containing sodium taurocholate and phospholipids in relevant concentrations to 
mimic fasting and fed conditions. 
In the current investigation, the aim was to explore itraconazole and ketoconazole 
dissolution in the presence of natural surfactants which can allow prediction of the drug 
behaviour in vivo. Furthermore, the effect of natural surfactants on the dissolution of 
both drugs was compared with the effect of synthetic surfactants. 
The impact of the following media on the dissolution and solubility of itraconazole and 
ketoconazole was assessed: 
1) Simulated gastric fluids containing either synthetic or natural surfactants. 
2) Simulated intestinal media containing only a single type of bile salt, sodium 
taurocholate. 
3) Biorelevant media simulating intestinal fluids in fed and fasting states containing 
bile salts and phospholipids. 
4) Simplified simulated intestinal media containing sodium dodecyl sulfate (SDS) 
as an anionic surfactant and cetyltrimethylammonium. bromide (CTAB) as a 
cationic surfactant. 
5) An oil in water (o/w) emulsion, composed of Soybean oil emulsified in SGF 
(pH 3) using Tween 20. 
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6.2 Materials and methods 
6.2.1 Materials 
Details of all materials used in the preparation of the dissolution media and in 
performing the experiments are listed in 2.1. 
6.2.2 Media preparation 
All media were prepared on the day of the dissolution experiment and the pH was 
measured using a calibrated pH meter as described in Section 2.2.1. 
6.2.2.1 Simulated fasting gastric media 
Fasted state simulated gastric fluid (FaSSGF) consisted of SGF pH 1.2 (0.1 M HCI and 
34.2mM NaCI) containing 80ýM NaTC and 20pM lecithin. 
Simulated gastric fluids containing synthetic surfactants were prepared by the addition 
of appropriate amount of surfactants to SGF pH 1.2. The assessed media were: SGF 
containing sodium dodecyl sulfate (SDS) (0.25%, w/v), Triton X-100 (0.1%, w/v) or 
Twecn 20 (0.02%, w/v). The final pH was adjusted to 1.2 when required. 
6.2.2.2 Simulated intestinal media 
The compositions of the biorelevant media; fasted state simulated intestinal fluid 
(FaSSIF) and fed state simulated intestinal fluid (FeSSIF) are listed in Table 6.1. The 
two media were prepared according to Marques (2004). Blank simulated fluids refer to 
buffer solutions without the addition of NaTC or lecithin. 
Table 6.1 Composition of FaSSIF and FeSSIF as listed by Vertzoni et al. (2004) 
Components FaSSIF FeSSIF 
Sodium taurocholatc 3 mM 
Lccithin 0.75mM 
NaI12PO4 28.66mM 
NaCl 106mM 
Acclic acid 
NaOl I pcilcts 13.8mNI 
Dcioniscd watcr to IL 
15 mm 
3.75 mM 
173mM 
144mM 
101mm 
to IL 
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6. ZZZI Fasted state simulated intestinalfluid 
Blank FaSSIF was prepared by dissolving 0.55g of NaOH, 3.44g of NaH2PO4 and 
6.19g of NaCl in IL of deionised water. The pH was adjusted to 6.5 using IM NaOll or 
IM HCL 
FaSSIF was prepared as follows: 1.65g of sodium taurocholate (NaTC) was dissolved in 
approximately 250ml of the blank FaSSIF. 0.57g of lecithin was dissolved in 5.7ml of 
dichloromethane and added to the NaTC solution. Dichloromethane was evaporated 
under vacuum using a Rotavap (Heidolph, Germany) at a temperature of 401C for about 
30min until no noticeable odor of dichloromethane was noticed indicating complete 
removal of the organic solvent. Finally, the volume was made up to IL with blank 
FaSSIF. 
6. ZZZ2 Fed state simulated intestinalfluid 
Blank FeSSIF was prepared by dissolving 4.04g of NaOH, 8.64g of glacial acetic acid, 
and 10.11 g of NaCl in IL of purified water. The pH was adjusted to 5 using IM NaOII 
or 1M HCL 
FeSSIF was prepared by, dissolving 8.06g NaTC in IL of blank FeSSIF. Then, 
2.87g lecithin was dissolved in 28.7ml of dichloromethane and added to the NaTC 
solution, resulting in an emulsion. Likewise to FaSSIF, the solvent was evaporated and 
the resulting emulsion was slightly hazy with no noticeable smell of dichloromethane. 
The volume was made up to IL with blank FeSSIF. 
6.2.2.3 Simulated intestinal media containing sodium taurocholate only 
Media containing NaTC with various concentrations of NaTC were prepared by 
dissolving 1.1,4.0,8.1 and 16.1 g of NaTC in IL of blank FeSSIF to prepare solutions 
of 2,7.5,15 and 30mM, respectively. The final pH of each media was adjusted to 5 
when required. 
6.2.2.4 Simplified intestinal media 
Simplified simulated intestinal media containing two types of surfactants: anionic 
surfactants (SDS) and cationic surfactants (CTAB) in various concentrations were 
developed. The media were prepared by dissolving the required amounts of the 
surfactant in blank FeSSIF (pH 5) or simulated intestinal fluid (SIF) (pH 6.8). The final 
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pH was adjusted to 5 for fed-simulating intestinal media and to 6.8 for fasted-simulating 
intestinal media. 
6.2.2.5 Emulsion of Soybean oil in simulated gastric fluid 
An o/w emulsion was composed of 10%, w/v Soybean oil in SGF (pH 3) emulsified 
using Tween 20 (Hsu and Nacu, 2003). The emulsion was prepared by mixing 
15%, w/w Tween 20 with Soybean oil and the resultant mixture was preheated to 60'C. 
Subsequently, the oil phase was introduced gradually into SGF medium, which was 
previously brought to 60'C. Further homogenization was performed with a mixer 
(Silverson Model L4 RT, England) at 3500rev min-' for 5min. To assess the effect of 
the fat content on drug dissolution, the resultant emulsion was diluted with SGF to 
prepare two solutions containing 20% or 50% of the original concentration. 
6.2.3 Media characterisation 
Viscosities of the media were measured using a vibrational rheometer according to the 
method described in Section 2.5.1.2. 
The surface tension of the dissolution media was measured using a Wilhelmy plate 
tensiorneter (Section 2.5.2). 
The critical micelle concentration (CMC) of SIF containing SDS or CTAB was 
determined by measuring the surface tension profile of solutions with various 
concentrations of the surfactants. The surfactant-containing solutions exhibited changes 
in surface tension with time and therefore, the measurements were taken after 30min. 
The surface tension values were plotted versus log concentration and the intersection of 
the two linear portions of the surface tension indicated the value of the CMC. 
6.2.4 Contact angle measurements 
The contact angles between the media and itraconazole and ketoconazole surfaces were 
evaluated using the Sessile drop method (Section 2.5.3). A drop of the fluid (4gl) was 
placed on the surface of compacts of the drugs and images were taken over a period of 
5min. 
6.2.5 Solubility determination 
The solubility of the drugs in the media was determined according to the method 
described in Section 2.2.2. An excess amount of the drug was added to the media and 
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the suspensions were shaken for 24h at 37*C. The solid was separated by centrifugation 
followed by filtration. 
6.2.6 Intrinsic dissolution studies 
The dissolution of the drugs in the media was assessed using stationary disk 
methodology. Itraconazole and ketoconazole were compressed to prepare disks with 
constant surface area. The die containing drug compact was placed at the bottom of flat 
vessel in USP Apparatus IL Stirring was applied at 37'C and aliquots were withdrawn 
from the bulk solution periodically and analysed. Details of disk preparation and 
dissolution conditions are given in Sections 2.2.3 and 2.2.4. 
6.2.7 Sample treatment and drug analysis 
6.2.7.1 Itraconazole 
Samples collected from simulated gastric and intestinal media were diluted (50: 50) with 
the mobile phase, whereas no dilution was required for samples collected from blank 
simulated media. Then, samples were submitted to HPLC analysis. 
Quantitation of itraconazole in samples collected from dissolution and solubility studies 
was performed using HPLC with fluorescence detection (Section 2.2.6.1). 
For samples collected from dissolution media containing Soybean oil emulsion, 
itraconazole was first extracted using solvent extraction according to the method in 
Section 2.2.5.1. The drug was then assayed using HPLC. 
6.2.7.2 Ketoconazole 
Samples collected from solubility tests in simulated gastric media were diluted as 
appropriate (10 to 16-fold) with a mixture of acetonitrile-water (50: 50). For experiments 
in simulated intestinal fluids, samples were diluted twice. No dilution was required for 
samples collected from the solubility test in blank simulated intestinal fluids. 
Samples collected from acidic media were analyzed by HPLC using UV detection 
whereas samples collected from simulated intestinal fluids were analyzed using HPLC 
with fluorescence detection (Section 2.2.6.2). 
Aliquots withdrawn from the dissolution media containing an emulsion were extracted 
according to the general method specified in Section 2.2.5.2. Ketoconazole was 
deprotonated using I ml of IM NaOH and then extracted with a mixture of acetonitrile- 
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n-butyl chloride (1: 4, v/v). The residues were reconstituted and subsequently analysed 
with HPLC with UV detection. 
6.3 Results 
6.3.1 Media Characterisation 
6.3.1.1 Viscosity 
Slight differences were observed in the viscosities of the simulated gastric fluids (Table 
6.2). However, by applying ANOVA test (0.05) it was found that these variations were 
not significant. This indicated that the addition of the surfactants in the stated amounts 
did not lead to an increase in the viscosity of the media. 
The viscosities of media containing bile salts were slightly higher than the 
corresponding blank buffer. The increase in NaTC concentration led to an increase in 
viscosity. The addition of lecithin to FaSSIF and FeSSIF induced further increases in 
viscosity. 
Table 6.2 Viscosity of gastric and intestinal simulated media at 371C. Each data point represents 
the mean ± S. D. of 3 measurements 
Medium 
SGF pH 1.2 
FaSSGF pH 1.2 
0.25%, w/v SDS in SGF pH 1.2 
0.1 %, w/v Triton-X in SGF pH 1.2 
0.02%, w/v Tween 20 in SGF pH 1.2 
Blank FaSSIF 
Blank FeSSIF 
FaSSIF 
FeSSIF 
2mM NaTC in blank FeSSIF 
7.5mM NaTC in blank FeSSIF 
15mM NaTC in blank FeSSIF 
30mM NaTC in blank FeSSIF 
Viscosity (mpa. s) 
0.719 ± 0.009 
0.719± 0.008 
0.721 ± 0.009 
0.724 ± 0.006 
0.717: k 0.007 
0.713 ± 0.004 
0.716 ± 0.005 
0.734 ± 0.009 
0.754 ± 0.009 
0.715 ± 0.005 
0.733 ± 0.003 
0.746 ± 0.005 
0.753 ± 0.009 
6.3-1.2 Surface tension 
The surface tensions of the investigated simulated media and their respective blank 
solutions are displayed in Figure 6.1. The inclusion of synthetic surfactants to SGF 
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induced a marked decrease in the surface tension, even when the surfactant was added 
in a small amount, such as 0.02%, w/v Tween 20. The maximum decrease was observed 
in media containing Triton X-100 and SDS where the measured values were 
31-32mN m-1. The surface tension of FaSSGF was higher than the other gastric 
simulated media. 
Surface tension 
Contact angle 
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el, -, rio Figure 6.1 Surface tension and contact angles for simulated gastric and intestinal media with 
itraconazole disks. Each data point represents the mean ± S. D. of 2 measurements 
FaSSIF and FeSSIF had surface tensions substantially lower than the corresponding 
blanks. A 2mM NaTC solution lowered the surface tension to 54.1 mN m- I and inclusion 
of 7.5MM NaTC induced a further decrease. However, with higher concentrations of 
NaTC the surface tension did not drop further. This indicated that the aggregation of 
NaTC to form micelles occurred at some point between 2 and 7.5mM. The literature 
value for CNIC of NaTC in solution at 37'C with 0.1 -0.1 5M ionic strength was reported 
as 3-4mM which indicated compliance with the present findings (Carey and Small, 
1972; Mithani et al., 1996). 
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The inclusion of lecithin led to a further increase in the surface activity and by 
comparing the surface tension of medium containing l5mM NaTC only with that of 
I FeSSIF, it was found that the latter had a lower surface tension by 5mN m- 
It is important to note, that the surface tensions of many of these assessed media appear 
in the literature. However, the existence of surface active impurities in the surractant 
may lead to change in the surface tension and this affects the solubilisation capacity 
which in turn can change the solubility and dissolution rate of the drugs (Crison et al., 
1997). 
The surface tension of SIF containing various amounts of SDS and CTAB was 
measured. The CMC was determined as the break point on the curves (Figure 6.2). The 
CMC in SIF containing SDS was in a range from 0.05%, w/v (1.7mM) to 0.1%, w/v 
(3.5 mM). The CMC in SIF containing CTAB was in a range from 0.003%, w/v 
(0.08mM) to 0.008%, w/v (0.22mM). 
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Figure 6.2 Surface tension versus log surfactant concentration (SDS, CTAB) at 370C in simulated 
intestinal fluid (SIF). Each data point represents the mean ± S. D. of 2 measurements 
6.3.2 Contact angle measurements 
6.3.2.1 Itraconazole 
The contact angles measured on itraconazole disks at 300s are presented in Figure 6.1. 
The smallest contact angle was found with SGF containing the synthetic surfactants, 
SDS 
CTAB 
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SDS and Triton X- 100. This reflected the surface tension values as both media showed 
the maximum surface activity. Less wettability was observed by FaSSGF. No 
significant difference was found between the values for FaSSGF and medium 
containing Tween 20. 
Better wettability was observed with FaSSIF and FeSSIF compared to their 
corresponding blank solutions. Media containing only NATC induced a decline in the 
contact angle, however, no significant variations were found among the contact angles 
of 7.5,15 and 30mM NaTC-containing media suggesting that a plateau was reached. 
This confirmed that both the interface liquid/air and the bulk liquid were saturated with 
NATC monomers which led to the formation of micelles. Consequently, no further 
enhancement in the wettability occurred with the higher concentrations of NATC. 
The contact angle between the itraconazole surface and simulated media containing 
SDS or CTAB decreased with an increase in the amount of the surfactant (Figure 6.3). 
No significant difference in the contact angle was observed between FaSSIF and SIF 
containing 0.01%, w/v SDS or 0.05%, w/v CTAB. 
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Figure 6.3 Contact angles for simplified simulated intestinal media containing various amounts or 
surfactants: SDS (n=2) or CTAB (n=3) with itraconazole disks. Each data point represents the 
mean d: S. D. of 2 measurements at least 
6.3.2.2 Ketoconazole 
Contact angles could not be determined on ketoconazole disks using simulated gastric 
media due to the fast wetting of the drug surface. The contact angles measured at time 0 
were in the range of 10-200 and subsequently, within a few seconds, the angle nearly 
declined to zero which indicated full wetting of the drug surface. 
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The contact angles formed between ketoconazole disks and simulated intestinal fluids 
were measured at 150s of placing the liquid drops on the drug compact surface (Figure 
6-4). The standard deviations for the measurements on the ketoconazole surface were 
high. FaSSIF and FaSSIF enhanced the wettability of ketoconazole compared to their 
corresponding blank fluids. A decline in the contact angle was also observed with the 
inclusion of 2mM NaTC and a further drop was observed with an increase in NaTC 
concentration indicating that wetting continued to increase beyond the CMC. No 
significant difference was found between the wettability of solutions containing l5mM 
and 30mM NaTC. 
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Figure 6.4 Contact angles for intestinal simulated media with ketoconazole disks. Each data point 
represents the mean ± S. D. of 2 measurements 
Simplified media containing SDS or CTAB induced a decrease in the contact angles 
which was proportional to the increase in the surfactant concentration despite exceeding 
the relevant CMC value (Figure 6.5). Wettability with FaSSIF did not vary significantly 
from that with SIF containing 0.05-0.1 %, w/v SDS, whereas solutions containing CTAB 
induced less wettability compared to FaSSIF. 
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Figure 6.5 Contact angles for simplified simulated intestinal media containing various amounts of 
synthetic surfactants: SDS or CTAB with ketoconazole disks. Each data point represents the mean 
I S. D. of 2 measurements 
6.3.3 Solubility and dissolution determinations 
6.3.3.1 Simulating fasting gastric fluids 
Human gastric fluid in the pre-prandial state has an average surface tension of 
35-45mN m-1 (Section 1.6.2.1). Therefore, in order to simulate gastric conditions, it was 
necessary to add surfactants to the media in sufficient amounts to match the surface 
tension of the human fluid. Several media containing surfactants to mimic the fasting 
gastric fluids are suggested in the literature. The effect of the following media on the 
dissolution of both drugs was explored: 
1) 0.25%, w/v of SDS (anionic surfactant) in SGF (Galia et al., 1999). 
2) 0.1 %, w/v of Triton X- 100 (non-ionic surfactant) in SGF (Dressman et al., 1998). 
3) FaSSGF, a medium containing physiologically-relevant amounts of bile salt, namely; 
NaTC, and lecithin developed by Vertzoni et al. (2005). The formulation of FaSSGF 
was modified by making the pH 1.2 instead of 1.6 to match the pH of the previously 
investigated simulated fasting gastric media. Furthermore, the gastric enzyme, pepsin, 
was excluded to avoid the complexity and stability problem of pepsin in the medium 
(Aburub et al., 2008). 
4) 0.02%, w/v Tween 20 (non-ionic surfactant) in SGF was developed as this medium 
had a surface tension equivalent to the simulated gastric media. 
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All these SGF media had a similar pH of 1.2. 
6.3.3.1.1 Itraconazole 
Each surfactant-containing medium enhanced both the solubility and the dissolution of 
the drug (Table 6.3). The maximum increase in solubility was seen in SGF containing 
0.25%, w/v SDS. 
Table 6.3 The solubility and the IDR data of itraconazole at 370C and the solubility of ketoconazole 
at 3711C in SGF containing 0.25%, w/v SDS, 0.1%, w/v Triton X-100,0.02%, w/v Tween 20 and in 
FaSSGF. Each data point represents the mean :k SD of at least 3 measurements 
Itraconazole Ketoconazole 
Medium Solubility 
Oag Ml-) 
Initial IDR 
(ftg min-' CM-2) 
(0-15min) 
Solubility 
(mg MI-1) 
FaSSGF 6.8 ± 0.1 60.7 ± 11.8 26.8 ± 0.4 
0.25%, w/v SDS in SGF 8.3± 1.9 13.9± 1.0 33.1 ± 1.3 
0.1 %, w/v Triton X- 100 in SGF 4.9 ± 0.8 13.3 ± 1.2 29.4 ± 2.3 
0.02%, w/v Tween 20 in SGF 7.710.3 13.0 ± 0.9 30.8 ± 0.6 
The dissolution in FaSSGF was greater than that in SGF with a significant initial burst, 
the initial IDR was 5 times greater compared to SGF (Figure 6.6). The medium 
containing SDS showed a different pattern of dissolution where a steadier increase in 
the amount dissolved versus time was observed. Since SDS induced the highest 
solubility, this may explain the steady rise in the dissolution in SDS medium, as the 
amount dissolved within 5h had not yet reached saturation solubility. 
The inclusion of 0.1%, w/v Triton X-100 induced a slight increase in the dissolution. 
The initial IDR in SGF containing 0.02%, w/v Tween 20 did not increase significantly 
compared to SGF but after one hour an increase in the dissolution was apparent (Figure 
6.6). 
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Figure 6.6 The intrinsic dissolution profile of itraconazole at 370C in SGF (pH 1.2) and in SGF 
containing 0.25%, w/v SDS, 0.1%, w/v Triton X-100,0.02%, w/v Tween 20 and in FaSSGF. Each 
data point represents the mean ± S. D. of 3 measurements 
The data collected for the initial IDR were normalised for solubility (Q according to 
Eq. (6.1). J denotes the IDR or the mass flux of the drug, S is the surface area of drug 
disks and V is the volume of the dissolution medium. 
.. .1 .1J. S normatisea(i) = vcs Eq. (6.1) 
Itraconazole had a similar normalized value of 0.002min"' in media containing SDS and 
Tween 20. A higher value of 0.004min"l was found in Triton X 100-containing media. 
Meanwhile the normalized value was greater in FaSSGF (0.013min"'). These figures 
indicated that it was not the solubilization effect that was responsible for the relatively 
higher initial IDR in FaSSGF and Triton X 100-containing medium, otherwise similar 
values for the normalized IDR would be obtained. 
Another two important factors can affect the dissolution process, namely, diffusion and 
wetting. The effect of Triton-containing solution was mainly due to wetting 
enhancement as the contact angle with itraconazole disk was the smallest (Figure 6.1). 
The contact angle with FaSSGF was the greatest among the gastric media indicating 
less wettability for the bile salt and lecithin. Consequently, differences other than 
changes due to solubility and wetting were the reason for the high initial IDR in 
FaSSGF, which were more likely related to the greater diffusivity of the drug in this 
medium. 
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6.3.3.1.2 Ketoconazole 
The dissolution studies of ketoconazole at pH 1.2 could not be performed because of the 
high solubility of ketoconazole at this pH (Section 3.3.2.2). Nevertheless, saturation 
solubility was determined in these media (Table 6.3). The greatest increase in solubility 
(1-6-fold) compared to SGF was recorded in SGF containing 0.25%, w/v SDS. A 
smaller increase was observed in FaSSGF (1.3-fold). The solubility of ketoconazole in 
SGF containing SDS was consistent with the literature value which was -32mg ml" 
(Vertzoni et al., 2007). 
6.3.3.2 Simulated intestinal fluid 
The behaviour of the drugs was investigated in media containing NaTC in various 
concentrations. NaTC was chosen as a representative for bile since it is prevalent in the 
human bile and its micelle aggregation number (number of monomers per micelles) is 
less sensitive to the changes in the pH and ionic strength of the media (Wiedmann and 
Kamel, 2002). 
Typical concentrations of bile salts in intestinal fluids are 4-6 mM in the fasted state and 
10-20 mM in the fed state (Section 1.6.2.1). Consequently, the range of NaTC 
concentrations was chosen in the current investigation to represent the fasting and fed 
states. In order to predict the degree of solubilisation by bile salts, solubilities of the 
drug were constructed as a function of NaTC concentrations. As aforementioned the 
CMC of the NaTC-containing solution at 37"C was found to be 3-4mM. Accordingly, 
concentrations of 2mM of NaTC represented sub-CMC levels, whereas higher 
concentrations (7.5,15 and 30mM) exceeded the CMC. The dissolution was further 
explored in more complex media containing NaTC and a phospholipid, namely, lecithin. 
6.3-3. Zl Itraconazole 
Both the solubility and the dissolution rate were significantly higher in media 
representing the fed state. In the media containing only NaTC, the solubility of 
itraconazole was enhanced by increasing NaTC concentration. 
A straight line relationship was found between the concentration of NaTC and drug 
solubility. Table 6.4 illustrates that the solubility improved in a range from 2- to 28-fold 
in media containing NaTC, compared to the corresponding blank FeSSIF which did not 
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contain NATC. Likewise, the dissolution increased in the presence of NaTC, however, 
the amount dissolved quickly levelled off. Figure 6.7 shows the amounts dissolved per 
unit area plotted versus 3h. 
Table 6.4 Solubility and IDR data of itraconazole at 3711C in FeSSIF, FaSSIF, blank FeSSIF, blank 
FaSSIF and in blank FeSSIF containing various amounts of NaTC. Each data point represents the 
mean: L S. D. of 3 measurements 
Medium 
Blank FaSSIF 
FaSSIF 
Blank FeSSIF 
FeSSIF 
2mM NaTC in blank FeSSIF 
7.5mM NaTC in blank FeSSIF 
15mM NaTC in blank FeSSIF 
30mM NaTC in blank FeSSIF 
Solubility 
(Ag tul") 
Initial IDR 
(0-15min) 
(Ag min"ýýCnf' 
-0.003 
0.070 ± 0.005 1.85 ± 0.47 
0.011 ± 0.004 0.39 ± 0.08 
0.201 ± 0.019 7.2811.04 
0.027 ± 0.004 0.71 ± 0.13 
0.095 ± 0.010 2.94 ± 0.32 
0.158 ± 0.003 4.23 ± 0.29 
0.311 ± 0.004 8.21 ± 1.02 
The initial dissolution rates were normalized by the solubility (Eq. (6.1). In medium 
containing 2mM NaTC, the normalized dissolution was calculated as 0.037min'l, the 
greatest value (0.044min") was found in 7.5mM NaTC medium. However, a slight 
decrease in the normalized value was noticed at higher concentrations of NaTC. 
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Figure 6.7 The intrinsic dissolution profile of itraconazole at 3711C in FeSSIF, FaSSIF, blank 
FeSSIF, blank FaSSIF and in blank FeSSIF containing various amounts of sodium taurocholate 
(NaTC). Each data point represents the mean -+ S. D. of 3 measurements 
At these micellar concentrations, 15mM and 30mM of NaTC, most of the drug 
molecules were likely associated with micelles resulting in slower diffusion of the drug- 
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loaded in micelles. At the sub-micellar concentrations, the slight enhancement in 
dissolution was explained by an increase in wetting as the contact angle dropped 
significantly compared to the blank buffer. 
The dissolution of itraconazole in blank FaSSIF could not be determined due to the 
extremely low solubility of the drug at this pH. An increase in the solubility and 
dissolution of itraconazole in FaSSIF and FeSSIF was observed compared to the 
corresponding blank media (Table 6.4). In FeSSIF, the solubility and dissolution 
enhanced around three times relative to FaSSIF. By comparing FeSSIF to 15mM NaTC- 
containing medium, which contained the same amount of the bile salt, it was noticed 
that the solubility and dissolution in FeSSIF were greater. 
6.3.3. Z2 Keloconazole 
The increase in ketoconazole solubility was insignificant in medium containing 
2mM NaTC, which represented a concentration below the CMC- At concentrations 
above the CMC, the solubilities increased linearly as a function of bile salt 
concentration (Table 6.5). 
Table 6.5 Solubility and IDR data of ketoconazole at 370C in FeSSIF, FaSSIF, blank FeSSIF, blank 
FaSSIF and in blank FeSSIF containing various amounts of NaTC. Each data point represents the 
mean ± S. D. of 3 measurements 
Medium Ketoconazole solubility (mg ml-1) 
Blank FaSSIF 0.008 ± 0.001 
FaSSIF 0.020± 0.004 
Blank FeSSIF 0.111 ± 0.008 
FeSSIF 0.5 17 :b0.050 
2mM NaTC in Blank FeSSIF 0.116 ± 0.042 
7.5mM NaTC in Blank FeSSIF 0.122 ± 0.008 
15mM NaTC in Blank FeSSIF 0.238 ± 0.032 
30mM NaTC in Blank FeSSIF 0.568 ± 0.050 
An increase in the dissolution rate was observed with the inclusions of NaTC (Figure 
6.8). The IDR in 30mM NaTC-containing media could not be determined due to the 
poor linearity where r2 was 0.89. 
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Figure 6.8 The intrinsic dissolution profile of ketoconazole at 37'C in FeSSIF, FaSSIF, blank 
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The initial intrinsic dissolution rates (0-15min) of' ketoconazoic in media containing 
NaTC were normalized by the solubility values (Figure 6.9). Since the obtained data 
were not similar, this suggested that a mechanism other than solubilisation aCCOLIIItCd 
for the increase in dissolution (Bakatsclou et al., 1991). A drop in the normalized 
dissolution with the two high concentrations of' NaTC was observed suggesting low 
diffusion coef'ficients in these media. The sub-iniccilar solution Increased 111C 
dissolution through increasing the wettability Ol'the drug SUITaCC. 
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Figure 6.9 The initial dissolution rates of ketoconazole normalized for solubility as a function 01' 
NaTC concentration in blank FeSSIF. Each data point represents the inean + S. D. of 2 
measurements 
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An increase in the solubility and dissolution of ketoconazole in FaSSIF and FeSSIF was 
observed compared to the corresponding blank media (Table 6.5 and Figure 6.8). In 
FeSSIF, the solubility increased 25-fold compared to FaSSIF, however the increase in 
the dissolution rate was to a lesser extent, around 8-fold. By comparing FeSSIF to 
l5mM NaTC-containing medium, it was noticed that the solubility and the dissolution 
were greater in FeSSIF. 
6.3.3.3 Simplified simulated intestinal fluids 
6.3.3.3.1 Comparison of the dissolution in FaSSIF and in SIF containing SDS 
The CMC of SDS in SIF could be determined from the solubility profile of the drugs 
versus SDS concentration (Figure 6.10). The inflection point in the curves of both 
itraconazole and ketoconazole solubility profiles indicated that the CMC of SDS in SIF 
was around 0.0 1%, w/v (0.35mM). 
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Figure 6.10 Solubility profiles of itraconazole and ketoconazole at 3711C in simulated Intestinal fluid 
(SIF) containing various amounts of SDS. Each data point represents the mean ± S. D. of at least 2 
measurements 
Itraconazole 
The solubility assessment of itraconazole indicated that 0.02%, w/v SDS in SIF induced 
a similar solubility to that in FaSSIF. However, the dissolution profiles (Figure 6.11) 
were different in these two media as the initial IDR was significantly greater in 0.02%, 
w/v SDS medium. 
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Figure 6.11 Comparison of the intrinsic dissolution profiles of itraconazole at 37*C In 0.02%, w/v 
SDS in SIT and in FaSSIF. Each data point represents the mean of 2 measurements i: S. D. 
The dissolution of itraconazole was further assessed in SIF containing amounts of SDS 
above the CMC. The initial dissolution rates increased linearly with an increase in SDS 
concentration (Figure 6.12). The data for 0.05%, w/v SDS in SIF were employed for 
comparison instead of that in SIF alone as itraconazole was extremely poorly soluble in 
SIF and consequently the initial IDR could not be determined. Both the initial 
dissolution rate and the solubility values increased at the same ratio in media containing 
0.05% or 0.1% of SDS. However in media containing higher concentrations of SDS a 
greater increase in the solubility was observed. In media containing 0.25,0.5 and 1%, 
w/v SDS the initial IDR increased 2.3-, 4.4- and 6.8-fold, whereas the solubility 
increased 41-, 74- and 206-fold, respectively. 
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Figure 6.12 The intrinsic dissolution profile of itraconazole at 370C in SIF containing various 
amounts of SDS (pH 6.8). Each data point represents the mean: L S. D. of 3 measurements 
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Ketoconazole 
The solubility of ketoconazole in 0.01%, w/v SDS in SIF was similar to that in FaSSIF 
but the dissolution rates in FaSSIF were greater (Figure 6.13). Therefore, the amount of 
SDS in SIF was increased to 0.02%, w/v to achieve a better simulation; nevertheless the 
initial IDR was still greater in FaSSIF. 
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Figure 6.13 Comparison of the intrinsic dissolution profiles of ketoconazole at 370C in FaSSIF and 
in SIF containing 0.01%-0.02% SDS (pH 6.8). Each data point in SDS-contalning media represents 
the mean of 2 measurements: h S. D. 
6.3.3.3.2 Comparison of the dissolution in FaSSIF and SIF containing CTAB 
The solubility profiles of itraconazole and ketoconazole in SIF containing CTAB 
(Figure 6.14) revealed that the CMC of CTAB was around 0.005%, w/v (0.14mM). 
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Figure 6.14 Solubility profiles of itraconazole and ketoconazole at 370C In SIF containing various 
amounts of CTAB. Each data point represents the mean: h S. D. of 2 measurements 
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Itraconazole 
The solubility of itraconazole in FaSSIF was similar to the solubility in SIF containing 
CTAB in a range of 0.005-0.01%, w/v. The dissolution of itraconazole was investigated 
in SIF containing various amounts of CTAB and it was found that dissolution in 
0.005%, w/v CTAB was similar to the dissolution in FaSSIF (Figure 6.15). 
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Figure 6.15 Comparison of the intrinsic dissolution profiles of itraconazole at 370C in FaSSIF 
(pH 6.5) and in SIF containing 0.005,0.01 and 0.1%, w/v CTAB (pH 6.8). Each data point In 
CTAB-containing media represents the mean of 2 measurements: k S. D. 
Ketoconazole 
Although concentrations of 0.005-0.01%, w/v CTAB in SIF generated similar solubility 
of ketoconazole to that in FaSSIF, higher concentration of CTAB, 0.05%, w/v was 
needed to approximate the dissolution in FaSSIF (Figure 6.16). 
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Figure 6.16 Comparison of the intrinsic dissolution profiles of ketoconazole at 370C in FaSSIF (pII 
6.5) and in SIF containing 0.05-0.1 %, w/v CTAB (pH 6.8). Each data point in CTAB-containing 
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6.3.3.3.3 Comparison of the dissolution in FeSSIF and in blank FeSSIF 
containing SDS 
The effect of SDS on the dissolution of ketoconazole was further investigated in 
medium at pH 5 which represented simulation of the intestinal fluid at fed state. 
The solubility of ketoconazole in FeSSIF was similar to the solubility in blank FeSSIF 
containing SDS in a range of 0.05-0.1%, w/v. The dissolution data mirrored the 
solubility (Figure 6.17) where the dissolution of ketoconazole in FeSSIF was similar to 
that in blank FeSSIF containing 0.05-0.1 %, w/v SDS. However, the dissolution profile 
was not completely identical to any of the investigated SDS-containing media. 
40 
30 
. 2: E 0U I tm :5E 20 
(D 
10 
0 50 100 150 200 250 
Time (minutes) 
Figure 6.17 Comparison of the intrinsic dissolution profiles of ketoconazole at 37"C in fed state 
simulated intestinal fluid (FeSSIF) and in blank FeSSIF containing 0.01%-0.05%, w/v SDS (pl 15). 
Each measurement in SDS-containing media represents the mean of 2 measurements ± S. D. 
6.3.3.4 Emulsion of Soybean oil in simulated gastric fluid 
The solubility and dissolution of itraconazole and ketoconazole were assessed in media 
containing emulsified fat; the pH of the media was 3 to mimic the fed stomach acidity. 
The dissolution tests were carried out in media containing only Tween 20 at 
concentrations equivalent to that in the emulsions. 
The solubilities of both drugs in the media containing diluted emulsions were slightly 
greater than in the corresponding media containing Tween 20 however the variations 
were not significant (West, 0.05 significant level) (Table 6.6). 
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Table 6.6 Solubility of itraconazole and ketoconazole at 371C in media containing either emulsions 
based on Soybean oil and Tween 20 or only Tween 20 (pH 3). Each data point represents the mean 
J: S. D. of 3 measurements 
Medium 
Itraconazole solubility Ketoconazole solubility 
(m Ml-) (mg mr) 
Emulsion (4.250 o fat, 0.75% Tween 20) 0.53 0.08 0.80 ± 0.0 
0.75% Tween 20 in SGF 0.48 0.08 0.76 ± 0.06 
Emulsion (1.7% fat, 0.3% Tween 20) 0.47 0.06 0.61 ± 0.06 
0.3% Tween 20 in SGF 0.44± 0.04 
6.3.3.4.1 Itraconazole 
0.5910.07 
The extent of dissolution of itraconazole in media containing emulsions and media 
containing equal amounts of Tween 20 were similar (Figure 6.18). The amounts 
dissolved within 4h approximated to the saturation solubility of itraconazole in the 
corresponding media. However, the initial IDR were greater in the absence of fat. 
0-- -- Emulsion (4.26% fat, 0.750/oTween 20) 
0.76% Tween 20 
Emulsion (1.7% fat, 0.3% Tween 20) 
0.3% Tween 20 
Time (minutes) 
Figure 6.18 Intrinsic dissolution profiles of itraconazole at 370C in media containing either 
emulsions based on Soybean oil and Tween 20 or in SGF containing equal amounts of Tween 20 
(pH 3). Each data point represents the mean ± S. D. of 3 measurements 
6.3.3.4.2 Ketoconazole 
The dissolution of ketoconazole was monitored over 3h as the surface of the disks 
started to erode forming holes after that time point. Slightly slower dissolution rates 
were observed in media containing emulsion compared to media of equivalent amounts 
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of Tween 20 (Figure 6.19). The extent of the amount dissolved throughout 3h in media 
containing more fat, 4.25 %, w/v were less than in the medium containing 1.7 %, w/v 
fat. 
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Figure 6.19 Intrinsic dissolution profiles of ketoconazole at 371C in media (pH 3) containing either 
emulsions based on Soybean oil and Tween 20 or in SGF containing equal amounts of Tween 20. 
Each data point represents the mean: h S. D. of 3 measurements 
6.4 Discussion 
6.4.1 Simulating fasting gastric fluids 
The CMC of SDS in SGF was reported as 0.05%, w/v at 37'C (Aburub ct al., 2008). 
Triton's CMC in water was in the range 0.01 to 0.015%, w/v (Sharmin ct al., 2006) at 
20'C. The CMC of Twcen 20 was reported as 0.006%, w/v in water (Luner et al., 
1996). Since the CMC is dependant on the experimental conditions such p1l, ionic 
strength of the medium and the temperature of the measurement, a drop in the CMC of 
these surfactants is expected under the present experimental conditions of 37T in 
acetate buffer (pH 5). Consequently, this suggests that the concentrations of the 
synthetic surfactants in simulated gastric media were well above their CMC. 
The CMC of NaTC was reported to be 3-4mM and with the addition of lecithin in a 
ratio (4: 1), it dropped to 0.25mM in simulating intestinal fluid (pH 5.5) at an ionic 
strength of OAM at 25*C (Naylor et al., 1993). The CMC of FaSSGF containing 80ýM 
NaTC and 20ýLM lecithin was predicted to be less than the CMC of NaTC (Aburub et 
al., 2008). Thus, the media with synthetic surfactants contained them in concentrations 
0 Emulsion (4.25% fat, 0.759/6 Tween 20) 
0 0.75% Tween 20 
v Emulsion (1.7% fat, 0.30/eTween 20) 
v 0.3% Tween 20 
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exceeding their CMC while the concentration of endogenous surfactants in FaSSGF was 
below the CMC. This suggested that the media containing synthetic surfactants had a 
different solubilising mechanism and wetting effect to that of FaSSGF. 
When molecules are associated with the micelles, their diffusivity is expected to 
decrease due to the bigger size of the drug-loaded micelles compared to individual drug 
molecules (Balakrishnan et al., 2004). Consequently, this may explain why the initial 
dissolution rate was greater in FaSSGF where no micelles were formed and the 
diffusion was mainly of the free drug molecules. 
FaSSGF was recommended as an appropriate dissolution medium that reflects the fasted 
state by Jantratid et at. (2008a). The distinct differences between FaSSGF, the medium 
containing physiologically relevant components, and the artificial surfactant-containing 
SGF could call into doubt the relevance of using an artificial component in the medium. 
Tween 20 (0.02%, w/v) in SGF provided a more reasonable simulation for FaSSGF in 
terms of solubility although the dissolution profiles were different. This suggested that 
this medium could be considered an alternative for FaSSGF for solubility determination. 
6.4.2 Simulated intestinal media containing only sodium taurocholate 
The linear increase in the solubility of the hydrophobic drugs observed in the presence 
of NaTC in micellar concentrations was attributed to the parallel increase in the number 
of micelles leading to more drug solubilisation. 
Micelles can solubilise poorly soluble non-polar molecules within the micelle core, 
while polar molecules are adsorbed on the micelle surface or between the hydrophilic 
heads whereas semi-polar substances are distributed along surfactant molecules in 
intermediate locations (Corrigan and Healy, 2007). Since the pKa of itraconazole is 3.6, 
nearly all the drug moieties were unionised at the pH of the investigation (PH 5). Thus, 
it would be expected for the drug to be solubilised in the hydrophobic core of micelles 
or deeply in the palisades layer. On the other hand, the pKa of the imidazole ring in 
ketoconazole is 6.5 so the ring is mostly ionised at pH 5, (Section 1.10.2.2). Thus, 
ketoconazole was partly protonated at pH 5 and so more probably positioned at the 
surface of the micelles or between the hydrophilic head groups (hydroxyl) of NATC. 
The side chains of NaTC (pKa 2) held a negative charge at pH 5 so ionic interactions 
are expected with ketoconazole however with itraconazole which present mainly in the 
neutral form, such ionic attraction is precluded. 
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The total solubility of a drug (C,,, t) in an aqueous surfactant system equals the solubility 
of the drug (Q in the absence of surfactant added to the micellar solubility of the drug 
(Cdm). 
The solubilization process in concentrations exceeding the CNIC was considered as a 
simple partition phenomenon between an aqueous and a micellar phase. Thus the 
relationship between surfactant concentration (C. ) and drug solubility (CIj) was given 
by Eq. (6.2), where P is the distribution coefficient of drug between the micelle and 
aqueous phase (Corrigan and Healy, 2007). 
Cl,,, = Cs + PCC. Eq. (6.2) 
The molar solubilities of the itraconazole and ketoconazole in media containing NaTC 
were plotted as a function of NaTC molar concentrations in these media. The slope of 
the linear curve (P. Q represented the molar solubilisation ratio of the micelles which 
was computed as Ix 10'5 for itraconazole and 0.04 for ketoconazole and P was 641 and 
181M-1, respectively. Thus, the proportion of itraconazole in the micellar phase was 
higher than the proportion of ketoconazole. However, the solubilisation capacity was 
greater with ketoconazole. This could be attributed to the variations in drug 
hydrophobicity and affinity to bile salt micelles. 
Although an increase in the solubility of both drugs with the increase in NaTC was 
observed, the increase in the dissolution rate of both drugs was smaller. This was 
probably due to slow diffusion for the drug incorporated in the miccllcs. 
The Noyes-Whitney equation (Eq. (1.3)) showed that the dissolution rate was linearly 
proportional to the solubility under perfect sink conditions. However, Higuchi (Higuchi, 
1964) developed a theoretical model that predicted that the effect of the solubility on the 
dissolution would be less than that predicted by the Noyes-Whitney equation in 
surfactant solutions. Hence, the dissolution in surfactant system is the result of two 
combined effects; solubilisation by the surfactant combined with slow diffusion of the 
drug loaded-micelles. 
6.4.3 Simulated intestinal media containing NaTC and lecithin 
Itraconazole and ketoconazole had significantly higher solubilities in the fed state fluid 
than in the fasted fluid. This was attributed to the greater bile salt and phospholipid 
content combined with the lower pH of FeSSIF (pH 5), compared to FaSSIF (pl-I 6.5). 
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The dissolution rates of the drugs also increased but with ketoconazole the increase in 
the dissolution rate was to a lesser extent than the increase in solubility. 
A greater solubilisation in FeSSIF was observed when compared to media containing 
the same amount of NaTC only (15mM). The concentration of NaTC in FaSSIF and 
FeSSIF exceeded the CMC due to the incorporation of lecithin into the bile salt micelle. 
Consequently, the formation of mixed micelle systems with lower CMC led to an 
increase in the number of the micelles and exhibited greater drug solubilisation than the 
corresponding simple micelle containing NaTC only. This agrees with the findings of 
Naylor et al. (1993) who studied the dissolution of hydrocortisone in similar media. 
The enhancement in the dissolution of the drugs in the simulated intestinal media was 
likely due to the combined effects of solubilisation and wetting enhancement. 
It is worthy of note that the composition of FeSSIF lacks the lipolytic products. 
Consequently, this medium was recently modified to better reflect the physiological 
conditions (Jantratid et al., 2008b) (Section 1.9.2). Thus, it would be interesting to 
investigate the dissolution in the presence of these components which are expected to 
enhance the dissolution of poorly soluble drugs. 
6.4.4 Simplified simulated intestinal fluid 
The reported CMCs of SDS and CTAB in water at 25*C are 8.3mM and I. OmM, 
respectively. The obtained values for the CMC of SDS and CTAB in SIF (from drugs 
solubility studies) were approximately 0.01%, w/v (0.35 mM) and 0.005%, w/v 
(0.14mM), respectively. Thus, a drop in the CMC from the literature values was 
probably due to the experimental conditions as the temperature of the current 
investigation was 370C and the presence of phosphate buffer increased the ionic 
strength of the medium. With ionic surfactants, the addition of electrolytes to a 
surfactant solution neutralizes the charge of the ionic head groups and so decreases the 
electrostatic repulsion between these groups which leads to a decrease in the CMC from 
that in pure water (Rangel-Yagui et al., 2005). 
The solubilisation capacity of itraconazole by SDS above the micellar concentration 
was found to be 0.0002 (mole drug per mole SDS) and the distribution coefficient P was 
4700OM-1. In contrast, the solubilisation capacity of ketoconazole by SDS was 0.2 and 
the distribution coefficient P was 15171M*l. This suggested good solubilisation capacity 
by SDS for both drugs which was more pronounced with ketoconazole. 
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A similar solubilisation capacity of itraconazole by SDS and CTAB systems was 
noticed. The solubilisation capacity of ketoconazole by CTAB in SIF was 0.09 (mole 
drug per mole CTAB) and the distribution coefficient P was 6523M". Hence, CTAB 
had less solubilisation capacity for ketoconazole than SDS. 
The CMC value of SDS in SIF acquired from solubilities of the drugs versus the 
concentration of SDS was lower than that determined from surface tensions (Figure 
6.2). Drug molecules frequently exhibit surface activity due to their amphiphilic 
structure; this could be the reason why the lower CMC was in the presence of the drugs 
through the formation of complex micelles. For example, Naylor et al. (1993) noted that 
the CMC of a NaTC containing-solution was lower in the presence of saturated 
hydrocortisone. 
The concentration of SDS (0.02%, w/v) required to induce similar dissolution for 
itraconazole and ketoconazole to that in FaSSIF was in a region corresponding to the 
CMC of SDS. Similar findings were noticed with the dissolution of itraconazole in 
CTAB-containing medium where the concentration of CTAB (0-005%, w/v) in SIF 
required for matching the dissolution in FaSSIF was around the CMC of CTAB. In 
contrast, the surfactant concentration in FaSSIF (3mM NaTC) was well above its CMC. 
Solutions containing SDS and CTAB which induced similar dissolution of itraconazole 
and ketoconazole to the dissolution in FaSSIF exhibited lower surface tension and 
different wettability of drug surfaces, compared to FaSSIF. This suggested that there 
were different mechanisms for the increase in drug dissolution in the presence of 
synthetic and natural surfactants. 
It was reported that the inclusion of 0.5%, w/v Tween 60 in blank FaSSIF produced 
similar dissolution of ketoconazole tablets (NizoralTM) to the dissolution in FaSSIF 
(Zoeller and Klein, 2007). The latter medium had a similar surface tension to FaSSIF 
which indicated that matching the physical properties of bile salts-containing media was 
an important issue for the simulation. 
Thus, the difference in the physical and chemical properties between the simulated 
intestinal media containing endogenous surfactants and the simplified media containing 
synthetic surfactants, in addition to different solubilisation mechanisms of the 
surfactants made matching the dissolution profiles unfeasible. However, the proposed 
media may be used for initial screening as an alternative to the bile salts media which 
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are expensive, their preparation is time consuming process and furthermore they need to 
be freshly prepared. 
6.4.5 Emulsion of Soybean oil in simulated gastric fluid 
This part of the work investigated the effect of lipid emulsions based on Soybean oil 
and Tween 20, on the dissolution of the drugs. The emulsion system induced a slight 
increase in the solubility of both drugs. However, the dissolution rate was slightly 
slower compared to the surfactant solution possibly due to the slow transfer of the drugs 
into the fat droplets of the emulsion. The concentration of Tween 20 in all media was 
greater than the reported value of CMC in water. 
Drug solubilisation in emulsions is through drug transfer into fat droplets and/or 
through surfactant micelles (Lobenberg and Amidon, 2000). Thus, the dissolution in the 
emulsion is similar to that in the micelle system in respect to the partition of the drug 
into emulsion droplets depending on the affinity of the drug to the interior phase which 
is Soybean oil in the present case (McNamara et al., 2000). 
Although the dissolution in the emulsion system is similar to dissolution in micellcs, the 
size of the fat droplets is usually bigger than the size of the micelles resulting in 
different mass transfer mechanism in each system (McNamara et al., 2000). 
Consequently, the drug loaded in the fat droplets of the emulsion will have slower 
dissolution compared to the surfactant solution. 
The micellar concentration in the emulsion is likely to be less than that in a surfactant 
solution which contains an identical amount of the surfactant because part of the 
surfactant surrounds the fat droplets. Therefore, the dissolution comparison with 
medium containing surfactant alone is probably not very accurate and an 
underestimation of the effect of fat on drug solubilisation. 
6.5 Conclusion 
The endogenous surfactants employed in biorelevant concentrations increased the 
dissolution of the assessed drug significantly. Such an effect was more pronounced in 
media representing the fed state than the fasting state which is in accordance with 
clinical studies (Zimmermann et al., 1994). Hence, the obtained results enforce the 
importance of the fed state in dissolving the poorly soluble drugs due to higher levels of 
bile secretion and lipids and increase the pH of the intestinal fluid. 
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A synergistic solubilizing effect for itraconazole and ketoconazole could possibly be 
generated using a certain amount of synthetic surfactants as an alternative to the bile 
components. The proposed media based on SIDS and CTAB allowed a considerable 
simplification since they were easily prepared and based on the use of an inexpensive 
surfactant. Although these media did not provide identical dissolution to that in the 
frequently used simulated intestinal fluid containing natural surfactants, they could 
provide quantification of drug behaviour in simulated intraluminal fluids. These studies 
need to be expanded to include the dissolution of drug formulations in the proposed 
media which contained synthetic surfactants to see whether they could substitute 
FaSSIF and FeSSIF so these media can possibly be used in routine quality control tests 
and substitute the costly bile components based media. 
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Chapter 7: General discussion & conclusion 
7.1 Discussion 
Dissolution of drugs is the rate-limiting step for absorption of Class Il drugs; therefore, 
it is an important factor to consider when developing new drug entities and during 
subsequent stages of formulation. The in vivo relevance to in vitro dissolution could be 
achieved by simulating the conditions prevailing in the GI tract. Compendial media are 
still simple media and so are not expected to distinguish between the fed and fasting 
conditions. Therefore, the use of biorelevant media that simulate post and pre-prandial 
condition is essential. 
7.1.1 Solubility versus dissolution 
The solubility of itraconazole and ketoconazole in various media was found to be the 
most important determinant of the dissolution rate. Sink conditions could not be 
maintained in itraconazole dissolution experiments which explains the general profile 
obtained for itraconazole dissolution, starting with a relatively fast dissolution which 
soon levelled off indicating that saturation solubility was reached. On the other hand, 
ketoconazole dissolution profiles were likely to be linear, in particular in acidic media, 
due to the higher solubility of ketoconazole at low pH. 
In cases of micelle-facilitated and emulsion-facilitated dissolution, the dissolution was 
not driven by solubility since a more pronounced enhancement in the solubility was 
observed, compared to the increase in the dissolution. These findings came in 
accordance with previous studies when the increase in dissolution in complex media of 
human and dog intestinal fluids (Persson et al., 2005) or in media containing synthetic 
surfactants (Balakrishnan et al., 2004) was less than that predicted from solubility. This 
shows the value in determining both parameters: solubility and dissolution rate, as the 
determination of the solubility alone may not allow accurate speculation of the 
dissolution rate. To further prove this point, evaluation of the diffusion constants for the 
free drug and drug loaded in micelles are required for each experiment. 
7.1.2 Simulated gastric media 
The dissolution of both drugs increased when the pH of the medium was highly acidic 
(pH 1.2) and a further increase was observed in the presence of pepsin. This could be 
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correlated to the pharmacokinetic data where drug bioavailability decreased by reducing 
the stomach acidity (Section 1.10.4.1). For the pre-prandial stomach, the simulation was 
based on mimicking the surface tension of the stomach using bile salt and lecithin or 
media containing synthetic surfactants. Both cases exhibited a significant enhancement 
in the dissolution of the drugs. FaSSGF was previously found to be a good surrogate for 
the gastric medium representing fasting conditions (Jantratid et al., 2008a) and 
subsequently the dissolution in this medium was expected to be reasonably similar to 
gastric medium in pre-prandial conditions. The use of simulating gastric simplified 
formulations containing 0.25% SDS, 0.1% Triton X-100 and 0.02% Tween 20 (w/v) in 
SGF did not provide similar dissolution profiles to FaSSGF rendering these media 
inappropriate for the simulation of gastric fluid. 
For fed stomach simulation, the composition of gastric fluid varies according to the 
ingested meal (Nicolaides et al., 1999). Hence, there was no specific medium that could 
mimic the fed stomach fluid. Therefore, a selection of media containing food 
components was assessed. Milk mixed with SGF (pH 1.2) (50: 50) was considered as a 
reasonable surrogate to common food as it contains all the main nutrients. The solubility 
and dissolution of both drugs was enhanced in milk-containing media. The mechanism 
of this influence was attributed to the entire complex structure of milk since the main 
components of milk; cascin and lactose did not induce the same discernible effect. The 
mechanism of the solubilising effect of milk was proposed to be through drug binding 
as indicated by the dialysis data. This supported the previous findings of Macheras et al. 
(1990) where milk was found to bind to drugs. 
The second direction of the studies was towards evaluating the effect of simpler media 
composed of a single protein. Consequently, the dissolution in media containing egg 
albumin in various concentrations was evaluated. The inclusion of albumin in the media 
induced an important effect on the solubility and dissolution of both drugs. This effect 
was attributed to drug-albumin complex formation as indicated by protein binding 
studies including dialysis and spectroscopic analysis. Gelatin presence in the medium 
also increased the solubility and dissolution of both drugs; however, no evidence of 
protein binding was obtained. The effect of gelatin-containing solutions was possibly 
due to its moderate surface activity which enhanced the wettability of the drug surfaces. 
Gluten inclusion did not induce a significant effect whereas casein slightly increased the 
dissolution. The effect of casein on drug dissolution was probably due to the decrease in 
the contact angle with the drug surface and, with its specific structure of sub-micelles 
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units, it could solubilise drug molecules. Thus, it was concluded that protein-containing 
media enhanced both solubility and dissolution of itraconazole and ketoconazole. Many 
factors accounted for this effect: complex formation, increase in the wettability and 
solubilisation into casein units. 
The effect of the inclusion of simpler additives such as sugars and amino acids on the 
dissolution of drugs was studied. Media containing carbohydrates, namely, glucose, 
lactose and starch did not exert any distinct effect on dissolution. The slight effect 
observed was probably due to interactions through hydrogen bonds. Amino acids 
slightly increased the dissolution of itraconazole, and in particular, neutral amino acids 
such as GLY and ALA. However, more interesting results were acquired with 
ketoconazole as the dissolution increased markedly with the inclusion of 1%, w/v 
neutral amino acids. 
The effect of emulsions on the dissolution of the drugs was evaluated in media of 
diluted Soybean emulsions using Tween 20 as an emulsifier. The dissolution in the 
emulsion was similar to that observed in media containing Tween 20 alone at the same 
concentrations. This suggested that emulsified fat did not affect the dissolution. 
However, this comparison did not seem very important due to the different solubilising 
capacity of Tween 20 in the presence and absence of fat. It could be concluded from the 
study in media containing emulsion or the three types of milk (varied in fat content) that 
there was no clear evidence of fat affecting drug solubility and dissolution. 
The data acquired from dissolution in the presence of food components revealed the 
importance of dissolution tests in biorelevant media in predicting the effect of food. 
Thus, a speculation based on the in vitro results obtained would be if a patient takes his 
medication with a glass of milk and/or with protein and amino acid-rich diet such as 
eggs, then the dissolution of the drug in the stomach will increase subsequently leading 
to more absorption and greater bioavailability. This means that patients may get variable 
bioavailability depending on their diet. 
These findings need to be taken further to investigate whether the dissolution of oral 
dosage formulations of itraconazole and ketoconazole will be similarly affected by food 
components. With the formulations, excipients can affect the dissolution process of the 
dosage forms and probably interfere with the additives in the dissolution medium which 
may in turn limit or increase the effect of the additives on the dissolution of the drugs. 
For instance, Shah (2006) reported that the dissolution of ibuprofen dosage forms 
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increased in the presence of casein however the IDR of the ibuprofen remained 
unaffected. Accordingly, the effect of casein was attributed to interactions between 
casein and excipients in the formulation. 
The salt and crystal form of the drug in the dosage form can affect the dissolution and 
so the presence of food may influence the dissolution of the formulated drug differently 
from the intrinsic pure drug. 
7.1.3 Intestinal fluid simulation 
The solubility of itraconazole and ketoconazole increased in the fed state compared to 
the fasted state due to an increase in bile and phospholipids levels. Dissolution in media 
containing NaTC alone at sub-micellar levels revealed that the mechanism of increase in 
dissolution was due to an increase in wettability, whereas above the CMC both 
solubilisation and wettability accounted for the enhancement in dissolution. Dissolution 
did not increase to same extent as solubility in media containing surfactants in 
concentrations above the CMC. This was probably due to the low diffusivity of drug- 
loaded in micelles. 
Dissolution in FaSSIF and FeSSIF reported good IVIVC (Nicolaides et al., 1999), 
however, the preparation of these media is costly and time consuming. SDS and CTAB 
could possibly be used to replace natural surfactants. The proposed media in the current 
investigation were: 0.02%, w/v SDS in SIF (pH 6.8), 0.005-0.05%, w/v CTAB in SIF 
(pH 6.8) to mimic FaSSIF (pH 6.5) and (0.05-0.1%), w/v SDS in blank FeSSIF (PH 5) 
to mimic FeSSIF. These media did not provide identical dissolution profiles for 
itraconazole and ketoconazole to that found in FaSSIF and FeSSIF. However, 
approximate simulation was achieved. Thus, these simplified media can be used to 
predict drug dissolution in intestinal fluids as alternatives to bile salt and lecithin 
containing-media. Further investigations need to be conducted on drug formulations in 
these media and if the dissolution of formulations complies with IDR data, the use of 
simplified media could be generalized to quality tests, lot-to-lot uniformity and bio- 
equivalency. 
The pharmacokinetic studies conducted in humans found that the bioavailability of 
itraconazole and ketoconazole increased in the post-prandial state. For example, the 
bioavailability of itrac9nazole capsules was reduced by 40% when it was administered 
under the fasting state (Heykants et al., 1989). Ketoconazole bioavailability increased 
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when tablets were taken with a standard breakfast (Gascoigne et al., 1981). 
Zimmermann et al. (1994) observed that a high-fat meal provided the greatest 
bioavailability of itraconazole and hence suggested that itraconazole absorption was 
promoted at the postprandial stage due to longer gastric retention and the high fat 
content of the co-ingcsted meal. The data presented here support the potential effect of 
co-ingested food on drug dissolution. Moreover, the meals given to Zimmerman's 
subjects were composed of white bread, butter, eggs, bacon, sausages and decaffeinated 
coffee, which is a protein-rich diet. Therefore, in addition to extending gastric residence 
time with food co-ingestion, the potential solubilisation of the lipophilic drugs by the fat 
in the food combined with the increase in bile secretion, the proteins in the diet might 
also promote the dissolution of the drugs and consequently their rate and extent of 
absorption 
7.1.4 Itraconazole versus ketoconazole 
Although both drugs have azole structures, differences were observed in their 
dissolution behaviours. The different physiochemical properties of the drugs, in 
particular, pKa and log P had an important impact on their solubility. Itraconazole is 
more lipophilic, extremely poorly soluble and can be ionised at pH < 4.6 where as 
ketoconazole is relatively more soluble and can be ionised over a wider range of pH 
values < 7.5. Accordingly, these variations led to different solubilities and interactions 
with the additives and consequently different dissolution patterns of the two drugs. In 
general, the same positive effect of the dissolution media containing food or surfactants 
on the dissolution of itraconazole and ketoconazole was observed, however, the extent 
of the effect varied between the two drugs. 
7.1.5 Physical properties of the dissolution media 
The change in the composition of the media led to a change in their measured physical 
properties. In general, the viscosity of the assessed media did not show important 
variations, apart from media containing milk, albumin, and gelatin. Although a negative 
correlation was expected between the viscosities of the media and initial dissolution 
rates of the drug, this was not apparent. This could be explained by the higher 
solubilising capacity of the media with higher viscosity, represented by the protein- 
containing media, which in turn compensated for the increase in the viscosity. 
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Surface tension was an important determinate of dissolution and solubility. Media with 
high surface activity exhibited high solubilising capacity of the drugs in addition to 
enhancing the wettability. 
This investigation was concerned with evaluating the viscosity and surface tension. 
However, further factors could also have an impact on the dissolution rate such as 
buffer capacity and osmolality. Therefore, the effect of these factors on the dissolution 
needs to be determined in future work. 
7.2 Concluding remarks 
The increased dissolution of the two assessed azole anti-fungal drugs in the presence of 
the investigated dietary and bile components more than likely accounted for the reported 
increases in their bioavailability when co-administered with meals. Consequently, 
biorelevant media based on food constituents and endogenous surfactants are 
recommended for the prediction of the behaviour of the drugs in the GIT as they appear 
as more realistically representative of the intraluminal. fluids than the simple compendial 
dissolution media. Such media have the potential to reflect changes in the performance 
of BCS Class 11 drugs due to fed and fasting conditions and, even more specifically, due 
to the type of the meal which in turn can affect drug bioavailability. Clinicians can 
benefit from such information when prescribing drugs to achieve the desired 
bioavailability and therapeutic efficacy. 
The investigating of the mechanism contributing to the effect of food additives 
suggested the interactions between additives and drug as a possible reason for drug 
solubilisation. Other factors also contributed like the increase in the wettability of the 
drug surface. These studies need to be further expanded to elucidate the mechanism on a 
molecular level and include all the components added to the dissolution media in the 
present investigation. 
The replacement of the bile components with the synthetic surfactants did not provide 
identical dissolution of the drugs but indicated that these media can be employed within 
the proposed concentrations to give an insight to the effect of the cndogcnous 
surfactants. 
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7.3 Recommendations for future work 
The following recommendations arc suggested for ftiture work: 
This research was concerned with studying the intrinsic dissolution of pure 
itraconazole and ketoconazole however it is also important to study the 
dissolution of dosage forms in biorelevant media containing food constituents. If 
the media induced the same effect observed with the pure drug then it is of value 
to expand the studies to the clinical level to evaluate drug absorption and 
bioavailability when co-ingested with meals or drinks containing the studied 
additives. Such information is useful for drug prescription regarding the time 
and type of the administrated meal. 
It is worthy to extend the study to include further azole anti-fungal drugs and 
moreover, include drug substances of different physical and chemical properties 
such as basic, acidic and neutral drugs of different solubilities and of various 
BCS Classes. 
The dissolution in conditions more akin to the in vivo environment is expected to 
provide better IVIVC. Literature showed some differences between the FeSSIF 
and human intestinal fluid such as the lack of lipolytic products in the former, 
which could affect the dissolution of lipophilic drugs. Consequently, the 
dissolution and solubility of the drugs need to be assessed in modified media 
containing fatty acids and monoglycerides. Furthermore, to provide an even 
more accurate picture about the dissolution in vivo, human aspirate fluids 
representing fed and fasting states could be employed and so a comparison with 
dissolution in the simulated media could be carried out. 
Studies performed to investigate the mechanism of drug solubilisation need to be 
further expanded using different techniques. For example, Circular Dichroism 
can allow the monitoring of protein conformational changes due to drug binding 
on the molecular level. Micro-calorimetery may detect the thermodynamic 
differences that occur due to the interactions between food components and 
drug. Solid dispersions of drug-protein can be prepared and analysed using 
thermal analysis and PXRD to elucidate of the mechanism of the interactions. 
Light scattering methods can be employed to detect the formation of casein 
micelles. 
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Trials to develop simplified dissolution media based on synthetic surfactants as 
alternatives to the biorelevant media containing endogenous surfactants can be 
expanded to include other surfactants. Simulation of the physicochemical 
properties is a vital issue that needs to be considered. 
Since food additives such as milk, egg albumin and gelatin increased the 
solubility of itraconazole and ketoconazole, it might be useful to employ these 
substances in developing drug formulations. The use of such natural vehicles in 
appropriately designed formulations may enhance the solubility of the poorly 
soluble drugs and provide safe and cheap alternative for the synthetic polymers. 
In vitro and in vivo studies need to be performed to validate the potential 
formulations. 
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